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Abstract
Glucosinolates and isothiocyanates have been known to possess anti-cancer properties. 
Harvesting these materials from cruciferous vegetables is problematic, the isothiocyanate is 
reactive and susceptible to hydrolysis, and the glucosinolate cleaves to give glucose and the 
isothiocyanate in the presence of the enzyme myrosinase (found within the plant). Therefore 
it would be useful if we were able to synthesise these materials.
Synthesising isothiocyanates with increased potency regarding their anti-cancer properties 
would also be sagacious. Dihydrothiazines are useful precursors to sulfinic esters, which in 
turn have the potential to be converted into chirally pure isothiocyanates. Synthesis of the 
glucosinolate glucoraphanin, dihydrothiazines and derivatives are discussed within this thesis.
Synthesis of the glucosinolates proved to be far more difficult than first expected. A simple 
model compound (methyl glucosinolate) was synthesised, however, the glucoraphanin proved 
to be problematic. Reported is a method that traps the oxime intermediate enabling successful 
synthesis of the hydroximate, precursor to the glucosinolate.
A series of new dihydrothiazines have been successfully synthesised. This portion of work 
has developed a novel synthetic procedure for their synthesis allowing three reactions to be 
performed in the one reaction apparatus. The result of this is to provide an efficient route to 
the dihydrothiazines.
The syntheses of an epoxide, allylic alcohol and sulfone dihydrothiazine derivatives are 
reported within this thesis in addition to the synthesis of sulfinic esters. It was also observed 
that it is possible for the dihydrothiazine to degrade through two separate hydrolysis routes 
depending on the environment it experiences.
© Robert Anthony Lucas, 2003
Convinced, by the most strict observation, that the mind is embarrassed by a thousand 
extrinsic difficulties, and sensible that a numerous library is the seat o f the greatest 
extravagancies and the most idle chimeras, we have made an election, by extracting 
numerous volumes, which have included in small duodecimos; not unlike sldlful chymists, who 
concentre the virtues o f many plants in a small phial, and cast aside the refuse. Innumerable 
quantities ofboolcs are made; it is our business to collect the scattered and valuable parts.
The ignorant babble eternally; the learned and sagacious speak little but well.
Francis Duke De La Rochefoucault, Literary Miscellany: Selections and Extracts, Classical 
and Scientific, Printed by G. Nicolson, 1802.
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S u m m a r y
Contained within this thesis is an introduction to glucosinolates and isothiocyanates, 
included therein is a description of how man unknowingly first utilised them through 
plants and seeds; the identification of the anti-cancer properties of plants containing 
glucosinolates through epidemiological experiments; the identification of 
isothiocyanates and glucosinolates as the source of the anti-cancer properties of plants 
and consequently how they interact and modify the metabolism of carcinogens in the 
body. Leading from this review of isothiocyanates and glucosinolates is an introduction 
to the synthetic work contained in this thesis followed by the results and discussion 
regarding the synthesis of glucosinolates, dihydrothiazines and sulfinic esters.
Introduction
Man’s interest in food and the medicinal properties it may deliver has always been keen. 
The characteristics we now associate with glucosinolates, sulphurous pungent odour and 
biting taste have been known since ancient times and the extracts/juices used for 
medicinal purposes have led to the cultivation of the plants they originate from 
throughout the world.
The evidence for this interest in food/medicine throughout history has been scattered all 
over the world, ranging from; carbonised seed of Brassica juncea and B.rapa being 
found at Ban Po village in Xi An city dated approximately 4000BC; carbonised seed of 
B. juncea ('Rajilea') dating back to 2000BC in Pakistan; the Chinese of the Cho dynasty 
(1122 to 247BC) made mention of mustard (B. juncea coss) and the Romans also 
mentioned the use of mustard as a condiment as well as a remedy for scoipion stings. 
The Romans were also aware of the benefits derived from particular vegetables and 
cultivated various species of cabbage, kale and broccoli1.
However, during the last century the fascination over our diet has increased 
dramatically and has achieved an unprecedented status in society2. This has been driven 
forward by our heightened concerns over diet and health, which are derived from our 
interest in nutrition, fitness and beauty that society now hold so important. The foods 
we eat are no longer perceived to have nutritional value alone but have assumed another
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degree of importance to which they can be referenced, this is ‘function’. ‘Functional 
foods’ provide additional physiological benefit such as preventing or delaying the onset 
of diseases as well as providing nutrition.
Protective effect of vegetables in the diet
The scientific community has been aware of the protective effects of fruit and 
vegetables for over 25 years3. There are many reviews detailing the preventative effects 
of these vegetables when included in the diets of individuals. The risk of contracting 
cancers of the mouth, pharynx and larynx is reported to be halved by high consumption 
(four to six servings per day) of fruit and vegetables as compared to a low consumption 
(one to two servings). Epidemiological studies have shown that oesophageal cancer and 
lung cancer risk can also be reduced by 40-60 % and 20-40 % respectively by 
consuming 4-5 servings of fruit and vegetables as compared to one or two servings per 
day4. The risk of developing other cancers including cancer of the breast, bladder and 
kidney are also reduced to varying degrees by the increased consumption of fruit and 
vegetables and particularly the Brassica vegetables such as Brussel sprouts, cabbage 
and broccoli. These observations are believed to be due to the minor dietary 
components (phytochemicals) of the fruit and vegetables such as the antioxidant 
vitamins, flavonoids and glucosinolates5 and6.
B. Laky and co-workers7 reported the treatment of Hep G2 cells (human carcinoma liver 
cells) with benzo[a]pyrene and one of its metabolites (±)-anti-benzo[a]pyrene~7,8~ 
dihydrodiol-9,10-epoxide and a combination of benzo[a]pyrenes and Brussel sprout 
juice. The findings of this study concluded that when small amounts of sprout juice 
were applied to human cells treated with benzo[a]pyrene, the degree of DNA damage 
was significantly reduced and thus the assumption was put forward that Brussel sprouts 
may also have chemoprotective properties in humans.
The total fruit and vegetable intake of a cohort of men over a ten-year period was 
examined in relation to bladder cancer risk8. 47,909 men were involved in the study 
and each completed a food frequency questionnaire at intervals through the ten-year 
period. Two hundred and fifty two cases of bladder cancer were diagnosed over the
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study period. The results showed no inverse correlation between the consumption of 
fruit and vegetables and the risk of developing bladder cancer; however, it was observed 
there was a statistically significant inverse relationship between the intake of 
cruciferous vegetables (broccoli and cabbage) and bladder cancer risk. The common 
component of these vegetables is the sulfur containing glucosinolate compounds, which 
are capable of inducing detoxifying enzymes within the Phase II metabolism (as will be 
discussed later). Fruit and vegetables as a whole had no beneficial effect regarding 
bladder cancer, only the cruciferous group alone exhibited an effect. It was proposed 
that the chemicals within the broccoli and cabbage, namely glucosinolates, might exert 
the anti-carcinogenic affects regarding bladder cancer.
A study investigating the relationship of fruit and vegetable intake and prostate cancer 
risk evaluated the diets of 628 men in King County (Seattle area) newly diagnosed with 
prostate cancer and compared them with 602 men from the same population9. The men 
were evaluated using a questionnaire designed to assess their diet over the previous 
three to five year period before diagnosis or recruitment. The investigation reported 
statistically significant protective effects from prostate cancer through a diet high in 
vegetables. A decrease in risk of 35 % for prostate cancer when consuming 28 or more 
servings of vegetables per week compared to 14 servings or less. The reduced risk was 
increased to 41 % when eating 3 to 4 servings of cruciferous vegetables per week as 
compared to one serving or less. The interpretation of these results was that the 
substitution of other vegetables with cruciferous vegetables may significantly reduce the 
risk of prostate cancer. Once again the connection with glucosinolates and the 
cruciferous vegetables was made and it was suggested the upregulation of detoxifying 
enzymes by these chemicals may be responsible for the reduction in risk relating to 
prostate cancer.
Numerous studies have reported the protective effect of fruits and vegetables within 
diet; these observations have often been the result of studies examining populations that 
have already consumed relatively large proportions of fruit and vegetables. An 
investigation in central Sweden where the population consume relatively low quantities 
of fruit and vegetables and large amounts of cereal was undertaken10. It was put 
forward that the effect of fruits and vegetables on the risk of colorectal cancer could be
- 7 -
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identified with more certainty than in previous studies where participants had a diet rich 
in vegetables previous to the study. Over ten years a food frequency questionnaire was 
used to collect data from 61,463 women; 460 cases of colorectal cancer were reported. 
The results of the study indicated that individuals with very low fruit and vegetable 
intake were at most risk of contracting colorectal cancer. Also, consumption of large 
quantities of cereal does not lower the risk of cancer, however, an increase in fruit and 
vegetables in this group of individuals was beneficial and reduced the risk of colorectal 
cancer.
Lung cancer has also been studied regarding the quantity of fruit and vegetables 
consumed within the diet11. Again a food frequency questionnaire was used to collect 
data from 77,283 women and 47,778 men regarding their diet, 519 women and 274 men 
were diagnosed with lung cancer during the study. An inverse association was observed 
between fruit and vegetable intake for men who had never smoked and women (whether 
they had smoked or not). It was reported that the benefits among the never smokers 
were likely to be valid as they were not confounded by smoking or the negative 
behaviour's associated with smoking.
Table 1 shows a brief summary of the epidemiological studies discussed in this thesis, 
detailing the test undertaken, the materials used and the cohort size (giving a rough 
indication of the degree of confidence one can have in the results reported).
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Table 1; Summary of epidemiological studies and animal studies that correlate vegetable consumption 
and cancer.
Reference Material Test Cohort size
4 Fruit+Veg' Cancer incidence (Review o f studies)
7 Brussel Sprouts juice Treatment of Hep G2 
cells
n/a
8 Fruit+veg' Bladder cancer incidence 47909 men
9 Fruit+veg' Prostate cancer incidence 1230 men
10 Fruit+veg1 Colorectal cancer 
incidence
61463 women
11 Fruit+veg' Lung cancer incidence 77283 women 
47778 men
27 BITC Forestomach+pulmonary 
adenoma incidence
263 rats
28 BITC Forestomach+pulmonary 
tumour incidence
81 female A/J mice
31 PEITC Oesophagus tumours 90 male F-344 rats
32 PEITC Lung tumours 120 male F-344 rats
33 PEITC Lung+pancreatic tumours 180 female Syrian Golden 
hamsters
34 Sulforaphane Mammary tumours 143 female Sprague- 
Dawley rats
35 BITC, PEITC, PPITC Oesophageal tumours 285 male F-344 rats
36 BITC, PEITC, PPITC Oesophageal tumours 210 male F-344 rats
37 PHITC Oesophageal tumours 90 male F-344 rats
Despite reports detailing the reduced risk of contracting cancer through a diet high in 
fruit and vegetables it must not be forgotten that other environmental factors such as 
radiation, pollution and smoking have a direct impact on the risk of developing cancer.
Initiating factors of tumourigenesis
The phytochemicals found within fruits and vegetables have received substantial 
attention from the research community of late. Research has concentrated on their role 
in preventing diseases that result from the cell’s exposure to carcinogens, enzymes that 
initiate cancer, or free radicals involved in oxidative stress.
Free radical initiation
Free oxygen radicals associated with oxidative stress have been connected with 
numerous disorders including cardiovascular malfunction, cataracts, cancers and many 
other autoimmune diseases as well as ageing12. The purpose of the phytochemicals 
involved is to scavenge the free oxygen radicals within the cell, fulfilling the role of cell 
defence regarding radical attack. The threat free radicals pose is their extreme
- 9 -
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reactivity; they are unstable highly reactive molecules having unpaired electrons. 
Examples of these include superoxide (CV), hydroxyl (OH ), hydroperoxyl (HOO ), 
peroxyl (ROO) and alkoxyl (RO) radicals. In general, the free radical reacts quickly 
with the nearest stable molecule, effectively capturing the electrons required for its 
stability. The molecule the free radical has just attacked now finds itself deficient of an 
electron, and is itself a free radical, thus the chain reaction is initiated. Once in progress 
the process can cascade; the peroxidation of lipid membranes by this method results in 
destabilisation and disintegration of the membrane or other cell components (e.g. 
proteins and DNA). Oxidation of this nature can contribute to serious illness including 
cancer, kidney damage, atherosclerosis and heart disease.
Free radicals arise in the body through natural defence mechanisms and are used to 
neutralise viruses and bacteria. They are also generated by other external factors such 
as pollution, radiation, cigarette smoke and herbicides. Despite being useful when 
generated in the right quantities and locations, they can, when delivered in excess, cause 
serious cellular damage as observed with the external sources described. To combat this 
threat the body has a defence mechanism that involves the use of antioxidants. These 
molecules are able to neutralise the free radicals by donating an electron while 
remaining stable themselves, this terminates the free radical chain reaction. By 
quenching or stabilising the radicals in this way the antioxidants effectively preserve the
• * • • 19cell before a radical chain reaction is able to fatally damage the cell .
Antioxidants of this variety include flavonoids, Vitamin C and E and carotene, however, 
phytochemicals use other mechanisms to combat cell damage by preventing the 
enzymes or carcinogens from having their effect, while others interfere with the 
reproduction of cells already exposed to a carcinogen.
Glucosinolates: Structure, properties and origin
A family of chemicals that have received a substantial amount of attention over recent 
years is the group of compounds known as glucosinolates. As will be discussed later in 
this chapter, these compounds impart their anti-cancer properties by preventing the 
carcinogen from initiating tumour formation. These compounds are found in all
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members of the botanical family of Brassicas, among those are vegetables such as 
watercress, mustard and horseradish but mostly crucifers (Brussel sprouts, broccoli and 
cabbage). In particular, it is cruciferous plants that contain the highest concentrations of 
the active glucosinolates. Talalay and co-workers13 examined the glucosinolate content 
of young broccoli sprouts compared with mature broccoli plants, subsequently the 
potency of the respective extracts was examined regarding mammary tumour formation 
in dimethylbenz[a]anthracene-treated rats. This work revealed that young Broccoli 
sprouts contained 10-100 times higher levels of glucoraphanin (the glucosinolate 
precursor of sulforaphane) than the corresponding mature plants. It was also reported 
that the incidence, multiplicity and rate of development of mammary tumours in 
dimethylbenz[a] anthracene-treated rats was reduced significantly. The young cultivars 
were also detailed as containing very little of the indole glucosinolates (glucobrassicin 
and neoglucobrassicin) found in the mature plants. The indole glucosinolates may on 
degradation yield products that can enhance tumourigenesis. Thus, consuming small 
quantities of the young sprouts may impart greater protection against cancer as 
compared to a larger consumption of the mature plant of the same variety.
Structure
Glucosinolates are involved in the activation of detoxifying enzymes (glutathione-S- 
transferase and quinone reductase) that conjugate active carcinogens with endogenous 
ligands, neutralising their carcinogenic capabilities. The glucosinolates associated with 
the chemoprotective effects of these vegetables possess a common structure comprising 
a (3-D-thioglucose group, an anomeric thio-oxime sulfate functionality and a variable 
side chain (Fig 1) depending on the plant origin.
Figure 1; General structure of glucosinolates.
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The glucosinolates can be. grouped into three main groups, those containing an alkyl or 
allyl side chain and those containing an aromatic side chain (Fig 2)14. Until today 128 
structurally different glucosinolates have been isolated and characterised.
Relationships between glucosinolates and reductions in incidence and multiplicity of 
cancers through the increased consumption of cruciferous vegetables have been made. 
The glucosinolates are not the active compounds involved in activating the metabolism 
of carcinogens14. The glucosinolates undergo hydrolysis forming several products one 
of which is an isothiocyanate (Fig 3). It is these compounds which initiate the 
mechanisms that result in suppression of the active carcinogen or tumour.
Figure 2; Common structures of glucosinolates14.
Systematic name: Methylthiobutyl glucosinolate 
Common name: Glucoerucin
Origin: A. Thaliana
2-Hydroxy-3-butenyl glucosinolate
Progoitrin
A. Thaliana
OH
4-Hydroxy-3-indoylmethyl glucosinolate HO 
4-hydroxy-glucobrassicin HO
B. rapa
K+ -03S0
- 12-
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The presence of glucosinolate break down products has been shown to modify the 
nutritional behaviour of invertebrates and they could be regarded as natural pesticides. 
Plants containing high levels of glucosinolates have been reported to impair the growth 
of invertebrate herbivores, and the grazing of slugs and pigeons are significantly 
reduced in comparison with plants containing lower levels of glucosinolates. However, 
other herbivores have adapted and selectively feed on specific plants containing specific 
glucosinolates. Humans are also sensitive to the breakdown products of glucosinolates 
and these compounds are therefore important in determining the flavour of Brassicas. 
Allyl isothiocyanates are responsible for the hot flavours of mustard and horseradish, 
also, the glucosinolate (and breakdown products) sinigrin imparts the bitterness 
associated with Brussel sprouts14.
Properties
The role of the glucosinolates and their breakdown products is to protect the plant from 
attack by bacteria and fungi. Isothiocyanates the products of the glucosinolates exert 
anti-bacterial, anti-fungal and anti-protozoal properties. Investigations have focused on 
the glucosinolate content of oilseed rape in response to fungal infection, attack by turnip 
root fly (Delia floralis) and cabbage stem flea beetle (Psylliodes chrysocephala), as well 
as mechanical wounding15, 16 and 17. The studies concerned reported a decrease in 
aliphatic glucosinolates and an increase in aromatic glucosinolates, in particular the 
indole glucosinolates of the oilseed rape. These observations may be a direct response 
to the plant being attacked, further experiments are required to clarify this.
Consequently the compounds are commercially important to plant breeders who may
• 1R •want to modify the flavour of plants to cater for consumer preference , or to improve a 
plants disease resistance increasing the proportion of crop survival. Research into 
isothiocyanates and the plants they originate from was with regard to these issues 
initially, before it was realised they also possessed the anti-cancer properties highlighted 
above.
Origin
The isothiocyanates are released from the plant in response to infection or mechanical 
wounding. The glucosinolates are hydrolysed by the enzyme myrosinase yielding
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isothiocyanates as one possible product depending on the environmental conditions and 
the glucosinolate in question as depicted in figure 3.
The degradation of glucosinolates by the myrosinase enzyme has been investigated. 
Studies have shown that the glucosinolates are located in vacuoles19 contained within 
the cell, while the myrosinase is located in the cytoplasm of the myrosin cell (Figure
^ 1 4  and 20
Figure 3; General scheme of glucosinolate hydrolysis.
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Figure 4; M yrosin ce ll20.
Disruption of the cell results in the glucosinolate being exposed to the myrosinase, 
resulting in the cleavage of the glucosinolate yielding an aglycone.
Hydrolysis of glucosinolates.
The molecular structure of the myrosinase and mechanism of action has not been 
studied extensively, however, there have been two proposals as to the structure of the 
active site of the enzyme and process of hydrolysis. Cottaz suggests a simple 
mechanism with the active site containing two carboxylic acid groups one of which is 
deprotonated. The aglycone is cleaved as the deprotonated acid group attacks the 
anomeric carbon, subsequent hydrolysis of the anomeric ester releases glucose (Figure 
5, (a))21. Alternatively, Iori and co-workers postulate a more complex mechanism 
involving an active site comprising a deprotonated carboxylic acid, a protonated imine 
and cationic moiety. The deprotonated carboxylic acid attacks the anomeric carbon of 
the glucosinolate as before, however the protonated imine provides the proton to the 
cleaved aglycone. The cation is then involved in removing the sulfate group from the 
aglycone to yield the isothiocyanate and the hydrogen sulfate anion. The glucose ester 
formed in the initial step is hydrolysed using one molecule of water, releasing D- 
glucose and thus regenerating the active site in preparation for receiving the next 
glucosinolate molecule (Figure 5, (b))22. This intermediate is highly reactive and 
frequently undergoes Lossen rearrangement to form the isothiocyanate (Figure 6).
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As alluded to earlier, it is possible for other products to be formed in place of the 
isothiocyanates23 and 24. Despite the aglycone requiring a proton for the Lossen 
rearrangement, at lower pH’s the formation of the nitrile is observed14 and 25, the 
suggested mechanism for this reaction is shown in figure 7.
Figure 5; Postulated structure o f  the myrosinase active site and m echanism  o f  glucosinolate hydrolysis21
and 22
(a)
(b) Step 1
HS- < RN
oscv
HS04'
+
R -N = C = S
Step 2
-  16 -
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Figure 6; Lossen rearrangement o f  the aglycone.
H T  )  <- R -N = C = S  + HS04-
H^PaSO) 11
7
The precise mechanism of the enzymatic route of degradation is not clear. An 
investigation into the effects of pH and the ferrous ion on the enzymatic cleavage of 
glucosinolates was -undertaken25. The observations indicated that isothiocyanate 
formation was inhibited by pH values below 3.5 and by the presence of the ferrous ion 
at pH values below 5.5. However, the liberation of glucose was not inhibited by the 
ferrous ion, suggesting the myrosinase assisted cleavage of glucose is affected by pH 
alone, this may be attributed to the proton blocking the Lossen rearrangement. The 
ferrous ion is only involved in the rearrangement of the subsequent aglycone.
If the isothiocyanate contains a double bond and is in the presence of an epithiospecifier 
protein it is possible for it to rearrange to yield an epithionitrile (Figure 8 (a)). Also 
glucosinolates that contain a p-hydroxylated side chain spontaneously rearrange to form 
the cyclic oxazolidine-2-thiones (Figure 8 (b))14.
Figure 7; Proposed m echanism  for the enzymatic cleavage o f  glucosinolates25 to y ield  isothiocyanates or 
nitriles.
S— p-D-glucose 
R—C SO f + H20  + Myrosinase
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As depicted in figure 3, thiocyanates are also a possible product from the degradation of 
the glucosinolates, although only three of the natural glucosinolates appear to yield the 
thiocyanate. These are the allyl, benzyl and 4-(methylthio)butyl glucosinolates. 
Hasapis and MacLeod investigated the degradation of benzylisothiocyanate in heat 
treated Lepidium sativium seeds and attempted to detect a thiocyanate forming factor. 
In this study the seeds were dried over varying time periods and at different 
temperatures, the autolysates of the seeds were then analysed for the degradation 
products of the benzyl glucosinolate. Drying for 4.3 hrs at 125 °C was sufficient to 
prevent any formation of the thiocyanate, however, it required 7 hrs at this temperature 
to prevent the formation of the isothiocyanate. It may be concluded that a separate 
factor is present and responsible for the formation of the thiocyanates. It was proposed 
that thiocyanate factor is an isomerase which acts upon the aglycone causing a Z-E 
isomerisation around the C=N bond26. In the natural (Z) configuration the aglycone 
undergoes the Lossen rearrangement to give the isothiocyanate. If the isomerase causes 
the (E) configuration to be formed then the anionic sulfate 7 (Figure 3) would block the 
attack of R. These circumstances may force R to migrate to the sulfur instead and form 
the thiocyanate. This process would only occur if the R group were capable of forming 
a stable cationic intermediate. This is true of the three glucosinolates capable' of 
producing the thiocyanates. The rate at which the isomerase must perform the 
transition from (Z) to (E) must be sufficient to compete with the Lossen rearrangement, 
which is itself very rapid.
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Figure 8; (a) Isothiocyanate rearrangement in the presence of an epithiospecifier protein, (b) Cyclisation 
of 2-hydroxy-3-butenyl glucosinolate14.
(a) (b)
-S.
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2-Hydroxy-3-butenyl glucosinolate
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Small changes in the structure of these glucosinolate products are important regarding 
their properties. The major flavour in Eruca sativa (rocket salad), 4-methylthiobutyl 
isothiocyanate (eracin) is volatile and pungent, while methylsulfinylalkyl glucosinolates 
are non-volatile and mild in flavour (for example the flavour associated with broccoli). 
Also the removal of the methylsulfinyl group and the addition of a double bond results 
in a volatile isothiocyanate.
Inhibitory effects of the glucosinolates and isothiocyanates
Numerous studies investigating the anti-cancer effects of fruits and vegetables have 
alluded to the glucosinolates and isothiocyanates as being the possible source(s) for the 
anti-cancer activity observed. The logical step in this line of research is to examine the 
anti-cancer effects of the glucosinolates/isothiocyanates themselves.
The inhibitory effects of benzyl and phenylethyl isothiocyanate has been investigated 
with respect to tumour formation in female Sprague-Dawley rats fed with a 
carcinogenic compound, either 7,12-dimethylbenz[a]anthracene (DMBA) or 
benzo[a]pyrene (BP)27. The isothiocyanates were fed to rats four hours prior to the dose 
of carcinogen as part of a controlled diet. In parallel, rats were fed the carcinogen or the
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controlled diet alone. After 20 weeks the rats were examined for both mammary 
tumours and pulmonary tumours. Wattenberg reported the administration of benzyl and 
phenylethyl isothiocyanates to female Sprague-Dawley rats was beneficial, although not 
preventing tumour formation they did dramatically reduce the formation of both 
mammary and pulmonary tumours.
After establishing that benzyl isothiocyanate did inhibit the formation of pulmonary and 
mammary tumours, Wattenberg studied its effects with regard to forestomach tumours 
in female A/J mice against diethylnitrosamine (DEN) and BP, thus illustrating that 
benzyl isothiocyanate is effective against different carcinogens and with respect -to 
different cancers. The mice were fed a controlled diet, once again a proportion of the 
mice were fed a carcinogen (20 mg/kg DEN and 2 mg BP), some were fed benzyl 
isothiocyanate (1 mg) 15 minutes prior to the carcinogen and some were fed the 
controlled diet alone as a control. The mice were sacrificed 26 weeks after the 
administration of the carcinogen and stomachs were examined for tumours. The study 
found that benzyl isothiocyanate did inhibit the formation of forestomach tumours 
regarding DEN and BP. Also, a higher concentration of benzyl isothiocyanate was 
administered to a proportion of mice dosed with BP, these mice showed a further 
decrease in the incidence of forestomach tumours suggesting the inhibition of tumour 
formation may be dose dependant28.
Further to establishing that A/J mice lung tumours are inhibited by treatment with 
benzyl isothiocyanate Hecht and co-workers have investigated the effects of benzyl 
isothiocyanate on DNA adduct formation in the A/J mouse29. The aim of this study was 
to establish whether it was the inhibition of the BP metabolism that prevents DNA 
adducts from forming. It has been suggested that the formation of DNA-adducts is an 
initiation event in tumourigenesis. Female A/J mice were maintained on controlled 
diets before being treated with benzyl isothiocyanate or phenylethyl isothiocyanate. 
After 6 hrs the mice were sacrificed and the lungs used to prepare microsomal 
preparations. These were treated with BP and incubated for 20 minutes at 37 °C. The 
samples were then worked up and analysed for metabolites of the BP. Both the benzyl 
and phenylethyl isothiocyanate inhibited the formation of BP metabolites. Mice were 
also administered BP alone or BP with either benzyl or phenylethyl isothiocyanate.
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After 9 weeks a group o f the mice were administered a further treatment o f BP, at 
intervals after the treatment the mice were killed. Two further groups were treated w ith 
a further dose o f isothiocyanate followed by BP, again the mice were killed  at intervals. 
DNA was isolated from the mice and hydrolysed releasing any BP-tetraols bound (Bp 
metabolites), these were isolated and identified using HPLC and fluorimetry, (the 
fractions were compared to BP-tetraol standards). This experiment indicated that the 
isothiocyanates did reduce the degree to which DNA adducts were formed. These 
results do indicate that the isothiocyanates involved prevent the metabolism o f BP into 
its active metabolites, thus preventing the creation o f a DNA adducts and the future 
development o f lung tumours in  A/J mice.
A  similar experimental design using a mixture o f BP and 4-(nitrosomethylamino)-l-(3- 
pyridyl)-l-butanone (NNK) as found in tobacco smoke. Once again the benzyl and 
phenylethyl isothiocyanates reduce the formation o f DNA adducts. The effects were 
modest and mechanisms other than the modification o f DNA were reported as being 
contributory factors for lung tumours30.
The inhibitory effects o f phenylethyl isothiocyanate (PEITC) w ith  regards the 
oesophageal tissue o f rats have been investigated, Stoner and co-workers fed F-344 rats 
a diet containing PEITC (3+6 pmol/g diet) over a period o f two weeks before 
administering a dose (0.5 mg/kg body weight) o f N-nitrosobenzylmethylamine 
. (NMBA) once a week for 15 weeks. The rats were then sacrificed and the oesophagus 
examined for preneoplastic and neoplastic lesions. Also, the oesophagi o f rats were 
removed and oesophageal explants prepared. The explants were then treated w ith 
PEITC and NM BA or NM BA alone and incubated for a period o f 12 hrs. Subsequently 
the DNA was isolated from the oesophagus explants and hydrolysed to cleave any 
DNA-adducts, the hydrolysates were analysed using HPLC and the fractions identified 
(i.e. DNA and cleaved adducts). The results o f this study reveal that PEITC is a potent 
inhibitor o f NM BA in  the oesophagus o f F-344 rats w ith 3 and 6  pmol/g causing a 99 
and 100 % inhibition in the m ultip licity o f NM BA induced tumours respectively. 
PEITC also inhibited the formation o f DNA adducts31.
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The anti-cancer properties o f PEITC have also been studied w ith regard to the lung o f 
F-344 rats. The rats were fed a controlled diet containing PEITC (3 pmol/g diet) for 21 
weeks, after the first week N NK (1.76 mg/kg body weight) was administered three 
times a week for 20 weeks, after 104 weeks the experiment was terminated and the rats 
examined. In parallel a group o f rats were fed a diet only containing the NNK, while 
another group was fed a diet without either the NNK or PEITC. DNA-adduct assays 
were also undertaken involving a group o f rats being fed a range o f diets containing 
variable quantities o f PEITC over 2 wefcks. The last four days involved the 
administration o f NNK (2.4 mg/kg body weight containing 0.5 mCi [3H-CH3] NNK and 
2.5 mCi [5-3H] NNK. Four hours after the last dose o f NNK the rats were sacrificed 
before the DNA was isolated from the liver, lung and nasal mucosa. The samples were 
purified and then subjected to acid hydrolysis, the hydrolysates were isolated and 
identified using HPLC and a radioflow detector. On examination o f the rats it was 
revealed that only the lung benefited from the protective effects o f the PEITC w ith a 50 
% reduction in tumours being reported. Consistent w ith these findings, a reduction in 
DNA adduct formation in the lung was reported when rats were exposed to PEITC32.
The chemopreventative effects o f PEITC have been investigated w ith respect to 
pancreatic and lung tumours o f hamsters when treated w ith N-nitrosobis(2- 
oxopropyl)amine (BOP). Four groups o f Syrian golden hamsters were taken and fed a 
controlled diet. The first group was given a 100 or 10 pmol PEITC followed two hours 
later by BOP (20 mg/kg body weight), the second group was given BOP alone, the third 
group was administered PEITC (100 or 10 pmol) alone and the fourth group was given 
com o il alone as a control. This was repeated at seven day intervals, after 52 weeks the 
experiment was terminated and the hamsters sacrificed and autopsied. The incidence 
and m ultip lic ity o f tumours in both the lung and pancreas was reduced dramatically by 
treatment w ith PEITC33.
Q u a n tita t iv e  s tr u c tu r e -a c tiv ity  r e la tio n sh ip s  o f  iso th io c y a n a te s
Not only aryl isothiocyanates have been reported as being inhibitors o f tumours, the
isothiocyanate sulforaphane (comprising a four carbon alipahatic chain terminated with 
a methylsulfmyl moiety) has also been reported as being a potent anti-cancer agent34.
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The properties o f sulforaphane have been investigated w ith respect to mammary tumour 
development in  Sprague-Dawley rats. The rats were fed a controlled diet before being 
split into 7 groups one o f which was a control group. Over a five day period the six 
treatment groups o f rats were treated w ith a dose o f sulforaphane or an analogue o f 
sulforaphane (Figure 9) (approx. 100 pmol) once every day. On the fourth day o f 
treatment 3 hrs after administration o f the isothiocyanate all rats were given a dose o f 
9,10-dimethyl-1,2-benzanthracene (DMBA). The rats were monitored for a further 152 
days before sacrifice and autopsy.
The results o f this study clearly show that all compounds when administered before the 
exposure to DM BA reduce to varying degrees the incidence, m ultip licity and weight o f 
tumours. However, sulforaphane 18 and 19 were the most potent exhibiting a greatly 
reduced incidence o f tumours (approx. 30 %) as compared to 2 0  and 21 with 40 % 
incidence o f tumours34.
Figure 9; Sulforaphane and analogues 
O
34
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endo-2-acetyl-exo-6-isothiocyanatonorbomane exo-2-acetyl-exo-5-isothiocyanatonorbornane 
20 21
Clearly the synthesis and assessment o f natural isothiocyanate analogues when in the 
process o f identifying potentially potent and effective anti-cancer materials is useful and 
may uncover a material w ith a higher efficacy than the natural materials at present. 
Thus it may be possible to establish some structure activity relationships. Stoner and 
co-workers have investigated the inhibition o f NM BA induced oesophageal 
tumourigenesis using arylallcy isothiocyanates o f different chain length35. Male F-344
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rats fed a controlled diet were divided into groups two o f which were used as controls 
and only exposed to the control feed or NMBA. The remaining groups were treated 
with one o f the follow ing isothiocyanates; benzyl isothiocyanate (BITC), PEITC, 3- 
phenylpropyl isothiocyanate (PPITC) and 4-phenylbutyl isothiocyanate (PBITC). The 
rats were treated over a 25 week period, for 15 weeks commencing in the second week 
the rats were administered N M BA (0.5 mg/kg body weight) once a week. A fter the 25 
week period the rats were sacrificed and autopsied. The result o f this work reported that 
while BITC and PBITC did not exhibit any inhibitory effect, both PEITC and PPITC 
exhibit potent inhibitory effects reducing incidence and m ultip lic ity o f oesophageal 
tumours and to a small degree appear to be dose dependant in their effect.
In order to establish the efficacy o f the PPITC w ith regard to other potent carcinogens 
such as N ’-nitrosonomicotine (NNN) a further study was established to investigate this 
point. Over a period o f 87 weeks male F-344 rats were fed controlled diets; one group 
was fed unadulterated water and a controlled diet, while another group was fed water 
containing NNN and the controlled diet. The remaining rats were fed adulterated water 
and a diet containing PPITC. A fter the 87 week period the rats were sacrificed and the 
oesophagi examined for lesions. The findings o f this study were that the incidence, 
m ultip licity and size o f tumours were decreased dramatically36. Although these results 
are not conclusive and it would need to be established that PPITC was effective against 
other carcinogens and other types o f cancer, however, PPITC does look promising as a 
potent anti-cancer compound.
The body o f work discussed here is impressive and isothiocyanates clearly have 
potential in offering a highly efficacious material or combination o f materials capable o f 
inhibiting carcinogens at different sites o f the body susceptible to cancer. However, it  is 
important to highlight that not all isothiocyanates are anti-carcinogenic in  nature, a 
number o f isothiocyanates have been classified as carcinogenic themselves, as w ill be 
discussed in the follow ing section.
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I so th io c y a n a te  to x ic ity
The dietary effects o f 6 -phenylhexyl isothiocyanate (PHITC) on NM BA induced 
oesophageal tumours was investigated. Six groups o f male F-344 rats were fed 
controlled diets, the first contained the controlled feed alone, the second contained 
NM BA (0.5 mg/kg body weight), the remaining groups contained varying 
concentrations o f PHITC. A fter two weeks o f administering the PHITC the NM BA was 
added to the rats diets once a week for the follow ing 15 weeks. A fter a total o f 21 
weeks the rats were sacrificed and the oesophagi removed and examined for tumours. 
In contrast to the other isothiocyanates o f similar structure the PHITC appeared to 
promote tumour m ultip licity in the rats exposed to NM BA in a dose dependant fashion, 
all rats exposed to PHITC and N M BA developed tumours37,
Kassie and Knasmuller have performed several experiments aimed at resolving the 
genotoxicity o f a lly l isothiocyanate38. Assays employed have included a 
Salmonella/microsomQ assay and a differential DNA repair assay. The 
Salmonella/micvosomQ test (Ames test) involves inoculating a nutrient agar plate 
(containing no histidine) w ith S. typhimurium bacteria strains TA 98 and TA 100 (which 
are unable to synthesise histidine), these bacteria have been exposed to an 
isothiocyanate, the plate is then incubated. A  control plate is also prepared w ith bacteria 
that have not been exposed to the test compound. The a llyl isothiocyanate did induce 
the bacteria to mutate at an increased rate compared to the control plate and thus can be 
considered to be mutagenic in  nature. The differential DNA repair assay takes two 
strains o f E. coli which d iffer vastly in  their ability to repair DNA, The two strains are 
exposed to the test compound and are used to inoculate nutrient agar before incubating. 
This test was performed using varying concentrations o f a lly l isothiocyanate. The 
results o f this study show the a lly l isothiocyanate to be genotoxic in  a dose dependent 
manner.
Musk and co-workers has investigated the potential for BITC to be carcinogenic. Their 
studies involved exposing Chinese hamster ovary cells to BITC in  concentrations from 
0.3-1.5 pg/ml and observing their survival rate39. The survival rate o f the cells was 
reduced by the BITC in a linear dose dependent manner.
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These studies illustrate that all isothiocyanates are not anti-carcinogenic and in fact 
appear to be carcinogens in their own right. It is important to analyse the 
isothiocyanates biological characteristics fu lly  and identify the particular compounds 
that exhibit the desired anti-cancer properties and do not possess any other detrimental 
mode o f action.
I so th io c y a n a te  p a th w a y ; in g e s t io n  th r o u g h  to  ex cre tio n
The studies described above concerning those isothiocyanates showing promise have 
illustrated they do inhibit the formation o f tumours and their participation in  such a 
process may involve the inhibition o f the carcinogen’s metabolism. As described 
earlier, isothiocyanates have been shown to prevent the formation o f DNA-adducts, the 
production o f these adducts are thought to be an in itia l phase in the mutation o f a cell's 
DNA and subsequent development o f a tumour. The ultimate aim o f this research area 
is to identify the most potent material(s) we can safely use to protect the body from 
carcinogens and thus prevent the formation o f cancers. The route o f 
administration/absorption into the body and the role o f the material w ithin the body’s 
metabolism must be evaluated. To understand the mode o f action and mechanisms 
involved, it must first be established how the glucosinolates/isothiocyanates are 
absorbed into the body from our diet. Do they remain intact to impart their anti-cancer 
properties or are they metabolised into an ‘active’ species?
In g e s t io n  a n d  h y d ro ly s is
Before examining how or where the glucosinolates are absorbed into the body it would 
be prudent to establish whether the microflora found in  the digestive tract are capable o f 
modifying the compounds in question. It can then be ascertained as to whether the 
glucosinolates are absorbed into the body intact or not.
Marangos and H ill discovered that glucosinolates present in  rapeseed were hydrolysed 
by the intestinal contents o f poultry, in particularly the contents o f the caecum were 
found to be most active40. Also, the activity was found to be isolated in  the particulate 
fraction o f the caecum contents suggesting the hydrolysing activity was to be found in  
the bacteria present in  the caecum and not the supernatant liquid contained therein.
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Further work attempted to identify the particular bacteria found in faeces that possess 
the myrosinase activity. This was studied by incubating 2-hydroxybutenyl 
glucosinolate w ith faecal bacteria and individual strains o f bacteria known to be 
contained w ithin faeces. The study did illustrate that the bacteria hydrolysed the 
glucosinolate into the corresponding isothiocyanate, however, the focus o f their 
investigation was not realised as it was not one particular bacteria providing the 
myrosinase activity but many different bacteria contained w ithin the microflora. The 
bacteria demonstrating the greatest degree o f myrosinase activity was E. Coli and 
Paracolbactum aerogenoides, Paracolbactum coliforme and Paracolbactum sp41.
Campbell performed a series o f experiments that involved hydrolysing intact 
glucosinolates w ith faeces from normal laying hens and hens that have been 
caecectomised42. The results indicated that concentrations o f recovered intact 
glucosinolates were low in the faeces and the concentration o f intact glucosinolates was 
also low in the blood analysis suggesting the glucosinolates had been modified 
(hydrolysed). The products were identified as isothiocyanates and the contents o f the 
caecum and caecum-colon proved to be the major source o f hydrolytic activity.
A  later study also investigated the ability o f bacteria to hydrolyse the glucosinolates to 
isothiocyanates43. B. thetaiotaomicron was used to convert sinigrin to the allyl 
isothiocyanate or a lly l cyanide. Germ free F-344 rats were fed a controlled diet 
containing B. thetaiotaomicron before administering a 50 pmol dose o f sinigrin, the 
treated groups o f rats were killed at intervals up to 36 hrs after administration o f the 
glucosinolate. In parallel a group o f rats were fed on a diet not containing the B. 
thetaiotaomicron and used as a control. The contents o f the stomach, small intestine, 
caecum and colon were collected separately, extracted and analysed for a lly l 
isothiocyanate and the a llyl cyanide using gas chromatography (GC)-mass spectrometry 
analysis. Neither the a llyl isothiocyanate or the allyl cyanide was detected in  the 
gastrointestinal tract o f the control rats, nor was the a llyl cyanide detected in  the treated 
rats. A lly l isothiocyanate was detected in large concentrations in  the colon and the 
caecum at 12 hrs, correspondingly the largest populations o f B. thetaiotaomicron were 
found at the same sites. These results indicate and confirm the bacteria found in the
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gastrointestinal tract are capable o f hydrolysing the glucosinolates and are found in  the 
colon and caecum. The period after 12 hrs exhibited a decrease in the level o f AITC, 
suggesting the AITC may be absorbed in the Caecum and colon. Also, the environment 
in which the glucosinolates are hydrolysed is not favourable for the formation o f the 
cyanide, which requires acidic conditions.
The microbial metabolism o f glucosinolates has again been investigated using a 
dynamic in vitro model designed to m imic the human colon44. The model uses 
peristaltic movement to m ix the contents, an anaerobic enviromnent is maintained by 
flushing w ith nitrogen and the pH was adjusted to 5.8. The system was inoculated w ith 
human microflora before feeding sinigrin or myrosinase-deactivated Brussel sprouts, 
the contents o f the lumen were then analysed using GC-mass spectrometry for AITC. A  
control experiment was performed using inactivated microflora, analysis indicated the 
absence o f AITC. The results show over a 12 hr period the levels o f sinigrin decrease 
steadily to zero, concurrently the levels o f AITC were foimd to be increasing and 
reached a maximum after 24 hrs. The Brussel sprout experiment gave sim ilar results, 
the sinigrin concentration decreased at a slower rate and s till remained in the lumen 
after 36 hrs, the AITC increased in concentration in a similar fashion to sinigrin 
experiment and attained a maximum concentration after 24 hrs. The study again 
illustrates human bacteria contained in  the microflora o f the gastrointestinal tract are 
capable o f hydrolysing the glucosinolates into the isothiocyanates.
This body o f work details the ability o f bacteria found in the human gut to hydrolyse 
glucosinolates in  the same fashion that myrosinase does in plants yielding the 
appropriate isothiocyanate. The colon and caecum have been identified as the sites 
where these bacteria are found and are the sites where the hydrolysis takes place. Once 
formed the concentration o f isothiocyanates in  the caecum and colon decreases over a 
period o f time43. One may deduce from these results that glucosinolates or 
glucosinolates contained w ithin food once ingested can be hydrolysed by the m icroflora 
present and the resulting isothiocyanates may then be absorbed into the body through 
the gastrointestinal tract.
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Although not proven conclusively, isothiocyanates have been shown to be the materials 
absorbed into the body after the hydrolysis o f the glucosinolate in  the gut. Once 
absorbed the isothiocyanates are able to take effect on the body’s metabolism and 
potentially modify the metabolism o f carcinogens w ithin the body.
T h e  b o d y ’s m e ta b o lism  o f  ca rc in o g en s; p h a se  I  +  I I
Before embarking on any discussions relating to the mechanism by which the 
isothiocyanates impart their anti-cancer properties (via the metabolism o f the 
carcinogens), it would be sagacious to describe the metabolism in the body. The 
forthcoming insight into metabolism o f the body w ill be brie f and w ill concern mainly 
the P450 isoenzymes and the glutathione transferases (GST), which the isothiocyanates 
interact with.
The routes by which drugs or xenobiotics may be metabolised (or transformed) are 
numerous and diverse and include the follow ing reaction types; oxidation, reduction, 
hydrolysis, hydration, conjugation and condensation. The metabolism o f a material can 
be split into two phases, phase I  (functionalisation o f the compound) and phase II 
(conjugation o f the compound). The reactions associated w ith the two phases are 
summarised Table 2.
Table 2; Summary of reactions involved in Phase I + II45.
Phase I Phase II
Oxidation Glucoronidation/glucosidation
Reduction Sulfation
Hydrolysis Methylation
Hydration Acetylation
Dethioacetylation Amino acid conjugation
Isomerisation Glutathione conjugation
Fatty acid conjugation
Condensation
The reactions o f phase I  metabolism functionalise the drug or xenobiotic, this is thought 
to be in preparation for phase II  reactions. The intimation is that phase I metabolism 
yields functional groups which the phase II  metabolism exploits. Phase II  metabolism
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produces materials which are deactivated and inert w ith respect to the body, this 
pathway is referred to as the ‘detoxification’ pathway as drugs, xenobiotics and 
endogenous compounds are transformed into inactive materials which are excreted w ith 
ease, thus detoxifying the body. Reactions o f both phase I + II  may take place on the 
same compound resulting in  reactions o f the two phases competing for the same 
substrate.
Phase I  metabolism.
The reactions o f phase I are listed in  table 2, the most important group o f 
transformations are the oxidation reactions involving the microsomal mixed-function 
oxidase system (cytochrome P450 dependant). This enzyme system is able to perform 
an extensive and diverse range o f reactions.
The mixed-function oxidase system (MFO) is found in microsomes (endoplasmic 
reticulum) o f many cells throughout the body, although a concentration o f the enzymes 
are found in  the liver, kidney, lung and intestine where you may expect the metabolism 
o f compounds to take place. The many reactions the MFO is capable o f performing are 
listed in  table 3 along w ith an example o f a drug or xenobiotic as a substrate.
A ll the reactions require the presence o f oxygen and NADPH as w ell as a complete 
mixed function oxidase system (cytochrome P450, NADPH-cytochrome P450 reductase 
and lip id). A  single oxygen atom is inserted into the substrate before a subsequent 
rearrangement or decomposition (this is not always necessary) yielding the final 
product. Figure 10 represents the hydroxylation o f a substrate (RH) and ROH the 
hydroxylated metabolite. During the reaction reducing equivalents o f NADPH and H+ 
are consumed and one atom o f oxygen is incorporated into the substrate while the other 
oxygen is reduced to water.
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Table 3; List of reactions performed by MFO.
Reaction Substrate
Aromatic hydroxylation Lignocaine 23
Aliphatic hydroxylation Pentobarbitone 25
Epoxidation Benzo[a]pyrene 27
N-Dealkylation Diazepam 29
O-Dealkylation Codeine
S-Dealkylation 6 -Methylthiopurine
Oxidative deamination Amphetamine 31
N-Oxidation 3-methylpyridine 33
2 -Acetylaminofluorine
S-Oxidation Chlorpromazine 35
Phosphothionate oxidation Parathion 37
Dehalogenation Halothane 39
Alcohol oxidation Ethanol
The cytochrome P450 integral to the MFO is one element in  an electron transfer system 
present in the endoplasmic reticulum, responsible for the oxidation o f many compounds. 
The enzyme is classed as haem-containing w ith iron protoporphyrin IX  as a prosthetic 
group (figure 11). This group is non-covalently bound to the enzyme, the name is 
derived from the observation that cytochrome (pigment) exhibits a spectral absorbance 
maximum at 450 nm when complexed w ith carbon monoxide. The MFO system has 
been studied and the process elucidated, however, it is inappropriate in  this instance to 
explain the intricacies o f the process. The system is delineated in numerous 
publications including ‘Introduction to drug metabolism’45.
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Figure 10; Generalised reaction involving MFO45.
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Figure 11; P450 prosthetic group: ferric protoporphyrin IX .
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Table 4 describes the reactions o f the MFO, the number o f individual reactions are too 
numerous to sensibly detail, however, table 4 gives a flavour o f the enormous capability 
o f the enzyme system.
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Table 4; Illustration of MFO transformations.
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Table 4 cont'd
Reactions other than those involving MFO are depicted in  table 5, most o f these 
transformations do not concern the metabolism o f drugs or xenobiotics but endogenous 
compounds. This however, is no indication that MFO only relates to drag or xenobiotic 
metabolism, the enzyme system is known to be involved in the biosynthesis o f steroids. 
Indeed P450s are integral for the conversion o f cholesterol to pregnolone, which can 
subsequently be transformed into aldosterone, oestrone or testosterone. A  number o f 
the steps required to achieve these transformations axe also dependent, on the P450 
enzymes. The MFO system is not restricted to this biosynthetic process and is involved 
w ith the activation o f vitamin D and the synthesis o f prostaglandins.
As indicated earlier, once the compound in question has experienced phase I  reactions it 
w ill have been converted into a material that is able to undergo one or more o f the
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conjugation reactions that constitute phase II  metabolism. The resulting material w ill 
generally be water-soluble and can be excreted in  the bile or urine.
Table 5; Phase I reactions not involving MFO.
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Table 5 continued.
Phase II  metabolism.
As found w ith phase I  metabolism, phase II  metabolism comprises many and various 
routes available for the metabolism o f a compound. The different classifications o f 
conjugation utilised w ithin phase II  metabolism are given in  table 6 . Plainly there are a 
plethora o f reactions w ithin the umbrella o f phase I I  metabolism. For the purpose o f 
this review glutathione conjugation w ill be the only reaction discussed in  further detail, 
however, one must remain aware that this is not the only route o f phase I I  metabolism’
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Many compounds including drugs and xenobiotics are converted into strong 
electrophiles during phase I  metabolism, these can react w ith glutathione to form, in 
general, non-toxic conjugates.
Table 6; Classification of reactions utilised in phase II metabolism.
Reaction Enzyme Functional group involved
Glucoronidation UDP-Glucoronyltransferase -OH
-COOH
-n h 2
-SH
Glycosidation UDP-Glycosyltransferase -OH
-COOH
-SH
Sulfation Sulfotransferase -n h 2
-s o 2n h 2
-o h
Metkylation Methyltransferase -OH
-n h 2
Acetylation Acetyltansferase -n h 2
-s o 2n h 2
-OH
Amino acid conjugation -COOH
Glutathione conjugation Glutathione-S-transferase Epoxide 
Organic halide 
-OH
Condensation Various
These observations have led to glutathione being recognised as a protective compound 
w ithin the body able to potentially remove toxic electrophiles w ithin the body. The 
glutathione conjugation involves glutathione (GSH), a tripeptide (figure 11a), in a 
reaction w ith an electrophile. The whole reaction is catalysed by glutathione transferase 
(an enzyme found in  the cytosol o f the tissues o f the body, mainly the liver, kidney and 
gut). Figure l ib  provides an example o f the conjugation reaction, the product o f which 
may be excreted from the body usually in the bile but can also be metabolised further to 
yield the N-acetylated cysteine conjugate or mercapturic acid derivatives as illustrated. 
The glycylcysteine, cysteine and mercapturic acid conjugates are commonly found as
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the final excretion products. Hiis is not necessarily die complete metabolic process, for 
sulfur containing conjugates such as 2-acetamido-4-(chloromethyl)-thiazole or caffeine 
a further transformation is possible. The enzyme C-S-lyase found in the intestinal 
microflora is capable o f separating die glutathione conjugate transferring the -SH group 
from the glutathione to the substrate. The compound is methylated before being 
reabsorbed into the body, the material is then oxidised in the liver before excretion 
(Figure 12). This extension o f the metabolism may be thought o f as a third phase, 
although it is evident that this route o f metabolism is restricted to those sulfur- 
containing compounds.
Figure 11a; Structure of the tri-peptide glutathione.
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Figure lib; Example of glutathione conjugation and subsequent metabolism.
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As with the P450’s that comprise die phase I metabolism die glutadiione-S-transferases 
are not restricted to the metabolism o f drug or xenobiotic compounds. GST is known to 
catalyse reactions that constitute die biosynthesis o f the prostaglandin like leukotrienes 
(derived from aracliidonic acid)45.
Background Chapter 1
This is a very b rie f summary o f drug or xenobiotic metabolism but it is clear that the 
process as a whole is made extremely complex by the shear number o f different routes 
available for both phase I  and I I  metabolism. Phase I  metabolism (occurring in  the 
endoplasmic reticulum o f cells) functionalises compounds and provides electrophiles 
for the subsequent phase II  metabolism (performed in the cytosol o f the cell), where 
compounds are conjugated w ith GSH. The conjugated product is excreted or 
metabolised further before excretion in  the form o f a cysteine conjugate or mercapturic 
acid. The enzymes utilised in  the process are also involved w ith metabolising 
endogenous compounds. These compounds compete w ith the drugs and xenobiotics for 
the enzymes, the result o f these interactions may be the toxic or pharmacological effects 
observed for the respective compounds.
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Figure 12; Phase II + III metabolism of 2-acetamido-4-(chloromethyl)thiazole. 
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Metabolism of isothiocyanates
Having an appreciation for the metabolism o f the body has lead investigations to study 
how the isothiocyanates interact w ith the metabolic pathway. Do they influence the 
metabolic pathway directly or are they themselves metabolised before imparting any 
effect on the metabolism o f other materials? Studies have examined whether
-40-
Background Chapter 1
isothiocyanates are metabolised or not, by analysing the metabolic products found in 
urine and faeces.
Brusewitz and co-workers46 investigated the metabolic fate o f benzyl isothiocyanate in 
W ilstar rats establishing a new fam ily o f compounds able to be metabolised by the 
mercapturic acid pathway. GSH, cysteine and cysteinylglycine conjugates o f benzyl 
isothiocyanate were added to rat liver or kidney homogenate and incubated (37 °C) for 
30 minutes. In addition, benzyl isothiocyanate and GSH were added to the 
homogenates and incubated. The precipitate formed was isolated by centrifugation, the 
supernatant was concentrated and subjected to t.l.c. using reference compounds for 
comparison. The results o f the chromatography indicated that the test compounds had 
been converted to the mercapturic acid, suggesting they had been metabolised through 
the mercapturic acid pathway. In parallel, W ilstar rats were administered the conjugates 
o f benzyl isothiocyanate as w ith the in vitro study. The faeces and urine were then 
analysed using chromatography for the metabolic products. The chromatography 
revealed the metabolic product to be mercapturic acid derivatives o f BITC once again, 
there was no indication o f any other conjugation products present. This is perhaps a 
little  surprising as Figure 13 illustrates, there are a number o f intermediate conjugate 
products which would be suitable for excretion in  preference to further metabolism. 
These results reinforced tire in vitro study, the benzyl isothiocyanate and its conjugates 
are metabolised via the complete mercapturic acid pathway before excretion.
The metabolism o f benzyl isothiocyanate has also been investigated using guinea pigs 
and rabbits47. The GSH (50 mg), cysteineglycine (50 mg) and cysteine (12 mg) benzyl 
isothiocyanate conjugates in addition to benzyl isothiocyanate (5 mg) were administered 
to male Pirbright white guinea pigs in the form o f mucilage. White Wiener rabbits were 
fed mucilage containing 30 mg benzyl isothiocyanate or 60 mg cysteine conjugate. The 
urine and faeces o f both groups o f animals was collected and analysed for metabolites 
using chromatographic techniques. It was apparent that the metabolite collected was 
not the mercapturic acid expected. After isolation and analysis using H 1 TsIMR it was 
established that the material was 4-hydroxy-4-carboxy-3-benzylthiazolidin-2-thione 
(figure 14). It was proposed that the benzyl isothiocyanate had conjugated w ith 
mercaptopyruvic acid before enolisation o f the conjugate to yield the
-41 -
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benzylthiazolidinethione. Besides highlighting the observation that metabolic products 
are not common to all animals and can differ from one animal to another, the study also 
illustrates that the benzyl isothiocyanate experiences the metabolism o f the guinea pig 
and rabbit to yield the cyclic mercaptopyruvic acid conjugate 82.
Figure 13; Mercapturic acid pathway for benzyl isothiocyanate in Wilstar rats.
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Figure 14; Cyclic mercaptopyruvic acid conjugate47.
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Further to their previous investigation Menniclce and co-workers 48 studied the 
metabolism o f isothiocyanates other than benzyl isothiocyanate. Methyl, ethyl, butyl 
and a lly l isothiocyanate (10 mg dose) was administered to male W ilstar rats, the urine
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and faeces o f the rats was collected. The metabolites were identified using t.l.c and lH 
NMR. The only compound to be identified was the corresponding dithiocarbamidic 
acid esters. The thioester bond o f the mercapturic acids was postulated as being too 
unstable, however, the existence o f the dithiocarbamidic acid esters suggests that the 
isothiocyanates employed are also metabolised.
Bollard and co-workers49 have also investigated the metabolism o f a lly l isothiocyanate 
in F-344 rats. The isothiocyanate was administered to the rats (2.5 mg/kg body weight 
per day) for a period o f 103 days before sacrifice. The rats were analysed for 
isothiocyanate and its metabolites. A t this concentration the observation was that the 
isothiocyanate had been metabolised to the cysteine conjugate and the mercapturic acid. 
The paper also reported a more worrying result, the allyl isothiocyanate and its 
conjugate products were found to be carcinogenic at higher concentrations.
The metabolic fate o f the isothiocyanate sulforaphane was investigated in male 
Sprague-Dawley rats. The animals were dosed w ith sulforaphane (50 mg/kg body 
weight), urine and bile was collected for the follow ing 24 hrs. The metabolic products 
were identified using HPLC-MS and NMR. The results indicated the isothiocyanate 
had been conjugated w ith GSH and metabolised into mercapturic acid. The metabolic 
fate o f sulforaphane is similar to that o f other isothiocyanates in  that it is metabolised 
via the mercapturic acid pathway to yield the excreted product (N-acetylcysteine 
conjugate)50.
These studies have proven that isothiocyanates do experience the body’s metabolism 
and are conjugated w ith GSH before a further metabolism into the cysteinylglycine, 
cysteine and N-acetylcysteine conjugates, which comprise the mercapturic acid 
pathway. This indicates that isothiocyanates may impart their anti-cancer properties as 
a metabolised product (mercapturic acid).
Iso th io c y a n a te s  a n d  th e ir  m o d u la tio n  o f  m e ta b o lism
The isothiocyanates have been established as the materials absorbed and subsequently 
metabolised by the body. Knowing o f  their anti-carcinogenic properties when
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administered as a constituent o f a vegetable or as a separate dose w ith in the diet, it  is 
important to delineate the interaction o f the isothiocyanate and its metabolic products 
w ith regard to the metabolism o f carcinogens. Recognising that metabolism consists o f 
phase I  (activating process, preparation for phase II) and phase II  (detoxification 
process, conjugation o f the electrophile), it is sensible to suggest that compounds 
exhibiting anti-carcinogenic effects may inhib it phase I  enzymes (P450’s) and/or induce 
the phase I I  enzymes (GST and quinone reductase). Inhibiting phase I  enzymes would 
prevent biologically inert compounds from being metabolised, thus preventing the 
production o f reactive electrophiles. As discussed earlier the activated electrophile 
possesses the potential to react w ith macromolecules such as DNA, foim ing DNA- 
adducts reported to be an in itia l phase in tumourigenesis. Inducing phase II  enzymes 
would predictably increase the degree o f electrophile conjugation w ith GSH and 
subsequent metabolism via the mercapturic acid pathway, followed by excretion from 
the body.
A  prospective anti-carcinogenic compound would inhibit phase I, or induce phase II, or 
more preferably, would inhibit and induce the phases o f metabolism respectively. The 
follow ing discussion concentrates on how the isothiocyanates interact w ith the two 
phases o f metabolism.
M o d u la tio n  o f  p h a se  I  m e ta b o lism
Hecht51 has written a comprehensive report on the inhibition o f carcinogenesis by 
isothiocyanates. The paper describes occurrence, formation o f isothiocyanates and 
inhibition o f tumourigenesis by isothiocyanates. In addition, the paper discusses the 
mechanisms o f chemoprevention by isothiocyanates. It reports isothiocyanates as being 
specific in  their action and inhibiting particular cytochrome P 450 enzymes and thus the 
isothiocyanates become specific chemopreventers w ith regard to the tumour formation 
they preclude.
Zhang and Talalay’s paper52 describing the activities o f organic isothiocyanates features 
a study where PEITC is administered to male F-344 rats. It was observed that the liver 
microsome content o f cytochrome P 450 was depressed, the effect was the reduction in 
NNK a-hydroxylation and formation o f NNIC reactive metabolites, which is critical for
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DNA-adduct formation. The possible importance o f the fine structure o f the 
isothiocyanates was also highlighted; a-naphthyl isothiocyanates were shown to depress 
the P450 content o f liver microsomes, whereas the (3-naphthyl isothiocyanate raised the 
P450 content.
Barcelo and co-workers53 have performed a' study investigating the ability o f 
sulforaphane to reduce the metabolic activation o f N-nitrosodimethylamine (NDMA) by 
the cytochrome P450 CYP2E1 (p-nitrophenol hydroxylase). The study assessed the 
ability o f sulforaphane to diminish the activity o f the CYP2E1 and to reduce the 
mutagenic effects o f the NDMA. This was achieved by using a CYP2E1 assay and the 
bacterial mutagenicity assay (Ames test). The CYP2E1 assay involved exposing liver 
microsomes to p-nitrophenol (100 pi o f 50-500 pM) and sulforaphane (100 pi o f 25-250 
pM) and incubating at 37 °C for 30 minutes. The generation o f the alcohol p- 
nitrocatechol was measured as the hydroxylated product o f p-nitrophenol. The 
sulforaphane was found to be a potent inhibitor o f the CYP2E1 activity in a dose 
dependant manner suggesting it may be a competitive inhibitor. The bacteria 
mutagenicity test was canied out by exposing S. typhimurium strain TA  100 to NDM A 
and sulforaphane, and sulforaphane alone at varying concentrations. The sulforaphane 
was found to be non-toxic and did not induce the reverse gene mutation o f the bacteria. 
Sulforaphane did exhibit a dose dependant inhibition o f genotoxicity w ith respect to 
NDMA. As CYP2E1 is the enzyme that activates NDMA, the implication is that 
sulforaphane reduces the activity o f the enzyme thus reducing the genotoxic effects o f 
NDMA. The conclusion o f this study was that sulforaphane was unlikely to be 
mutagenic and that it may provide protection against carcinogenic substrates o f the 
CYP2E1 enzyme.
The deallcylation o f ethoxyresorufin (EROD), pentoxyresorufin (PROD) and 
methoxyresorafm (MROD) are predominately mediated by the cytochrome P450 
enzymes 1A1, 1A2 and 2B1, and 1A2 respectively54. A  number o f isothiocyanates have 
been used to assess their ability to inhib it these reactions and thus establish their 
inhibitory activity towards the P450 enzymes. Liver microsomes taken from male F- 
344 rats were treated w ith PROD, EROD or MROD and an arylalkyl or alkyl
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isothiocyanate (differing in  chain length), before incubating at 37 °C. The assay was 
assessed continually using a fluorescence spectrometer. Many o f the isothiocyanates- 
GSH conjugates were also tested. For both arylalltyl isothiocyanates and alkyl 
isothiocyanates there appeared to be an optimum chain length o f six carbons suggesting 
the structure o f the active site o f the P450 enzyme may provide optimum binding for 
isothiocyanates containing hydrophobic Chains o f six carbons in length. The arylalkyl 
isothiocyanates were particularly potent in the inhibition o f the dealkylation o f the 
PROD as compared to the alkyl isothiocyanates. As the arylalkyl isothiocyanates are 
potent inhibitors o f N NK tumourigenesis while the alkyl isothiocyanates are not, it was 
suggested the P450 enzyme involved in  dealkylation o f PROD (CYP2B1) may be 
involved in the metabolism/activation o f NNK. It was further suggested the PROD 
assay might be used to screen for isothiocyanates that display inhibitory properties w ith 
regard to NNK.
The effect o f sulforaphane on the PROD and EROD assays has been studied as 
described above using a number o f different concentrations o f the isothiocyanate. As 
observed in the previous study, the effects on PROD were not great, however, the 
sulforaphane did produce a dose dependant inhibition o f the dealkylation o f EROD. 
Once again the isothiocyanates are proven to inhibit cytochrome P450’s involved in the 
phase I metabolism o f carcinogen and reveal their mechanisms to be specific to 
particular P450 enzymes55.
Another study56 has focussed on characterising the enzymes responsible for NNK 
metabolism by mouse lung microsomes and the affects o f isothiocyanates on the 
metabolism. Lung microsomes were prepared from female A/J mice and the P450 
content was determined. The preparation was buffered and treated w ith N N K (10 pM) 
and incubated at 37 °C for 30 minutes. The sample was then co-injected w ith NNK 
metabolic standards into a reverse phase HPLC and the metabolic products identified. 
When studying the effect o f an isothiocyanate the mouse was administered a 5 or 25 
pmol dose o f the appropriate isothiocyanate 2  horns prior to sacrifice and subsequent 
microsome preparation. The metabolites were identified as described in  figure 15.
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Figure 15; P450 metabolism of NNK.
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employed in  particular experiments to investigate the involvement o f the P450’s. These 
studies conclusively proved that the NNK is metabolised by the P450 enzymes, 
(metabolism ceased in inhibition o f the P450’s). The affect o f addition o f the 
isothiocyanate PEITC (25 pmol) was to reduce the formation o f the N N K metabolites 
by 70-80 %. The PEITC exhibited both competitive and non- competitive inhibition o f 
NNK metabolism.
The first can be attributed to the isothiocyanate competing w ith the N N K for the P450 
active site, the latter may be due to the isothiocyanate reacting w ith the histidyl, 
cysteinyl or amino groups o f the protein, de-activating the P450. This study re-enforces 
the role o f isothiocyanates as compounds that are capable o f inhibiting the metabolism 
o f carcinogens and provides further illum ination on the mechanisms involved regarding 
the P450 enzymes.
In light o f the results o f the above study56 illustrating P450’s to be involved in NNK 
metabolism, Smith and co-workers chose to identify the specific P450’s involved57. 
The above experiment was repeated, however the lceto alcohol and keto aldehyde were 
analysed and the kinetics o f their formation determined separately, this was not the case 
in the previous experiment. Antibodies were employed once again (inhibiting specific 
P450’s) and proved to be selective in inhibiting the formation o f the keto aldehyde and 
to a lesser extent the keto alcohol but did not inhibit the formation o f the NNK-N-oxide. 
The results suggested the P450’s 2A1 and 2B1 and related enzymes were involved in 
the metabolism o f NNK in  mouse lung microsomes.
Contained w ithin a short review the recent work by Smith and co-workers has been 
discussed and acknowledges that the predominant mechanism o f protection from NNK 
tumour formation when administering PEITC is the modification o f the P450 catalysed 
metabolism as opposed to the phase I I  metabolism. This is not reported as a common 
observation for isothiocyanates and others may rely on inducing phase I I  metabolism to 
exert their anti-cancer effects58.
The body o f work discussed clearly indicates that the isothiocyanates and in particular 
PEITC is capable o f modulating the metabolism performed by the MFO system. The
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studies have highlighted the ability o f the isothiocyanate to inhibit particular 
cytochrome P450’s that are concerned w ith the metabolism o f compounds, which upon 
oxidative metabolism are capable o f forming DNA-adducts. Formation o f these adducts 
is recognised as one o f the first phases towards tumour formation. As a consequence o f 
the increased levels o f certain isothiocyanates, the degree to which electrophiles are 
produced in  the body is reduced, thus diminishing the risk o f developing tumours.
Modulation of Phase II metabolism
Induction o f GST activity and GSH levels.
The anti-carcinogenic action o f the isothiocyanates is not restricted to the modulation o f 
phase I  metabolism, as eluded to earlier, the modification o f phase II metabolism may 
also result in  the reduction o f tumour formation due to electrophiles.
It was highlighted previously that the isothiocyanates were metabolised via the 
mercapturic acid pathway (phase I I  metabolism). The subsequent step in the 
investigation into isothiocyanates and phase II  metabolism is to examine how 
isothiocyanates or their metabolic products interact, is it  the metabolic products that 
impart the anti-cancer properties on the system?
An investigation was undertaken concerning the inhibition o f lung tumourigenesis in 
A/J mice by PEITC and its N-acetyl-L-cysteine conjugate59. A/J mice were 
administered a mix o f the carcinogens BP and NNK over a 7 week period. Groups o f 
mice were fed PEITC or PEITC (3 pmol/g diet) throughout the administration o f the 
carcinogens, throughout the whole 27 week experiment period, through the latter part o f 
the carcinogen administration and to the finish o f the experiment or only after the 
administration o f the carcinogen had ceased. The animals were sacrificed 19 weeks 
after the final treatment o f carcinogen and examined for lung tumours. The results 
illustrated when the mice were administered the PEITC or PEITC-N-acetylcysteine 
during the whole experiment or throughout the latter period o f carcinogen 
administration and to completion o f the experiment, the inhibition o f tumour formation 
was greatest (50-65 % reduction in tumour incidence). Mice treated only while being
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administered the carcinogen did s till exhibit a reduction in lung tumours but it was 
reduced (40 %).
W hile establishing the metabolic products o f the isothiocyanates are active and inhibit 
tumour formation, i f  they are to inhibit tumourigenesis through phase II metabolism 
then the examination o f the enzymes involved in metabolism is the next logical step to 
take.
Talalay, Zhang and co-workers60 have investigated the inducing effect o f broccoli 
extracts on quinone reductase and GST, both phase II enzymes. Hepa lc lc 7  murine 
hepatoma cells were grown for 24 hours before being exposed to a solution o f the 
broccoli extract. The activity o f the enzymes was then assessed and using HPLC the 
identity o f the broccoli component w ith the greatest activity established. The extract 
approximately doubled the activity o f the enzymes, the majority o f the activity was 
attributed to one compound, which after analysis was identified as sulforaphane.
Similar reports61 and 62 detail the ability o f sulforaphane and sulforaphane nitrile 
(hydrolysis products o f glucoraphanin) to induce both quinone reductase and GST in the 
Hepa lc lc 7  cell culture. As before the cells were grown in medium for 24 hours prior 
to exposure to the test compounds. The activities o f the respective enzymes were then 
assessed. As previously observed, the activity o f the two enzymes was increased, 
although the activity o f the quinone reductase was enhanced to the greater degree. (The 
sulforaphane was also shown to be more potent than the nitrile, suggesting that as well 
as requiring a high glucosinolate content, the hydrolysis products o f glucosinolates 
should also favour the production o f the isothiocyanates to maximise the anti-cancer 
effects o f vegetables.)
Also, W allig and co-workers have fed male F-344 rats diets containing constituents o f 
Brussel sprouts, namely PEITC (0.1 mg/kg body weight) and crambene (l-cyano-2 - 
hydroxy-3-butene isothiocyanate, 50 mg/kg body weight). After a 6 day period the rats 
were sacrificed and the GSH and quninone reductase content o f the pancreas 
determined. The GSH and quinone reductase content was compared to rats fed a diet 
deficient in the isothiocyanates. The result o f the study did show the Crambene to
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induce the activity o f the quinone reductase and GST, and also produced an increase in 
pancreatic GSH. PEITC did induce the GST, however, it  would not be wise to make 
any conclusions as to the relative potencies o f the isothiocyanates, as the crambene was 
used at higher concentrations than PEITC.
Acknowledging the induction o f phase II by isothiocyanates, Jiang and co-workers64 
have used this when developing assays that have the potential o f identifying new 
chemopreventative agents. In a sim ilar fashion to assays employed in  studies reported 
earlier 61-63, the ability to induce the enzymes GST and quinone reductase is observed. 
Promising compounds are expected to show inductive properties towards these 
enzymes, this theory was proven using the isothiocyanate sulforaphane. As expected 
the isothiocyanate induced the activity o f GST and quinone reductase.
In addition to establishing GST’s as the enzymes involved in  metabolising 
isothiocyanates, individual GST’s have been identified as the enzymes most like ly to be 
involved in the phase I I  metabolism o f isothiocyanates. Kolm and co-workers65 have 
taken four different GST’s, namely, A l-1 , M l-1 , M4-4 and P l-1. A ll four GST’s were 
used to catalyse the reaction between a range o f aryl and alkyl isothiocyanates and 
glutathione. Rates o f enzymatic reaction measurements were carried out for all 
reactions. The study revealed that the GST M l-1  was the most efficient catalyst 
followed by P l-1. Only four o f the ten known GST’s were used in this study but it is 
plain that GST M l-1  + P l-1 plus possibly others are involved in the metabolism o f the 
isothiocyanates. Hexyl isothiocyanate produced the highest rate o f reaction while BITC 
and PEITC delivered the highest rates o f reaction for the aryl isothiocyanates. 
Surprisingly sulforaphane exhibited the slowest rate o f reaction implying it was the 
poorest substrate for the GST enzymes employed, despite its non-enzymatic rate being 
among the higher rates determined.
Having established that the isothiocyanates are metabolised by the GST’s and more 
specifically, the metabolism o f isothiocyanates may he the responsibility o f particular 
GST’s and not the group as a whole. Zhang and Talalay recognised the mechanistic 
details o f the isothiocyanate involvement w ith the GST mediated metabolism needed to 
he clarified. Subsequently they devised a study to investigate whether the
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isothiocyanates accumulate to any degree in the cell, whether the concentration o f the 
isothiocyanates correlate w ith the induction o f GST’s and, do the levels o f GSH 
influence the potency o f the isothiocyanates regarding their potential to induce the 
GST’s66? The isothiocyanate content o f Hep lc lc 7  cells was established by exposing 
the cells to isothiocyanates over a 3 day period. The cells were isolated and the cell 
lysate prepared. A  specific assay was developed to quantify the isothiocyanate present 
in the cell lysate. This involved reaction o f the lysate w ith 1,2-benzenedithiol, the 
cyclic condensate could then be isolated using HPLC and spectroscopically quantified. 
Figure 16 depicts the formation o f the cyclic condensate from the isothiocyanate or the 
dithiocarbamate found w ithin the cell. Using Hep lc lc 7  cells the induction o f quinone 
reductase and GST’s was measured for cells w ith varied GSH content (GSH 
concentration was reduced by varying additions o f buthionine-(R,S)-sulfoximine 
(BSO), a compound that inhibits y-glutamylcysteine synthetase). On exposure to the 
isothiocyanate the assay was left for 24 hours. The cells were harvested and the 
activities o f the GST’s and quninone reductase established. The GSH content o f the 
cells was determined by a fluorimetric technique, cell lysates were reacted w ith ortho- 
phthaldialdehyde, the resulting conjugate was quantified using a luminescent 
spectrometer.
Figure 16; Cyclocondensation of 1,2-benzenedithiol with isothiocyanates and dithiocarbamates.
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The five isothiocyanates used (sulforaphane, PEITC, BITC, phenyl isothiocyanate and 
a-naphthyl isothiocyanate) accumulated in the cell to very different degrees. The
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sulforaphane and BITC accumulated in  the cell at high concentrations while PEITC was 
the only other isothiocyanate accumulating to any modest concentration. After 30 
minutes the level o f BITC cell content decreased rapidly over the follow ing 12 hours, in 
contrast the sulforaphane maintained a high concentration for 12 hours and only 
decreased in  concentration moderately over the follow ing 12 hours. The 
isothiocyanates achieving the highest intra-cellular content also achieved the greatest 
induction o f. GST’s and quinone reductase, suggesting that cellular isothiocyanate 
content be involved in the induction o f the phase I I  enzymes. The cells exposed to BSO 
(to reduce their levels o f intra-cellular GSH) exhibited a reduced accumulation o f the 
isothiocyanates as compared to the cells not treated w ith BSO. The GSH level o f the 
cell only appeared to affect the accumulation o f the sulforaphane and BITC, implying 
GSH is isothiocyanate specific regarding their accumulation in  the cell. These results 
prompted the study to look into whether GSH concentration may affect their GST and 
quinone reductase inductive properties. Cells treated w ith BSO or ethyl-GSH 
(compound known to induce GSH levels in  a cell) were tested for the phase II  enzyme 
activities regarding the isothiocyanates tested w ithin the study. It was concluded that 
decreased levels o f GSH increased the activity o f the phase II  enzymes. To summarise 
this study has established that different isothiocyanates accumulate in  cells to different 
degrees and the higher the intra-cellular concentration o f isothiocyanate the greater the 
induced GST’s and quinone reductase activity. The cellular GSH level appears to 
negatively modulate the potency o f the isothiocyanates regarding the induction o f the 
phase I I  enzymes.
Zhang was to carry out a further study, he postulated that GSH may be connected w ith 
the uptake o f the isothiocyanate in the cell. This study67 established the GSH content o f 
human breast cancer cells using the fluorimetric assay employed in reference66. Second 
order rate constants were determined for the non-enzymatic reaction o f GSH and an 
isothiocyanate (PEITC, BITC, sulforaphane and a lly l isothiocyanate). The GST activity 
o f the human breast cancer cells was measured by exposing the lysed cells to 
isothiocyanates and examining the absorbance changes at 340 nm before calculating the 
rate o f dithiocarbamate production and thus the GST activity. Measurement o f the 
intra-cellular uptake o f the isothiocyanates was measured using the cyclocondensation 
assay described previously66. Zhang correlated the in itia l cellular uptake o f
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isothiocyanate and the second order rate constants for the conjugation reaction. The 
observed results clearly indicate the higher the rate o f conjugation the greater the in itia l 
uptake o f isothiocyanate. This result reinforces the proposal that cellular GSH may be 
involved in the cell uptake o f isothiocyanates. The concentration o f GSH was 
subsequently increased in  the cells (using glutamylcysteine synthetase) and the intra­
cellular isothiocyanate uptake measured once again. Increasing the levels o f GSH in the 
cell increased the uptake o f the isothiocyanates, confirming the previous results and 
indicating the uptake o f isothiocyanate is linked w ith the cellular GSH concentration. 
Zhang now sought to make the connection between isothiocyanate uptake and GST 
activity. Determining the isothiocyanate cellular* uptake o f cells exhibiting different 
GST activities would confirm this hypothesis. Human breast cancer cells w ith low GST 
activity (MCF-7/wt and MCF-7/neo) and those exhibiting a high activity (MCF- 
7/hGSTAl, MCF-7/hGSTMl and MCF-7/hGSTPl, expressing high activities for the 
GST’s A l-1 , M l-1  and Pl-1 respectively) were used (all contained similar levels o f 
GSH, determined by the fluorimetric assay as used earlier). The in itia l levels o f 
isothiocyanate uptake were determined again using the cyclocondensation assay 
employed previously. The result indicated Zhang’s theory to be correct, the cells 
exhibiting the higher GST activities did yield increased levels o f intra-cellular 
isothiocyanates. These experiments were only examining the uptake o f isothiocyanates 
over the in itia l period o f exposure. Interestingly when cells exhibiting high GST 
activities were exposed to the isothiocyanates over a longer period o f time then the 
uptake o f the isothiocyanates was more moderate and comparable to cells w ith normal 
GST levels. This point although highlighted by Zhang could not be explained. This 
investigation illuminated the mechanism o f phase II induction. The work illustrates that 
high concentrations o f both GSH and GST increase the cellular uptake o f 
isothiocyanates, which in some cases can induce cellular GST activity, GSH levels and 
other phase II  enzymes. Thus increasing the ability o f the cell to defend itse lf against 
carcinogens.
Induction o f DNA responsive elements.
Ye and Zhang have since illustrated that accumulation o f isothiocyanates in the cell can 
be achieved and the process is dependant on the intra-cellular levels o f GSH and the 
activity o f GST’s and quinone reductase using other cell lines68. Using the
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cyclocondensation assay utilised in previous studies the intra-cellular
accumulation o f the isothiocyanates (a lly l isothiocyanate, BITC and sulforaphane) was 
measured. In brief, HepG2 and mouse skin papilloma cells (PC) were exposed to the 
isothiocyanates for 24 hours in  the appropriate media before lysation. The lysates were 
subsequently reacted w ith  1,2 -benzenedithiol and the cyclic product quantified using 
HPLC. As before the GSH levels o f the cell were determined by isolating cells and 
lysing them before analysing the contents for GSH at 405nm using a luminescent 
spectrometer. The quinone reductase and GST activity was measured by determining 
the rate constants for reactions catalysed by the respective enzymes68. Both cell lines 
examined in  this study showed accumulation o f intra-cellular GSH and an increase in 
phase I I  enzyme activity 011 exposure to the isothiocyanates. On correlation o f the GSH 
levels and enzymes activities w ith intra-cellular accumulation levels o f isothiocyanate it 
was apparent that the study had confirmed the previous report conclusions but using 
different cell lines. W ith increased GSH levels and increased quinone reductase and 
GST activities the intra-cellular isothiocyanate uptake increases. In addition to the 
confirmation that isothiocyanate is able to accumulate in cells other than MCF-7, Ye 
and Zhang were interested in  the precise mechanics o f how the isothiocyanates induce 
the phase II  enzymes. They acknowledged that phase II  enzyme and GSH induction is 
mediated by regulatory DNA elements, namely, antioxidant responsive element (ARE) 
and electrophile responsive element (EpRE). Their studies focussed on determining 
whether the isothiocyanates interact/affect these DNA responsive elements. This was 
achieved by using two strains o f HepG2 cells (one containing the EpRE and one 
without the EpRE) and monitoring the expression o f the green fluorescence protein 
(GFP) gene using a luminescent spectrometer. The expression o f the GFP gene was 
shown to be under the control o f EpRE. The two cell strains were incubated in the 
presence o f the isothiocyanates for 24 hours. Only the cells containing the EpRE 
showed any increase in GFP, indicating that the isothiocyanates interact w ith the EpRE. 
The levels o f GFP for the HepG2 cells were determined after exposure to the 
isothiocyanates. On correlation w ith isothiocyanate accumulation the results indicate 
that the GFP levels increase w ith the concentration o f intra-cellular isothiocyanate. The 
study has illustrated the induction o f GSH levels and phase II  enzymes by 
isothiocyanates may be through transcriptional activation o f DNA responsive elements.
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Also, this mechanism o f induction may be common to cells and not specific to one cell
type-
Binding w ith Keapl and activation o f Nrf2.
Fahey and co-workers69 have proven that in  addition to phase I I  enzymes being induced 
by isothiocyanates, the ARE’s responsible for their activation are in turn activated by 
Nrf2 (a member o f the NF-E2 fam ily o f nuclear basic leucine zipper transcription 
factors). Mice deficient in  the Nrf2 factor were treated alongside normal mice with 
sulforaphane (7.5 pmol per day), after 20 weeks the mice were sacrificed and the 
forestomachs examined for tumours. The mice deficient o f the Nrf2 factor did not show 
any decrease in tumour formation as compared to the normal mice in  the study. The 
results provide in itia l indication that Nrf2 may be involved in the induction o f phase II 
enzymes and subsequent inhibition o f tumours.
Dinkova-Kostova and co-workers have investigated the sensors that activate the phase 
I I  enzymes70. Two proteins are known to be involved in the transcriptional activation o f 
phase II  genes, Nrf2 and Keapl (a cytoplasmic actin binding protein). The Nrf2 is 
largely bound to the Keapl, however, inducing agents (e.g. isothiocyanates) may disrupt 
this association. The Nrf2 is then free to migrate to the nucleus where it  is able to bind 
to the regulatory ARE regions o f the phase II  genes and accelerate their transcription 
and subsequently elevate the levels o f phase II  enzymes. Figure 17 depicts a possible 
mechanism for phase II  regulation.
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Figure 17; Possible mechanism for phase II regulation70.
The investigation involved isolating the K eapl proteins from E. coli, subsequently the 
thiol groups of the Keapl were studied regarding their reactivity towards 
isothiocyanates (other electrophiles were also used in this investigation). The Keapl 
was exposed to sulforaphane and the reaction was monitored through the production of 
dithiocarbamates at A,max 240 nm absorbance using a spectrometer. The reaction was 
shown to be proportional to the concentration of sulforaphane. The study included an 
experiment examining the effect o f sulforaphane on the Keapl-Neh2 complex (Neh2 
being a cysteine deficient domain o f the Nrf2 moiety). The complex was treated with 
increasing concentrations o f sulforaphane (0-0.5 mM). On increase o f the 
isothiocyanate a concentration dependant loss o f the complex was observed. This study 
illustrates the ability o f sulforaphane to successfully react with the cysteinyl thiol 
groups o f the K eapl. Once bound it is capable o f disrupting the Keapl-Nrf2 complex, 
releasing the Nrf2 enabling it to bind with the phase II gene, inducing the increased 
transcription of ARE70.
A review71 concerning the antioxidant signal transduction pathways discusses the 
induction o f ARE’s through the release o f Nrf2 and subsequent binding with phase II 
genes. This report demonstrates the complexity of the systems involved, the 
mechanisms discussed above do not run in isolation! This report illustrates the point
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well, highlighting interactions w ith the MAPK pathway (involved in the activation o f 
cell death).
Transport o f the isothiocyanates.
To date Zhang had established that isothiocyanates accumulate in  the cells and this 
event is assisted by the conjugation o f the isothiocyanate w ith GSH. This process 
increases the level o f isothiocyanate in the cell, which can result in  the induction o f 
higher levels o f GSH, and activities o f GST’s, thus further increasing the rate o f 
isothiocyanate absorption into the cell. After accumulating in the cell the level o f 
isothiocyanate in the cell diminishes slowly over a period o f time. Does the conjugate 
undergo further metabolism in the cell or is it transported from the cell thus reducing the 
isothiocyanate level?
T7r? * • *Zhang and Callaway sought the solution to this question through the investigation into 
transporter mediated export o f the isothiocyanate-glutathione conjugate. The study 
measured the cellular accumulation and export o f sulforaphane. Human prostate 
carcinoma cells were exposed to sulforaphane and subsequently isolated and lysed. The 
lysates were subjected to the cyclocondensation assay as reported in  previous studies to 
determine the intra-cellular concentration o f the isothiocyanate. Establishing the degree 
o f export o f sulforaphane was achieved by incubating cells w ith a specific concentration 
o f sulforaphane (50 pM). An aliquot o f the sample was removed and the sulforaphane 
accumulation determined as before. Cells o f the remaining sample were isolated and 
resuspended in  medium not containing sulforaphane and incubated at 37 °C. Removing 
an aliquot o f sample and determining the intra-cellular sulforaphane concentration was 
repeated after 0.5, 1, 2, 3, 4 and 4.5 hour intervals. In parallel the experiment was 
repeated incubating the cells at 4 °C to assess the effect o f temperature on the export o f 
sulforaphane from the cell. By taking samples at specified intervals and resuspending 
the cells in  fresh media it was possible to measure the amount o f sulforaphane exported 
from the cell over a particular time period. The results indicated an extremely fast 
reduction in intra-cellular concentration o f sulforaphane, however when the cells were 
incubated at 4 °C the reduction in  intra-cellular sulforaphane was very small indeed. 
Also, an experiment was performed where the cells were incubated in  the presence o f a 
low concentration o f sulforaphane (5 pM) and samples taken for intra-cellular
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sulforaphane determination as before. The cells were not resuspended in  fresh media 
after removal o f an aliquot but remained in the sulforaphane media. The intra-cellular 
sulforaphane concentration in this experiment reduced very slowly but remained above 
the media concentration. It could be concluded from this portion o f work that the fast 
elimination o f sulforaphane from cells could not be attributed to cellular leaks alone. 
Also, the near cessation o f sulforaphane export at lower temperatures gives further 
indication that the sulforaphane may be actively exported from the cell. In addition it 
was thought that the cells may absorb sulforaphane as fast as they exported it, as the 
intra-cellular concentration changed little  when the cells remained in  media containing 
sulforaphane. Zhang and Callaway then identified the form in which the isothiocyanate 
was exported from the cell and that on inhibition o f membrane transport the export o f 
sulforaphane was reduced. The identity o f the exported sulforaphane was achieved by 
exposing human prostate carcinoma cells to sulforaphane, isolating the cells before 
resuspending in  media deficient o f the isothiocyanate. After incubation the cells were 
isolated using a centrifuge, the supernatant was then analysed using an HPLC and MS. 
The supernatant was found to contain the sulforaphane-GSH conjugate, indicating the 
isothiocyanate is absorbed and exported as the conjugate. The combination o f the 
reduction o f membrane transport when the cells are exposed to either low temperatures 
or membrane transport inhibitors strongly suggests that the sulforaphane-GSH 
conjugate is actively transported out o f the cell. The blocking o f membrane transport 
(multidrug resistant associated protein-MRP) appears to reduce the export, a further 
experiment was devised to confirm this observation. Two groups o f cells were exposed 
to sulforaphane and the intra-cellular accumulation o f the isothiocyanate was 
determined using the cyclocondensation assay as before. The two cell lines were human 
leukaemia HL60/S cells and HL60/AR cells (which over-expressed the MRP-1). 
HL60/AR cells was shown to have a intra-cellular sulforaphane level 36 % lower than 
the HL60/S cells, confirming the earlier observation that active transport (MRP-1 (GSH 
pump)) is like ly to be involved in the export o f isothiocyanates from the cell.
The research presented here suggests that in addition to the isothiocyanate being 
transported into the cell as the GSH conjugate, it is also transported out o f the cell as a 
conjugate. Acknowledging the conjugation reaction as a reversible reaction, it would be 
possible for the conjugated isothiocyanate to be transported into the cell, revert back to
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the free isothiocyanate and perform a function w ithin the cell (bind w ith the Keapl 
protein). Once this function has been completed (the isothiocyanate is freed from the 
Keapl) it would be possible for the isothiocyanate to conjugate w ith the GSH once 
again and be metabolised or be transported directly out o f the cell.
This review is not exhaustive by any degree but hopefully it is evident that 
isothiocyanates are important non-nutritional components w ithin our diet and decrease 
our susceptibility to tumour formation. Figure 18 describes very brie fly the metabolic 
pathway o f isothiocyanates from ingestion to excretion and highlights the modulation o f 
the body’s metabolism. The biological studies discussed here are summarised in  table 7 
indicating the analysis undertaken, the materials used, the result o f the study and the 
reference.
Table 7; Summary of biological studies discussed.
Reference Analysis Substrate/Cell line Material used Result
29 DNA adduct 
formation
Mouse lung and 
liver microsomes
BITC+PEITC Isothiocyanates 
reduce adduct 
formation
38 Microsome assay 
DNA repair assay
Salmonella 
typhimurium 
TA98+TA100 
E. coli
AITC AITC shown to be 
genotoxic
39 Single cell 
electrophoresis 
assay
Chinese Hamster 
ovary cells
BITC Shown to be 
cytotoxic
52 P450content of liver 
microsomes
Liver microsomes PEITC P450's depressed in 
microsomes
53 CYP2E1 
Ames test
Liver microsomes 
S. typhimurium 
TA100
Sulforaphane Inhibited P450 and 
was not genotoxic
54 Dealkylation of 
PROD, EROD, 
MROD.
Liver microsomes Aryl+alkyl
isothiocyanates
Inhibited P450's
55 Northern blot 
analyses
Rat+human
hepatocytes
Sulforaphane Induce GST's
56 P450 content 
determination
Lung microsomes PEITC P450 content 
decreased
57 P450 content 
determination
Lung microsomes PEITC P450's involved in 
NNK metabolism
58 P450 activity of 
liver microsome
Liver+lung
microsomes
PEITC Reduction in P450 
activity
60 Quinone
reductase+GST
activity
Hepa lc lc7  murine 
hepatoma cells
Broccoli extracts Increased activity of 
enzymes
61 Quinone
reductase+GST
Hepa lc lc7  murine 
hepatoma cells
Sulforaphane Increased activity of 
enzymes
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activity
62 Quinone
reductase+GST
activity
Hepa lc lc7  murine 
hepatoma cells
Sulforaphane Increased activity of 
enzymes
63 Quinone
reductase+GST
content
Human colorectal 
adenocarcinoma 
HT29 + human 
hepatoma HepG2
Sulforaphane Increases quinone 
reductase and GST 
content of cells.
64 Phase II enzyme 
activities
Hepa lc lc7  cells Sulforaphane Enzymes were 
activated in this cell 
line.
65 Isothiocyanate 
structure activity 
study with GST's 
Al-1, M l-1, M4-4 
+P1-1
n/a Aryl and alkyl 
isothiocyanates
Reaction rate varied 
between 
isothiocyanates.
66 Isothiocyanate 
conc. Vs GST 
activity
Hep lc lc7 Aryl and alkyl 
isothiocyanates
High isothiocyanate 
content induced the 
highest GST 
activity.
67 Isothiocyanate 
uptake in cell
Human breast 
cancer cells MCF-7
AITC+BITC High GSH content 
of cell results in 
higher uptake of 
isothiocyanate in 
cell
68 Isothiocyanate 
uptake in cell
Hepa lc lc7  cells AITC+BITC+
PEITC
High GSH content 
o f cell results in 
higher uptake of 
isothiocyanate in 
cell. Also 
demonstrate 
induction of DNA 
responsive 
elements.
69 Tumour incidence 
in nrf2 gene 
deficient mice
Female IRC mice 
stomach
Sulforaphane Indication nrf2 is 
involved in 
induction o f phase 
II enzymes.
70 Involvement of 
Keapl-Neh2 
complex in phase II 
induction.
Keapl proteins 
fromZ coli
Sulforaphane Complex and nrf2 
was shown to be 
involved in phase II 
induction.
72 Transport of 
isothiocyanate-GSH 
conjugate.
Human prostate 
carcinoma cells
Sulforaphane Isothiocyanate 
shown to be 
transported out of 
cell as conjugate.
Review
The isothiocyanate is first ingested in the form o f the glucosinolate, which is hydrolysed 
by the enzyme myrosinase present in the intestinal microflora. The isothiocyanate is 
then absorbed into the body at which point it may be transported into the cell. 
Conjugation of the isothiocyanate and glutathione is known to be reversible, it is 
thought to be transported into the cell as the conjugate at which point the conjugate may
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separate to yield the isothiocyanate. The isothiocyanate/conjugate is then able to inhib it 
the cytochrome P450 enzymes (CYP2E1, CYP2B1 and CYP2A1) involved in phase I 
metabolism through competitive inhibition o f their active site or deactivation through 
possible reaction w ith a histidyl, cysteinyl or amino group o f the enzyme. Alternatively 
the isothiocyanate may react w ith the cysteinyl-thiol groups o f the Keapl protein 
sensor, releasing the Nrf2 factor, which is able to migrate and bind w ith the phase II  
genes inducing increased transcription o f DNA responsive elements. The subsequent 
increased release o f ARE/EpRE induces the activation o f phase II  enzymes (GST’s and 
quinone reductase) and GSH content o f the cell. It may be possible for the 
isothiocyanate to be cleaved from the ICeapl and for it to be conjugated w ith the GSH. 
The GSH conjugate could then be metabolised further to the mercapturic acid and 
excreted, or actively transported from the cell for excretion. Both the inhibition o f 
phase I  metabolism and induction o f the phase I I  metabolism constituents result in the 
reduction o f tumour formation, establishing isothiocyanates as important 
chemopreventors against cancers. There is no one isothiocyanate that protects against 
all tumours, the individual isothiocyanates only provide protection for a selection o f 
tumour types. It is like ly that an isothiocyanate-based preparation would be formulated 
around a selection o f isothiocyanates affording an individual protection from a number 
o f different cancers.
The mechanisms o f prevention reported and discussed at any length here only concern 
the modulation o f metabolism, and metabolism o f isothiocyanates. 
Glucosinolates/isothiocyanates also impart other responses including anti-inflammatory 
effects and apoptosis (cell death). The inhibition o f tumour growth73 or activation o f 
tumour cell death (apoptosis)74 t0 82 by isothiocyanates has not been discussed. 
Apoptosis is a distinct form o f cell death differing from necrosis both biochemically and 
morphologically. Necrosis is characterised by cell swelling and lysis, whereas 
apoptosis is associated w ith cell shrinkage and the ultimate formation o f apoptotic 
bodies that can be engulfed and degraded by macrophages81. Apoptosis has been 
studied extensively and many o f the complex processes involved have been established, 
however, despite work focussing around the activation o f apoptosis by isothiocyanates 
the exact interaction has not been established to date.
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Heiss and co-workers83 investigated the anti-inflammatory effects o f the 
isothiocyanates, as inflammation and carcinogenesis have been thought to be linked. 
The study reported the decrease in secretion o f pro-inflammation and pro-carcinogenic 
factors thus illustrating those anti-inflammatory mechanisms may contribute to the anti­
cancer effects o f the isothiocyanates.
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Figure 18; Possible metabolic route of isothiocyanates and modulation of metabolism.
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Glucosinolate synthesis.
The glucosinolate fam ily o f compounds are naturally occurring thioglucosides mainly 
located in the botanical fam ily Cruciferae. As described in the preceding review these 
compounds have been associated w ith strong and diverse physiological effects on both 
plants and animals. Figure 1 is representative o f the general structure o f glucosinolates, 
w ith the individual glucosinolates only differing in  the aglycone side-chain.
A  number o f glucosinolates have been isolated from vegetables through dedicated 
extractive and separative processes. This route has proven to be problematic and 
tedious. As indicated in  the review the glucosinolate is hydrolysed to the isothiocyanate 
when brought into contact w ith the enzyme myrosinase. It is plain to see the 
mechanical wounding involved in isolating the glucosinolate from the plant w ill result 
in a large proportion o f the glucosinolate being hydrolysed. This would not be an issue 
i f  the isothiocyanate were not reactive, however, it w ill react w ith any nucleophiles 
present (i.e. water). Specialised extraction methods have been developed for the 
isolation o f glucosinolates84. These involve heat or sulphate treatment o f the plant 
extracts to deactivate or inhibit myrosinase. Other extractive methods remove the 
glucosinolate sulfate group prior to isolation and yield de-sulfo glucosinolates.
The preferred route in  acquiring glucosinolates is the synthetic approach that has been 
shown to be applicable to the synthesis o f a small selection o f glucosinolates. Also, 
glucoemcin has been isolated from rocket seeds and subsequently oxidised to 
glucoraphanin85. In addition analogues o f the naturally occurring glucosinolates can be 
prepared for analytical and biological applications.
For the reasons stated above the synthesis o f these compounds has been o f interest to 
chemists for a long time now. The synthesis o f sinigrin by Benn and Ettlinger86 was 
one o f the first reports detailing the synthesis o f glucosinolates, there have been 
subsequent reports detailing the synthesis o f numerous glucosinolates containing alkyl, 
allyl, and arylalkyl aglycone side-chains87 t0 97. The investigations to date have all 
utilised a common synthetic approach to the synthesis o f glucosinolates, figure 19. The 
synthetic route involves the coupling o f an hydroximoyl chloride (chloro-oxime) 101
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and a l-thio-j3-glucopyranose 100 forming the (Z)-thiohydroximate 102. The hydroxyl 
group o f the hydroximate is then sulfonated to give the glucosinolate 103.
Figure 19; General synthetic approach to glucosinolates* 
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This synthetic approach introduced by Macleod87 has been used to produce a number o f 
glucosinolates including phenylethylglucosinolate87 glucoviorylin, glucoibervirin, 
glucoerucin89, indole glucosinolate92 and glucotropaeolin96, which have subsequently 
been investigated w ith regards their biological properties. It is quite surprising therefore 
that the glucoraphanin (the glucosinolate precursor to sulforaphane) has not been 
synthesised and yet this compound has been shown to be one o f the most potent 
compounds regarding its anti-carcinogenic properties.
Dihydrothiazme synthesis.
After their in itia l discovery in the early 1950’s dihydrothiazines received little  attention 
before the 1980’s at which point Weinreb and co-workers98,99+100 investigated their 
synthesis and chemistry. The [4+2] cyclo-addition reaction between a 1,3 diene 104 
and a sulfinylim ine 105 employed in their synthesis occurs readily and is quite general 
providing an electron withdrawing group is present in  the dienophile, figure 2 0  (e.g. 
tosyl in  105).
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Figure 20; [4+2] Cycloaddition.
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Weinreb has also found the hetero Diels-Alder reaction to be stereoselective, giving 
products ofsyrc addition to the 1,3 diene. It was also reported that the selectivity o f the 
addition was improved by using a Lewis acid such as TiCL or SnCfi at reduced 
temperatures (0 or -50 °C). Single isomers were produced when utilising the Lewis 
acids and decreased temperatures, the exact involvement o f the Lewis acid was not 
established and it was concluded the stereochemistry must be derived from the diene 
attacking from the least hindered face o f the dienophile.
The chemistry o f the dihydrothiazines is lim ited, Weinreb's work has centred on the 
mechanistic strategy for the hydrolysis o f dihydrothiazines proposed by 
Mock/Nugent101. The mechanism entailed the production o f an allylic sulfinic acid, 
formed by the in itia l opening o f the dihydrothiazine ring, followed by the loss o f sulfur 
dioxide via a retro-ene reaction in a chair transition state (figure 2 1 ) yielding the 
homoallylic amine 109.
Figure 21; Hydrolysis o f dihydrothiazine'lOO. 
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Using this methodology the hydroxide anion nucleophile could be replaced w ith a 
phenyl magnesium bromide producing a similar structure to 108. this was then reported 
to undergo a [2,3] sigmatropic rearrangement before treatment w ith trimethylphosphite 
to yield a vicinal amino alcohol 113 (figure 22). In addition vicinal diamines were 
synthesised using this methodology.
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Figure 22; Synthesis of vicinal amino alcohol.
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The production o f the isothiocyanate enantiomers may be accomplished by utilising the 
follow ing synthetic route, Figure 23. This involves the synthesis o f a dihydrothiazine 
that is subsequently opened using an alcohol to yield a czs-allyl sulfinic ester, which is 
free to under go [2,3]-sigmatropic rearrangement. The amine protecting group can then 
be removed and the isothiocyanate group introduced.
The use o f a homochiral alcohol in synthesising the sulfinic ester would only produce 
two possible diastereomers. However, i f  the reversible [2,3]-sigmatropic rearrangement 
occurs stereoselectively w ith regard to the configuration o f its transition state, only one 
chiral sulfinic ester could be produced i f  a homochiral alcohol is used when 
synthesising the ester. I f  enantiomerically pure sulfinic esters were synthesised then 
one could infer that the chirality o f the sulfur moiety obtained could be exploited in the 
enriched synthesis o f enantiomerically pure sulforaphane analogues. It is worth noting 
that nucleophillic substitutions on sulfinic esters are known to proceed under inversion 
o f configuration at sulfur. Also, w ith enantiomerically pure isothiocyanates resulting 
from the sulfinic esters, the chirality could be assessed regarding the isothiocyanates 
biological potency.
[2,3,]-sigmatropic rearrangements used in this project were first reported by Bickart and 
co-workers102 in 1968 regarding the interconversion o f a llylic sulfoxides and sulfenates 
and the involvement w ith the racemisation o f a llylic sulfoxides. It was proposed that 
the racemisation o f the allylic sulfoxide involved an intermediate (sulfenate) that existed 
in equilibrium at low concentrations. The study anticipated that the rearrangement o f 
the sulfoxide into the sulfenate comprising a cyclic transition state as depicted in figure
24.
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Figure 23; Generalised synthetic route to isothiocyanates.
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Figure 24; sulfoxide-sulfenate rearrangement 102,
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Brickart described how the [2,3]-sigmatropic rearrangement could be performed on cis 
and trans a lly lic  groups exhibiting endo and exo configurations102 w ith regard to the 
sulfenate group. Rotation about the allylic group through the adjacent carbon bond 
and/or the carbon-sulfur bond enable the intermediate sulfenates to interconvert between 
the possible conformations in addition to the sulfoxides, as illustrated in  figure 25.
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Figure 25; Interconversion o f  the sulfenates and sulfoxides102.
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Despite all the sulfenates being possible intermediates, some are favoured energetically 
as compared to others depending on the substituents o f the allylic group. Furthermore 
the transition states leading to the various sulfenate intermediates vary according to the 
stereochemistry o f the starting allyl sulfinyl compound and their substituents. Figure 26 
depicts four o f the possible transition states and the energy differences between them.
A detailed analysis was provided by Hoffmann103 using the above system w ith R as n- 
pentyl in  the cis and trans configurations. W ith the tfranj-configuration the reaction was 
shown to proceed predominantly through the endo route (70 %) while the cis- 
configuration used the endo route almost exclusively. The relative energy required for 
the exo-cis probably prevented it from playing any significant role in  the rearrangements 
observed. From this analysis it becomes obvious that excellent stereoselectivities
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should be obtained from ds-allylsulfm yl compounds. The [4+2] cycloaddition route to
dihydrothiazines sets up stereospecifically such a cis a lly l sulfinyl moiety.
Figure 26; Relative energies of four possible sulfenate intermediates103.
This project intended utilising the [2,3]-sigmatropic rearrangement w ith regard to 
sulfinic esters comprising a cw-double bond. The nitrogen o f the dihydrothiazine and 
subsequent ester w ill be protected using a toluenesulfonamide group and the alcohol 
used w ill be o f sufficient bulk to mimic the model system represented by Hoffmann103, 
(figure 27).
The resulting sulfinic ester has the potential to be bristling w ith groups that could 
influence the configuration assumed by the sulfenate when experiencing the [2,3]- 
sigmatropic rearrangement. R1+2 could be particularly influential in addition to 
toluenesulfonamide-R5 interaction. The combination o f the R4 and toluenesulfonamide 
group should be sufficient to force a particular configuration during the rearrangement 
and therefore produce only one enantiomer o f the sulfmic ester. By altering the 
absolute stereochemistry o f R5 it  may be possible to produce both enantiomers o f the 
cis-allylic sulfmic ester.
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Figure 27; Opening of a dihydrothiazine and representation of the rearrangement of the resulting sulfinic 
ester.
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It can be appreciated that synthesising the dihydrothiazines is a particularly convenient 
route to the allylic sulfinic esters required for this work. As mentioned earlier the 
dihydrothiazines are a group o f compounds that have not been investigated to a great 
extent and synthesising derivatives o f them not only would extend this fam ily o f 
compounds but also would elucidate their chemistry further. The objective o f this 
section o f the project was to synthesise a range o f dihydrothiazines containing different 
groups and functionality before attempting to produce the sulfmic esters using 
homochiral alcohols.
The fam ily o f dihydrothiazines represents a group o f compounds that have received 
very little  attention from the scientific community. The dihydrothiazines have been 
synthesised w ith very lim ited functionality and have only been opened using very 
simple nucleophiles. It would prove interesting to explore the structural and chemical 
possibilities o f this group o f compounds. One possibility would be to increase the 
functionality o f the dihydrothiazine cycle using hydroxyl groups producing a structure 
that could be described as an aza sugar analogue.
Their chemistry w ill be elaborated on and mechanisms suggested for a number o f their 
reactions as w ell as their degradation. The structural conformation o f the 
dihydrothiazines w ill also be discussed and compared w ith sim ilar systems.
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The final chapter w ill conclude the work contained w ithin this thesis and discuss 
problems encountered throughout the project that remain unresolved and the possible 
solutions for them.
Scope of this thesis.
This project is concerned w ith the synthesis o f glucosinolates and isothiocyanates 
containing 5/6 carbons in  the side chain and to subsequently test their anti-cancer 
properties (Ames test). The follow ing undergraduate students Sandra Dorrenbacher, 
Dave Folkened and Anja Kasten have assisted w ith this project through the synthesis o f 
isothiocyanates, their isothiocyanate synthesis is shown in the Appendix A. Thus the 
combination o f research w ill produce some interesting work regarding the chemical 
synthesis o f the glucosinolates/isothiocyanates and the biological properties o f the 
compounds produced. The body o f work included in this thesis w ill discuss the 
synthesis o f anti-cancer Brassica glucosinolates and dihydrothiazines. In addition the 
various issues connected w ith the synthetic procedures used w ill be examined and 
elaborated on further.
In Chapter 3, the synthesis o f glucosinolates containing a five and six carbon side- 
chains w ill be discussed. The aim o f this work was to synthesise glucoraphanin and a 
range o f analogues (figure 28) that would be submitted for chemo-protective 
characterisation.
The procedure outlined by G il and Macleod87 was used in itia lly  to synthesise the 
glucosinolates from a-D-glucose and an alkyl bromide, Figure 29. This synthetic route 
has proven to be particularly problematic and we have elaborated on the difficulties 
encountered in this area and the solutions developed in overcoming problems.
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Figure 28; Proposed glucosinolates to be synthesised.
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Figure 29; Syntlietic procedure used for the synthesis of glucosinolates.
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Chapter 4 will be concerned with the synthesis o f the dihydrothiazines, their chemical 
stability and chemistry. The objective o f this work was to synthesise a range of 
structurally diverse dihydrothiazines and to subsequently derivatise them. One aspect 
o f this section of work was to synthesise enantiomerically pure sulfinic esters from the 
dihydrothiazines, these would have the potential to be converted into enantiomerically 
pure isothiocyanates.
py.SO3/0 H 2 CI2
K H C 03 
 > ,
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Aims and objectives
As described in the previous chapter one o f the aims o f this thesis is to synthesise a 
number o f glucosinolates containing a functionalised four or five carbon side chain. 
The method devised by G il and Macleod87 was used as a starting point, which involves 
the synthesis and coupling o f a chloro-oxime and tetraacetylpyranosylthiol, figure 29.
Results and discussion
To confirm the procedure as viable, a model glucosinolate was synthesised. Methyl 
glucosinolate was synthesised and nitroethane was used as a starting material to 
dispense w ith the first nitration step.
The a-bromo-tetraacetyl-D-glucose was synthesised successfully follow ing a standard 
procedure104. The bromide was used without delay as it was found to degrade over a 
relatively short period o f time. 133 was dissolved in acetone and reacted w ith thiourea 
under reflux for 1 hour before the acetone was removed under reduced pressure. The 
resulting crude thiuronium salt was then reduced using an excess o f sodium 
metabisulfite solution. The structure o f the thio-sugar 100 was confirmed by proton and 
carbon NMR and IR  spectroscopy. The V h c c h  coupling constant o f the anomeric 
proton was 10Hz indicating the sugar 100 was produced exclusively in  the (3- 
configuration. A  coupling constant o f 2-4Hz would have indicated an a-conformation 
for the sugar.
Figure 30; Synthetic procedure for 100.
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The diastereomeric excess witnessed through this reaction can be explained through the 
well-known anomeric effect. The bromo-sugar is produced in the a-conformation as 
the highest occupied molecular orbitals (HOMO) o f the anomeric oxygen lone pair ( ijp) 
overlap w ith the lowest unoccupied a molecular orbital o f the carbon-bromine cr-bond. 
This interaction in  orbitals results in  two new molecular orbitals being formed as
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illustrated in figure 31. This interaction is not possible for stereoelectronic reasons in 
the (3-configuration, thus the a-configuration is preferred for electronegative 
substituents such as the bromide.
The [3-configuration observed in the thio-sugar is formed due to the interaction o f the 
acetate group adjacent to the anomeric carbon atom. Figure 32 demonstrates how the 
acetate is able to form a cyclic oxonium ion. The formation o f the cyclic oxonium ion 
prevents the thiourea attacking in the a-position, thus the [3-isomer is produced via an 
Sn2 type attack w ith inversion o f configuration o f the anomeric carbon.
Figure 31; Mechanism and energy diagram explaining why the bromination is directed to the a- 
configuration.
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Figure 32; Acetyl bridge mechanism directing the (3-thiosugar. 
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The nitroethane was deprotonated w ith one equivalent o f sodium methoxide in  the 
minimum quantity o f methanol. A fter 1 minute a large excess o f diethyl ether was 
added and the sodium salt isolated and dried. The following step was to prepare the 
chloro-oxime employed by different groups in  the past including Viaud and R ollin92. 
The nitronate salt was stirred in CH2CI2 at -78 °C before the addition o f thionyl 
chloride, stirring was continued for 10 minutes producing an intense blue solution. This 
was filtered and the filtrate washed in iced water before being dried over CaC0 3 . One 
equivalent o f 100 was added to the blue solution and the mixture was allowed to warm 
to room temperature over 30 minutes before working up. It must be stressed the CH2CI2 
used was not dried over a s till and the reaction was not performed under nitrogen. The 
crude hydroximate was confirmed using NMR and subsequently sulfonated using 
pyridine sulfur trioxide producing methyl glucosinolate (figure 33). Washing the 
glucosinolate w ith a 10% KHCO3 solution removed the acetate protecting groups 
efficiently from the sugar in addition to producing the potassium glucosinolate salt.
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Figure 33; Methyl glucosinolate synthesis.
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The methyl glucosinolate was characterised and its structure confirmed as follows; the 
doublet characteristic o f the th io l group at 2.30 ppm disappeared and the anomeric 
proton changed from a triplet to a doublet and shifted from 4.53 ppm to 4.97 ppm. A ll 
other NMR signals were found in the expected region.
The stereochemistry o f the hydroximate functionality was investigated by reacting the 
hydroximate 140 w ith benzoylchloride (figure 34) and performing a NOESY NMR 
experiment to establish i f  there is interspacial coupling between the benzoyl group and 
the sugar. Interaction between the benzoyl group and the sugar would only be expected 
i f  the hydroximate is in the cis configuration. The NOESY did indeed exhibit coupling 
between the benzoyl group and the protons attached to the carbons 5+6 o f the sugar.
Figure 34; Reaction of 146 with benzoyl chloride and nOE effects between the benzoyl group and the 
sugar.
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W ith the successful synthesis o f the methyl glucosinolate, glucoraphanin was to be 
synthesised. 1,5-dibromopentane was used as the starting material for the side-chain, 1-
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bromo-5-nitropentane 144 was obtained using ha lf an equivalent o f sodium nitrite. The 
nitronate was prepared as previously described using sodium methoxide. The same 
procedure as described previously was followed for the synthesis o f the chloro-oxime, 
however, on addition o f thionyl chloride it was apparent that the reaction was not 
follow ing the same route as the previous synthesis. A  vivid blue solution was not 
produced but instead a hazy green solution. The chloro-oxime is known to be in 
equilibrium w ith the tautomer depicted in figure 35, w ith the nitroso compound known 
to display a characteristic v iv id  blue colour87. Despite completing the experimental 
protocol, it was not an unexpected discovery to find that the coupling reaction had not 
occurred. Crude proton NMR indicated that a multitude o f reactions had occurred and 
isolating any one compound was attempted without success.
Figure 35; Oxime-nitroso tautomerisation.
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This reaction was repeated w ith fresh thionyl chloride, dry CH2CI2 and the synthesis o f 
the oxime was carried out under nitrogen. The washing step was also erased from the 
experimental protocol ensuring the oxime remained under a dry nitrogen atmosphere 
once formed. This too had no effect on the reaction's success.
In itia lly  thoughts were directed towards improving the process. The sodium 
bromopentylnitronate salt proved to be more d ifficu lt to isolate than the ethyl 
counterpart. Endeavours were made in isolating the salt and removing any methanol 
residues and ensuring the material was thoroughly dry. Also, the salt was finely ground 
to ensure good dispersal in  the DCM and increased reaction as in  many cases 
particulates remained in the solution indicating the salt had not fu lly  reacted. These 
modifications did not produce any success.
It was noticed that the solution did intensify in  its green appearance as the temperature 
increased above -30 °C. It was thought that the temperature may not be low enough to 
prevent the degradation o f the oxime-nitroso material, taking this point into account a
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number o f experiments were performed over a prolonged period o f time (30 minutes) at 
-78 °C, the coupling reaction was also earned out at this temperature. These previsions 
did not prove successful.
Alternative solvents were also used including dimethylformamide, acetonitrile and 
tetrahydrofuran, none o f which improved the performance o f the reaction.
Early in  the efforts to synthesise the chloro-oxime it  was observed that when preparing 
the 1 -bromo-5-nitropentane the nitronate salt is generated washed w ith  ether to remove 
any excess dibromopentane before treatment w ith dilute acid to yield the nitro group 
once more. Interesting observations were made when the acid was added to the salt, the 
solution turned blue. The blue colour dissipated after a short period o f time and the 
bromo-nitropentane was isolated on work up. The colour observed was reminiscent o f 
the oxime-nitroso solution, however, adding acid to the salt (which was itse lf prepared 
by treatment w ith base) did not appear to be a logical step towards the synthesis o f the 
chloro-oxime. Due to the isolation o f the expected product the observation was not 
researched any farther which in hindsight may have been a little  naive. (A  possible 
solution to the synthesis o f the chloro-oxime and subsequent coupling reaction 
regarding this observation are discussed in the conclusion o f Chapter 5.
Figure 36; Synthesis o f the nitroalkane.
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After modifying the experimental procedure without success it  was thought the reagents 
might not be satisfactory for this particular reaction. The chloro-oxime has been 
synthesised by using a number o f different chlorinating agents, namely, SOCI289’ 913116 92, 
NCS97, CI2105, T iC fi88, 95, 106 and 107. The experimental procedure used in this instance 
does not form the oxime prior to chlorination, therefore it was decided TiCU or oxalyl 
chloride would be used, both o f which should follow  a similar mechanism to thionyl 
chloride (figure 37). The result in both cases was an intense green solution that did not 
couple successfully w ith the thio-sugar.
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Figure 37; Mechanism for chloro-oxime synthesis.
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What initially appeared to be a straightforward synthetic procedure that had been 
applied successfully to similar model molecules had become problematic and very 
lengthy in its execution. The attention of the project turned to the oxime system; is this 
particular oxime sensitive to degradative reactions? Casnati and Ricca105 described the 
dimerisation of the nitroso compound (figure 38), suggesting it maybe possible that this 
oxime favoured the dimerised product. If this was the case the formation of the oxime 
and subsequent coupling with the sugar may be hindered.
Figure 38; Dimerisation of nitroso compound105
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If the dimerisation is possible it is conceivable that the oxygen is able to attack the 
carbon in the alpha-position substituting the chlorine. It is evident that many side 
reactions are possible and may occur in preference to the formation of the chloro-oxime.
After examining the rearrangement between the dimer, nitroso and oxime it was 
proposed the oxime may be isolated by trapping with an appropriate electrophile. By 
using the oxygen anion the opportunity for the rearrangement to the nitroso compound 
is removed thus enforcing the exclusive formation of the oxime. Over a period of time 
as the nitroso compound rearranges between the dimer and oxime, the trapped oxime 
would eventually be the only species present (figure 39).
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Figure 39; Trapping of the oxime.
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This approach was attempted and acetyl chloride added after the addition of the thionyl 
chloride. The solution did turn an intense blue on addition of the acid chloride, after ten 
minutes the thio-sugar was added to the solution and stirred as before for 30 minutes
and started to discolour suggesting the nitroso-oxime (if present) was degrading as seen 
previously. On analysis the major product was [3-S-acetyl-tetraacetylpyranose, it may 
have been possible that the nitroso compound was present to producing the blue colour, 
however it may have been in small quantities.
Consequently addition of the acetyl chloride after the thionyl chloride was not possible. 
Would adding the acetyl chloride prior to the thionyl chloride be feasible? A proposed 
mechanism for this procedure (Figure 40) did indicate that it might be possible to treat 
the nitronate salt with the acid chloride followed by the thionyl chloride and still form 
the chloro-oxime. As depicted below (figure 40) the nitronate anion 144 attacks the 
acetyl chloride before attacking the thionyl chloride with the oxygen anion. The 
acetylated nitronate 148 is likely to be significantly less nucleophillic as compared to 
the original nitronate anion, due to the molecule being neutral. It was anticipated that 
the reactivity of the thionyl chloride together with the formation of the sulfur dioxide 
would drive the reaction forward. The mechanism when adding the acid chloride after 
the thionyl chloride is very similar to the mechanism of the original oxime synthesis 
using the chloride ion as a base to abstract a proton delivering the nitrile oxide. On 
addition of the second chloride ion the acetylated chloro-oxime is produced. This
before working up. Prior to the addition of the thio-sugar the solution had become hazy
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method would not afford the nitroso compound in theory, as it would not have the 
opportunity to tautomerise.
The new experimental procedure was followed, after the addition of the acetyl chloride 
it was necessary for the solution to be stirred for 30 minutes before the nitronate salt had 
reacted completely. On addition of the thionyl chloride an intense blue colour appeared 
suggesting the reaction was proceeding as anticipated. However, since the vast majority 
of the thio-sugar was recovered, it has been suggested the protected oxime species may 
be too hindered by the acetyl group and does not react sufficiently with the thio-sugar.
Figure 40; Alternative synthesis of the chloro-oxime.
-HCI
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After work up and isolation using column chromatography (1:1, ethyl acetate:hexane) a 
hydroximate was retrieved in moderate yield. However, it was not the intended 
acetylated derivative but a chloro-acetylated hydroximate. The hydroximate was 
characterised and spectra indicated the anomeric proton appeared as a doublet with a 1 0  
Hz p-coupling and had shifted from 4.53 ppm (anomeric proton of thio-sugar) to 4.78 
ppm. Also the side chain signals were seen as multiplets and triplets at 3.38, 2.63, 1.8 
and 1.7 ppm. In addition there were two doublet peaks at 4.61 and 4.85 ppm 
representing the methylene group of the chloro-acetyl functionality. Due to the 
diastereomeric nature of the protons they exhibited typical Vhch of 12 Hz. In addition
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the HMQC did illustrate that the protons were attached to the same carbon with a 
chemical shift of 45.4 typical of CH2CI and the accurate mass confirmed the mass of 
152. The glucose protons appeared as expected.
It must be noted that some side chain signals were obscured by additional signals 
indicating the sample may contain impurities from unreacted oxime. The data provided 
within the proton NMR describes the presence of a single enantiomerically pure 
hydroximate. If the sugar moiety had provided a more complex spectra one may have 
concluded the sample contained a mixture of hydroximates or products and reactants.
The following mechanism has been proposed for the formation of the chloroacetyl 
chloro-oxime (Figure 41).
Figure 41; Proposed synthesis of chloroacetyl chloro-oxime.
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Initially the nitronate salt reacts with the acetyl group followed by the thionyl chloride 
in a similar manner to that described previously. As illustrated above, the acetyl is 
capable o f forming the enolate, (possibly with the aid of a chloride anion acting as a 
base) which may be capable of attacking the sulfmyl chloride producing the six
-86-
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membered ring intermediate 154. Subsequently a chloride may attack the ring 
methylene carbon and effectively reduce the sulfur. The positive nitrogen has been 
maintained in the resulting intermediate 155 and the structure is very similar to previous 
intermediates described in the oxime synthesis. A chloride anion is able to deprotonate 
the carbon alpha to the nitrogen forming the nitroso compound and a second chloride is 
available to attack the alpha carbon directly afterwards, forming the chloro-oxime 
arrangement
The low yield recovered from the reaction suggests the reaction pathway described in 
figure 38 is probably a minor route and the rate limiting factor is most likely the ability 
of the acetyl group to form the enolate in the absence of a strong base. Stirring the 
solution for an extended period at -78 °C prior to the addition of the thio-sugar may 
allow a higher proportion of the intermediate to form the enolate and subsequently the 
chloro-acetyl derivative.
Despite the reaction only being partially successful and only isolating a minor product, 
the reaction has proved very useful affording an insight into the chemistry of the 
nitronate salt and the chloro-oxime. Through formation of the chloro-acetyl group, the 
reaction between the nitronate salt and the acetyl chloride is confirmed. It is not 
unreasonable to imply the reaction between the nitronate salt and the acetyl chloride is 
successful to a large degree and only a small proportion undergoes the transformation 
described in figure 41 producing the chloro-acetylated derivative.
On the assumption that the chloro-oximes 151+157 are both produced but only the 
chloro-acetyl derivative reacts with the thio-sugar it can be deduced that the presence of 
the chloride activates the oxime enabling the coupling reaction to occur. This has clear 
implications for future work, using a halogenated acetyl chloride to protect the oxime 
would produce an activated oxime that in theory could produce the hydroximate in 
greater yields.
In summary, what appeared to be a straightforward synthetic procedure has proven to be 
more difficult than could have been predicted. It is puzzling as to why the pentylchloro- 
oxime is so unstable, when the aryl oximes have been reported to be stable and the ethyl
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oxime produced as a model compound was stable also (despite being synthesised in the 
absence of an inert atmosphere and using wet solvents). Trapping the oxime with the 
acid chloride appears to be a promising approach in the synthesis of the hydroximate. 
Once the coupling reaction with the thio-sugar has been optimised then the trapping of 
the oxime will have been established as a convenient technique in the synthesis of the 
glucosinolates or other compounds that require the synthesis and reaction of unstable 
oximes. Modified synthetic strategies for the synthesis of glucosinolates where happing 
the oxime is employed are detailed in the conclusion section of this thesis.
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Aims
The strategy behind the inclusion of dihydrothiazines in this project was to synthesise 
ds-allylic sulfinic esters. By doing so we could establish (through their [2,3]- 
sigmatropic rearrangement) whether there was a preferred conformation with regard to 
the sulfur atom of the ester group. In turn the corresponding isothiocyanate in theory 
could be synthesised from this compound (figure 23) and assuming enantiomerically 
pure, the potency of the individual chiral isothiocyanates could be assessed with regard 
to their anti-cancer properties.
The dihydrothiazine structure is particularly suited for the synthesis of the 
isothiocyanates (figure 42).
Figure 42; Illustration of dihydrothiazine functionality.
C/s double bond available for 
synthesis of c/s-sulfinic esters
CU .NCS
Sulforaphane
Dihydrothiazines contain a sulfur and nitrogen functionality as found in sulforaphane 
and the cis double bond makes it a good scaffold for the synthesis of sulfinic ester 
analogues and subsequently the isothiocyanate derivatives.
Also, the dihydrothiazine group of compounds has received little attention and their 
known chemistry is limited. Their derivatisation has been limited to their hydrolysis, 
esterification and production of allylic amines as highlighted in the introduction. This 
project provided the opportunity to expand on dihydrothiazine chemistry.
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Results and discussion. 
Synthesis of sulfinylimine.
The target dihydrothiazines 163 (figure 43) are obtained in a [4+2] addition of 
sulfinylimine 162 and a selected diene. N-Tosylsulfinylimine was obtained following a 
general procedure reported in the literature98 10 100 and 1 0 8 10 no. The procedure employed 
by Kim110 was followed initially. Most procedures for the synthesis of sulfinylimines 
involve treating an amine with thionyl chloride, however it was reported by Kim 
advantageous to use N,N’-sulfinylbisimidazole as the sulfmylating agent. Figure 43 
illustrates the synthetic procedure used in the synthesis of the sulfinylsulfonamide and 
the subsequent [4+2] cycloaddition reaction to yield the dihydrothiazines.
Kim reported the synthesis of sulfinylimines and described filtering the solution and 
subsequent isolation, mention of the instability of these compounds was not made with 
regard to heat and moisture. It was reported that purifying the materials using column 
chromatography proved unsuccessful as the sulfinyl group hydrolysed to the amine 
originally employed in the synthesis.
In addition to these observations it must be emphasised that these materials were 
extremely sensitive and despite all efforts to maintain an inert atmosphere, filtering and 
isolation of the solid compound proved to be very difficult and the majority product was 
the hydrolysed amine.
After many attempts to improve the procedure and isolate the sulfinyl material, it was 
clear exposing the material to the atmosphere was not a practical option during the 
synthesis. The suggestion was made that it may be possible to perform the subsequent 
hetero-Diels Alder reaction in-situ, thus dispensing with any requirement for the 
material to be exposed to the atmosphere. The N-tosylsulfinylimine was to be 
synthesised in a flask connected to a sintered glass filtering tube, the opposite end of the 
tube was fitted with a second flask.
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Figure 43; Synthetic procedure for dihydrothiazines.
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The N,N’ -sulfmylbisimidazole was synthesised in one flask before addition of the 
toluenesulfonamide producing a yellow solution indicative of the N-tosyl sulfinylimine 
compound. A combination of imidazole and imidazole hydrogen chloride salt 
precipitates out over the preceding reactions. The apparatus was then inverted thus 
removing the imidazole as a filter cake in the filter tube leaving a clear yellow solution 
of N-tosylsulfinylimine.
Synthesis of dihydrothiazines.
Using the in-situ prepared sulfinylimine, the [4+2] cycloaddition was explored. A slight 
excess of diene was then added to the solution and left to stir for 1 2  horns before 
working up and isolation. This process has proved to be successful in incorporating 
three reactions in the one reaction vessel, the synthesis of the sulfmylbisimidazole, N- 
tosyl sulfinylimine and the dihydrothiazine. In addition to being convenient the process 
ensures the sulfmyl compound is not exposed to the atmosphere, the dihydrothiazine is 
produced in good yields, also the quantity of materials used is reduced, which is always 
an advantage in a working laboratory.
On analysis of the compounds prepared it was noticed that the coupling constants for 
the protons of the dihydrothiazine ring were particularly large. However, all 
dihydrothiazines display unusually large 2J h c h  coupling constants at around 16Hz. This 
unusually high value of J  has been reported for a series of related six membered ring
- 9 2 -
Dihydrothiazine synthesis Chapter 4
heterocycles111 + U2. It can be assumed that the value of a coupling constant depends on 
hybridisation or the s-character of the bonding orbitals that are affected by the presence 
of the sulfur atom.
Figure 44; Dihydrothiazines synthesised.
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Figure 44 cont'd.
172 c/'s-1 6 2 173
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Compounds 165, 167, 169, 171 and 173 were produced as single regioisomers. This 
can be rationalised in terms of frontier orbital theory.
Figure 45; Illustration o f  m olecular orbital coefficients o f  diene and dienophile113.
HOMO of diene LUMO of dienophile
EWG = Electron withdrawing group
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A 2 -substitued diene shows a large coefficient at C-l in its HOMO, which interacts in 
the transition state with the LUMO of sulfinylimine that has a large orbital coefficient at 
sulfur (figure 45). Additionally smaller orbital coefficients are found at C-4 of the diene 
HOMO and nitrogen of the dienophile LUMO. Hanson and Stockbum114 reported the 
reaction of N-sulfmyl compounds with dienes to be concerted pericyclic reactions as 
illustrated in figure 46.
Figure 46; Overlap o f  frontier orbitals in  cycloaddition o f  diene and sulfinylim ine dienophile.
Compound 171 was obtained as a single regioisomer and a single diastereomer. Its 
stereochemistry could be proven unambiguously by an X-ray structure showing a syn- 
arrangement of the S=0 and methyl group.
The stereochemistry can be rationalised using the Alders endo rule. As described in the 
literature 115 a sulfinylimine should exist in the cis geometry. Hence the possible 
transition states for the [4+2] cycloaddition have to be considered for a concerted 
mechanism.
An exo transition state would give the anti-product whereas an endo transition state 
would result in the syrc-product (figure 47). From the stereochemistry observed we can 
conclude that this [4+2] cycloaddition proceeds via an ercrfo-transition state hence 
following the Alders endo rule.. This can be attributed to the secondary interactions 
between the diene and the dienophile substituents forcing an endo conformation.
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Figure 47; Exo and endo-cycloaddition.
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Compounds 175 and 177 were obtained as single diastereomers. As expected the 
stereochemistry of the diene was retained in the product. However the observed 
stereochemistry of the products 175 and 177 suggest the reaction proceeds through the 
exo-transition state. This may be explained when examining the endo and exo transition 
states when employing a bulky diene (figure 48). The bulky substituents of the diene 
interact with the toluenesulfonamide group of the sulfmylimine in the endo- 
configuration, whereas the exo-configuration does involve this steric interaction, hence 
the anti-products are formed.
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Figure 48; steric effects in endo and exo transition states.
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The dihydrothiazines shown in figure 44 were not the only dihydrothiazines attempted. 
Other dienes were used without success; dienes such Danishefsky’s diene and 
trimethylsiloxybutadiene were used. These compounds produced black sticky syrups 
from which nothing could be isolated. Dienes including 2H-pyran-2~one and 
acetylbutadiene that comprise activating groups were used also but did not react at all, 
only starting materials were recovered.
Crystal structure discussion.
It was possible to obtain a crystal structure of the 4,5-dimethyldihydrothiazine 171 
(figure 49). The data for the crystal structure is contained within Appendix B, relevant 
bond lengths and angles have been compared with other similar compounds (fig 50) in 
table 8 .
The crystallographic data reveals the C4-S1 bond (1.827 A) to be very similar to those 
compounds containing the sulfoxide functionality (171b,d+e\  while those containing a 
sulfone group (171c+f) exhibited a bond which is - 0 . 1  A shorter. This observation is
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rather surprising as one may expect the increased oxidation state and electron deficiency 
of the sulfur of 171c+f to increase the bond length, this not the case.
Figure 49; Crystal structure of 4,5-dimethyl-N-toluenesulfonamide-dihydrothiazine 171.
Figure 50; Crystal structures of compounds compared in table 6.
l-/?-FluorophenyI-3,5-bis(iodometkyl)piperidme 171a116.
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2-Cyano-4,5-dimethyl-2-phenyl-3,6-dikydro-2H-tMopyran-l-oxidel71b117.
l,2-Dihydro-l-methyl-2-(5,-pheiiyltIiiopyran-2,ylidene) pyridine-S-dioxide 171c118
-99-
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6-Benzyl-2-n-butyl-3,6-dibydro-l,2-thiazme 1-oxide 171d119.
Phenylmethyl (+-)-(lalpha 3beta 6beta)-3,6-dihydro-3,6-dimethyl-2H-l,2-thiaziiie-
2-carboxylate 1-oxide 171e99.
- 100 -
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tram- Octahydro-l-methyl~lH-2,l-benzothiazme-2,2-dioxide 171 f120.
Table 8; Comparison of bond lengths and bond angles of dihydrotliiazines and similar compounds.
Compound 171 ’ 171a 171b ” 171c 171d l?ie 171f
Bond lengths(A)
C4-S 1.827 n/a 1.819 1.721 1.825 1.813 1.764
c rx 1.485 1.468 11/a 1.403 1.460 1.499 1.490
s-x 1.720 n/a n/a 1.738 1.658 1.170 1.638
S-0 axial(Ax) or Ax n/a Ax n/a Ax Ax n/a
equatorial(Eq) 
Bond angles(o)4
C4-S-0 107.10 n/a 106.9 108.7 105.9 106.8 108.0
C4-S-X 94.84 n/a 96.4 101.9 95.8 96.2 103.3
X-S-0 110.22 n/a 105.1 110.8 111.8 108.3 106.9
Sum of angles 312.16 n/a 308.4 321.4 313.5 313.5 318.2
around S.
Ci-X-S 120.31 113.3 n/a 117.2 117.5 122.3 112.0
Ci-X-R’ 114.71 111.6 n/a 126.0 112.7 115.6 116.5
R’-X-S 116.21 115.3 n/a 115.7 113.8 117.1 115.1
Sum of angles 351.23 340.2 n/a 358.9 344.0 355.0 343.6
around X.
* Bond angles were calculated using the axial oxygen where the sulfur dioxide moiety is concerned.
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Figure 51; Numbered structure for reference when comparing compounds 171-171f.
c>CV °
The Ci-N bond length of 171 (1.485 A) is longer than the C-C bond found in the 
compounds being compared (those not containing a nitrogen), however, the C-N bond is 
slightly shorter than the comparable bond in the thiazine dioxide 171f.
The S-X bond length of 171 (1.720 A) is longer than the thiazine compounds being 
compared, this may attributed to the electron withdrawing effect of the tosyl group. It is 
generally accepted that electron withdrawing substituents increase the bond length of 
adjacent atoms.
The sum of three bond angles around an atom gives an indication of the geometry 
exhibited by that atom within the molecule. If the sum is 360 0 the geometry is planar, 
if  the sum of angles is less the geometry is pyramidal and if  the sum is 327 0 one can 
describe the geometry as tetrahedral. Contained within table 8  is the sum of bond 
angles for the sulfur and nitrogen.
The sum of the bond angles around the sulfur atom of 171 is very similar to those 
compounds containing the sulfur oxide moiety. However the sum of bond angles is 
significantly less than compounds 171c+f that contain the sulfur dioxide moiety. This 
does suggest that the lone pair of the sulfur may be more sterically demanding than the 
oxygen, thus increasing the pyramidicity of the sulfur and reducing the bond angles 
between the remaining substituents.
The pyramidicity of the nitrogen was comparable to the thiazine 171e, although 
thiazines 171d+f and the piperidine 171a exhibited significantly greater pyramidicity.
Further reactions of sulfinylimine with dienes.
There were a number of other instances where dienes were used, however the products 
isolated were not the expected materials. Reaction of N-tosylsulfmylimine with diene
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180 gave a homoallylic amine 181 as a single product after workup. In addition the 
reaction of 162 with 182 yielded a homoallylic amine 184 and an aminoalcohol 185 as 
products after workup. Fortunately, if  one can describe it as so, both dihydrothiazines 
165 and 173 degraded to give related amine products on storage. It is reasonable to 
assume that the 'decomposition products' originate mechanistically from unstable 
dihydrothiazine intermediates. Thus our first thoughts were of hydrolysis, the products 
of hydrolysis and their parent compounds are shown in figure 52. As illustrated in 
figure 52 the products of degradation are not the same for all compounds suggesting 
there may be two degradation routes available to the dihydrothiazines.
Weinreb and co-workers" and 100 and Bayer and Gautun121 have demonstrated that the 
dihydrothiazine framework is susceptible to hydrolysis, when exposed to sodium 
hydroxide. The dihydrothiazine is opened and on loosing sulfur dioxide the allylic 
amine is formed as depicted in figure 53. The same transformation can not 
accommodate the production of 185, another mechanism of degradation must exist. 
Earlier work by Weinreb and co-workers describe a reaction that produces an 
aminoalcohol of the same configuration as 185. It is possible that a mechanism similar 
to that employed for the reactions (figure 54) reported is responsible for the degradation 
reaction observed.
The mechanism proposed for the synthesis of the hydroxyallylamine involves a [2,3]- 
sigmatropic rearrangement that was discussed earlier. The
hydroxycycloheptaallylamine was isolated by column chromatography column in the 
process of isolating the alternative degradation product. This precludes the involvement 
of trimethyl phosphite or anything similar in removing the sulfur moiety and the 
environment was most probably slightly acidic and not basic, which implies the 
previous two mechanisms have failings with regard this compound.
It was suggested that the [2,3]-sigmatropic rearrangement was likely to occur thus 
achieving the basic structure of the homo-allylamine. With the slightly acid conditions 
in mind the following mechanism was proposed where by the acidic silica mediates the 
reaction. Initially the sulfmyl group is attacked by a hydroxyl group of the silica, thus 
opening the dihydrothiazine ring. The oxygen of the sulfinic ester is then able to
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perform a [2,3]-sigmatropic shift producing a compound similar to 185. Upon 
hydrolysis the silica is liberated along with sulfinic acid to yield the aminoalcohol 
(figure 55).
The homoallylic amines 178. 179 and 181 were identified with ease as they exhibit very 
distinctive singlet peaks at approx. 4.5-5.0 ppm for the terminal double bond present in 
each. The toluenesulfonamide group displayed peaks at 12-1.1 ppm and approx. 2.3 
ppm, the methyl groups were found between 1 - 2  ppm and the methylene signals were 
found between 2-3 ppm. The amine group was located around 4.8 ppm in the lR NMR 
spectra of these compounds. The cyclic allylamine produced a slightly more complex 
spectra as one might imagine as the allylic protons found at 5.4-5.9 ppm and the amine 
signal had shifted to 5.2 ppm while the majority of the ring protons were found between 
1.3 and 2.3 ppm in the form of complicated multiplets.
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Figure 53; Proposed hydrolysis mechanism of dihydrothiazine.
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Figure 54; Synthesis o f hydroxy-allylamine100.
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Figure 55; Proposed mechanism of dihydrothiazine degradation in acid conditions utilising the [2,3] 
sigmatropic rearrangement.
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The amino alcohol 185 produced a more complex spectrum, in comparison with the 
allylamine 184 the NH peak had shifted to 4.4ppm and the signal relating to the proton 
alpha to the hydroxide was now situated at 5.06ppm. The hydroxyl proton was also 
visible in this spectrum and located underneath the allylic signal at 5.6ppm. A full 
characterisation was performed on these compounds to confirm their structure as 
detailed in the experimental section.
To establish unambiguously the stereochemistry o f 185 it was necessary to determine 
whether the amine and alcohol are trans or cis to each other. H. Schroder and co­
workers122 have characterised artabsin derivatives (containing a seven membered ring 
and oxygen containing functionality) using NMR techniques. The 3/ h .h coupling 
constant of the proton trans to the Gf/OR proton of the seven membered ring was 11Hz 
and the cis proton was 3.6 HZ. The coupling constants associated with the proton 
CHOH of 185 are 10.6 and 7.1Hz. The 7.1Hz coupling corresponds to the allylic proton 
adjacent to it, while the 10.6Hz must correspond to the C77NH proton. Unfortunately it
(MeO)3P/MeOH  
N H C H 02Bz N H C H 0 2 Bz
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is not possible to confirm this coupling constant by direct comparison with the Gf/NH 
proton signal as it is a broad multiplet. However, I believe it is fair to state the coupling 
between the protons adjacent to the amine and alcohol to be 10.6Hz and in light of the 
work carried out by H. Schroder and co-workers, the protons are arranged in a trans 
configuration.
Having established the stereochemistry around the aminoalcohol functionality, it does 
throw into question the proposal that the dihydrothiazine undergoes a [2,3] sigmatropic 
rearrangement when forming 185 (figure 55). It is not possible for the oxygen to attack 
the opposite face of the ring during a [2,3] sigmatropic rearrangement as can be 
visualised in figure 55. This implies the silica attacks independently from the sterically 
less hindered face to produce the aminoalcohol 185 (figure 56).
Figure 56; Proposed alternative mechanism for dihydrothiazine degradation in acidic conditions.
Epoxidation of dihydrothiazines.
The first step in functionalising the dihydrothiazines was to oxidise them by epoxidising 
the double bond. The epoxidation of the double bond was intended to be carried out in 
a stereoselective manner by using an epoxidising agent which was capable of 
associating with the sulfinyl group and thus epoxidising one face of the dihydrothiazine 
in preference to the other, figure 57.
Figure 57; Stereoselective epoxidation of dihydrothiazines.
O
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m-Chloroperbenzoic acid (m-CPBA) was the epoxidising agent of preference, however, 
the initial results obtained using this were not promising. The peroxide was used in 
slight excess and instead of the epoxide being produced it was the sulfone that was 
generated as the major product. This is quite clear when examining the proton NMR as 
the signal relating to the methylene groups of the ring are broad with no coupling. The 
sulfur of the sulfmyl group is a stereo genic centre, therefore the protons of each 
methylene should be diastereotopic. In contrast the sulfone is devoid of a stereo genic 
centre and the methylene protons are equivalent producing one broad signal for each 
methylene group.
Other epoxidising agents were used in an attempt to produce the epoxide, these included 
magnesium monoperoxyphthalate and oxone (potassium monopersulfate), these 
produced the sulfone as the sole derivative.
In an effort to optimise the reaction the equivalents of m-CPBA used in the reaction 
were varied. It became apparent that the greater the excess of m-CPBA the greater the 
fraction of product was epoxide. This work demonstrated that 0.9 equivalents produced 
the sulfone as sole product but 6  equivalents produced the epoxide as the sole product 
when using the 5-methyldihydrothiazine. The 5-chloro-dihydrothiazine only produced 
the sulfone despite treating with 50 equivalents of the peroxide, figure 58 presents the 
results o f epoxidation using m-CPBA. Epoxidation of all dihydrothiazines used was 
found to produce diastereomerically pure epoxides, the oxirane ring being found on the 
same face as the oxygen of the sulfoxide group, thus confirming the association of the 
mCPBA with the sulfmyl group directing the face of attack regarding the peroxide 
oxygen.
This observation was interesting and it was postulated that the epoxide was formed in 
every case, however the epoxide was then able to oxidise the sulfur of any unreacted 
dihydrothiazine producing the sulfone (figure 59). Thus any epoxide formed in the 
reaction was expended oxidising the unreacted dihydrothiazine until no reactant was 
available. The dihydrothiazine is regenerated in this reaction after the epoxide has 
oxidised a dihydrothiazine, which explains the almost quantitative production of the
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sulfone when using equimolar quantities of epoxide and the absence o f the expected 
epoxide.
Figure 58; Results o f treating dihydrothiazines with m-CPBA.
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Figure 59; Theoretical competition of epoxidation and oxidation reactions.
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By increasing the reaction rate of epoxidation (ki) in relation to the rate of oxidation 
(k2) of the dihydrothiazine sulfur, any free dihydrothiazine will be consumed before
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oxidation of the dihydrothiazine occurs. The theory appears to be sound and accurately 
describes the observations, although there has been no work to date performed on the 
kinetics of this system to confirm this hypothesis.
The exception to the trend was the chlorodihydrothiazine that only gave the sulfone. 
The chloride may activate the dihydrothiazine epoxide and despite increasing the 
concentration of the m-CPBA, the rate of epoxidation (ki) may never approach the rate 
of oxidation (k2) resulting in the sulfone being the only product formed.
Compounds synthesised within this study were fully characterised; the sulfones were 
easily identified as mentioned earlier with simple proton NMR spectra. The 
toluenesulfonamide exhibited signals for the aromatic and the methyl as had previously 
been seen with the dihydrothiazines. The remaining peaks included one at 5.65 ppm for 
the allylic proton, one at 4.65 ppm representing the protons adjacent to the nitrogen and 
one peak at 3.63 ppm representing the protons adjacent to the sulfone group.
As one may expect identifying and determining the stereochemistry of the epoxides was 
more demanding. As alluded to earlier the sulfur is stereogenic and produces protons 
with different chemical shifts. The X-ray crystallography utilised in previous work 
proved useful. We are certain that the sulfoxide is axial as we have depicted in the 
dihydrothiazine (figure 49) and syn to the methyl group. Using this knowledge and in 
addition to characterising the compounds as is normal practice, a proton NMR was 
performed in benzene and a NOESY NMR was run in each case.
Benzene as a solvent is able to associate with the positive end of the sulfoxide dipole in 
the dihydrothiazine ring. The benzene shields the protons on the positive end of the 
dipole and deshields the protons on the opposite side thus producing a shift in the 
protons as compared to the proton NMR run in deuterated chloroform (figure 60, 
Aromatic Solvent Induced Shift 123). Utilisation of this technique allows the 
orientation of individual protons with respect to the face of the dihydrothiazine ring to 
be determined.
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Figure 60; Arrangement o f benzene in Aromatic Solvent Induced Shift.
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NOESY NMR is a technique that reveals interspacial coupling between protons in 
contrast to coupling through bonds, allowing the orientation of protons to be 
established. By combining these two techniques it is possible to establish which 
protons are able interact with each other spatially using the NOESY NMR and which 
side of the thiazine ring the protons reside using ASIS. Thus one can unambiguously 
describe the stereochemistry of the compounds in question.
Table 9; List of dihydrothiazines with their assigned chemical shifts in deuterated chloroform and 
benzene.
Dihydrothiazine Chemical shifts in chloroform and benzene/ppm
syn-171
194
A ' X  ' T se *  V
199 O
' R ..... Hb Hc Hd He Mea Meb
5 CDCI3 3.45 3.92 3.45 5.53 N/A 1.37 1.69
5 CgHg 2.71 3.85 3.41 4.98 0.91 1 . 2 2
AS 0.74 0.07 0.04 0.55 0.46 0.47
5 CDCI3 3.25 3.58 4.22 4.89 3,06 1.48 N/A
5 CgHg 2.36 3.30 3.74 4.63 2.05 0 . 6 6
AS 0.89 0.28 0.49 0.26 1 . 0 1 0.82
8  CDCI3 3.24 3.65 4.09 4.73 N/A 1.44 1.50
5 CgHg 2.39 3.37 3.72 4.57 0 . 6 6 0 . 6 8
AS 0.85 0.28 0.37 0.16 0.78 0.82
8  CDCI3 3.26 4.09 4.80 3.16 N/A 1.33 1.44
5 C6 H6 2.60 3.73 4.62 2.33 1 . 2 0 0.78
AS 0 . 6 6 0.36 0.18 0.83 0.13 0 . 6 6
S CDC !3 5.00 2.96 N/A N/A N/A N/A N/A
5 CgHg x. 5.33 3.22
AS -0.33 -0.26
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The results of this work show the epoxidation of dihydrothiazines involves the insertion 
of the oxygen in a syn configuration with regard to the sulfoxide, confirming the 
association of the peroxide and the sulfoxide during the reaction, directing the oxygen's 
face of attack.
For a detailed stereochemical assignment compounds 194 and 198 are considered. 
Starting from the certain relative stereochemistry of 171 an ASIS effect o f 0.74 for the 
proton anti to S=0 can be established. All other protons display smaller ASIS effects. 
Using the ASIS technique the anti to S=0 (syn to lone pair) proton alpha to S=0 can be 
unambiguously identified, e.g. AS = 0.89 in 194 and AS = 0,66 in 198. The assignment 
of the proton syn to S=0 follows automatically after COSY analysis. The
knowledge of identity of both alpha to S=0 protons allows the use of NOE 
spectroscopy to determine the relative stereochemistry of the neighbouring methyl 
groups. E.g. in 194 a strong NOE effect from Ha to Me (Figure 61) can be observed and 
in 198 from Ha to Mei,.- From this the relative stereochemistry of the epoxide follows as 
oxygen syn to S-O. Figure 61 and 62 depicts the protons involved in the ASIS effect 
and those protons showing strong NOE effects. The NOESY NMR represented in 
figure 62 illustrates spacial cross coupling between the Ha proton (3,25ppm), the methyl 
protons (1.48ppm) and the proton adjacent to the epoxide ring (3,06ppm), thus 
confirming their orientation with repect to each other.
Figure 61; Protons involved in ASIS and NOE effects in 194.
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Figure 62; Proton and NOESY NMR of 194.
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The stereochemistry of bicyclopentyl dihydrothiazine derivative 199 has only been 
established for the two protons highlighted as the spectra obtained for the two pentyl 
rings was cluttered and unclear preventing the identification of the individual protons. 
Due to the orientation of the two protons Ha and Hb and of the oxygen in the previous 
epoxides, it was thought to be a reasonable step in assigning the orientation of the 
epoxide.
Synthesis of 4-Hydroxydihydrothiazine derivatives.
With the dihydrothiazine epoxides in hand, further derivatisation of the group of 
compounds was embarked on through the ring opening of the epoxide to produce the 
allylalcohol (figure 63).
Figure 63; Ring opening of the epoxide.
194 200
This transformation is relatively simple, the base sodium hydride was used to abstract 
an acidic proton adjacent to the sulfinyl group in an EiCb type elimination, thus opening 
the epoxide ring producing the alcohol in the 4-position. The following 
allylalcoholdihydrothiazines listed in table 10 were synthesised using this method. The
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relative stereochemistry between OH and S=0 was expected to be retained. A proton 
NMR in benzene and a NOESY NMR was measured. The protons Hc and H<i did not 
exhibit significant ASIS effects preventing unambiguous assignment of the relative 
stereochemistry.
Table 10; List of allylalcoholdihydrothiazines.
Allylalcoholdihydrothiazine Chemicals shifts in chloroform/ppm
Hc HTd He Mea Meb
Hb ^
M e. i o' 8  CDCI3 6.29 4.34 4.42 4.19 2 . 0 1 N/A
—  HO ft sc6h6 5.85 4.33 4.47 3.91 1.53
j X  Ts A8 0.44 0 . 0 1 -0.05 0.28 0.48H* 4, Hd
Hb ..
lviea \
8  CDCI3 6.17 4.08 4.26 N/A 1.39 1.95
2 0 1  w n 1 U 5 CeHe 5.59 4.02 4.24 0.93 1.26
Me+ ss/ Hd
0.58 0.06 0.46 0.69
Synthesis of sulfinic esters.
As discussed in the introduction to this chapter the intention was to open the 
dihydrothiazines using a homo-chiral alcohol to produce an enantiomerically pure 
sulfinic ester. By using a homo-chiral alcohol we were ensuring that if only one 
configuration of the sulfenate was possible during the [2,3]-sigmatropic rearrangement 
then only one sulfinic ester would be formed and thus a mixture of similar products 
would not have to be separated. The alcohols used initially were methanol, cholesterol 
and menthol. The following reaction procedure was used in attempting to synthesise 
these materials, figure 64.
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Figure 64; Synthetic procedure for sulfmic esters.
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This reaction when using either the cholesterol or the menthol did not react and the 
starting materials were initially recovered quantitatively. When using the primary 
alcohol methanol the reaction proceeded smoothly as depicted in figure 65. The metal 
salts of the secondary alcohol were formed with sodium, lithium and potassium acting 
as the counter ion. It was hoped the sulfinyl group might be activated by a particular 
counter ion allowing reaction with the alkoxide, unfortunately this was not to be the 
case.
It was proposed this might be due to the sulfinyl group not being activated sufficiently 
for reaction with the alcohol. The subsequent attempts utilised SnCl4 to activate the 
sulfinyl bond. When the dihydrothiazine was allowed to associate with the SnCl4 
before addition of the cholesterol the reaction appeared to be successful. The 
cholesterol ester 205 was isolated as a single diastereomer and characterised, figure 65. 
However, the reaction was found to be extremely capricious. This was puzzling, despite 
being meticulous with regard to the reaction protocol and the purity of the materials 
being used the reaction proved to be unsuccessful. A number of other Lewis acids were 
employed including TiCl4, BF3 and A1C13, none of which were successful. In addition 
two different esterification catalysts were used to try and solve this situation, namely 
hydroxybenzotriazole and hydroxysuccinimide, alas, these too did not prove to be the 
solution.
Although the cholestanoate sulfinic ester had been synthesised, a substantial amount of 
time had been spent in trying to make this reaction succeed reliably without any 
progress being made. Another approach to opening the dihydrothiazine ring and 
forming the sulfinic ester was sought.
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Figure 65; Synthesis of sulfinic esters using methanol and cholesterol.
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After synthesising the dihydrotliiazines and a number of derivatives as described earlier 
it was apparent that the protons adjacent to the sulfmyl group were acidic as one may 
expect. It was suggested that using a sufficiently strong base it might be possible to 
abstract one of these protons and form a double bond with the sulfur and thus break the 
sulfiir-nitrogen bond. On treatment with the appropriate alcohol it was hoped the 
sulfine group would react forming the sulfinic ester, figure 6 6 .
Figure 66; Alternative synthesis o f sulfinic ester. 
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This reaction was not successful and a sulfinic ester was not isolated from the reaction 
mixture. However, there was a majority product isolated from the reaction mix. On 
characterisation and comparison with the literature120, this proved to be the N-tosyl-3- 
methylpyrrole, the likely mechanism for this product being formed is depicted in figure 
67. A dimethyl pyrrole derivative 210 was also synthesised from the dihydrothiazine 
171.
NHTs
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Figure 67; Synthesis of pyrrole
Bh
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Pyrroles are certainly not novel compounds, however this discovery (although a rather 
elaborate route) in the synthesis of pyrroles does expand on our knowledge of 
dihydrothiazine chemistry. Unfortunately despite all the efforts and attempts to 
synthesise the sulfinic ester, it did not prove possible within this project.
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Synthesis of glucosinolates
Synthesis of the glucosinolates proved to be far more problematic than first expected. 
As discussed earlier other glucosinolates containing bulkier aromatic groups had been 
synthesised without problem in the past. A simple derivative could be obtained 
successfully but for reasons not yet clear, the chloro-oxime intermediate has been 
shown to be very unstable when the side chain only contains five or six carbons. When 
attempting to resolve this problem the oxime was trapped using an acetyl chloride. The 
hydroximate produced was not the expected compound but a chlorinated derivative. 
The majority of the oxime trapped as the ester did not react, it was proposed that this 
might be due to the chloride being hindered by the acetate. Unfortunately the synthesis 
of the target glucosinolate has not been completed within this thesis.
The unresolved problem of this project can be approached from two different 
viewpoints, one can take encouragement from the observations that the oxime has been 
made, and was stable and capable of forming the hydroximate and persevere with this 
synthetic route. Alternatively a new route may be pursued, when isolating the 
bromonitropentane by treatment with dilute acid the solution turned blue which suggests 
the nitroso compound was present for a period of time, providing a new synthetic 
pathway.
Since making these observations it has come to our attention that it is possible to 
produce the oxime through treatment of the nitronate salt with HC1. Yao and co­
workers investigated the synthesis of hydroximoyl chlorides 124, nitro alkenes, and the 
synthesis o f nitrile oxides for 1,3-cycloaddition 125. The synthesis of the hydroximoyl 
chlorides (chloro-oximes) involved the reaction of the nitroalkene with 
triethylaluminium before work up in HC1 acid as described in figure 6 8 . Once the 
diethylaluminium species has been remove to leave 214 this compound is very similar 
to the nitronate salt used earlier. Treating the nitronate salt with concentrated HC1 as 
opposed to dilute acid may well yield the chloro-oxime.
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Figure 68; Synthesis o f chloro-oxime using nitroalkene 124.
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This synthetic pathway is reinforced by Nolands report regarding the N ef reaction 126. 
Here the nitronate salt is discussed and reacted with cold HCI that is reported to produce 
the 1-nitrosoalkanol. On substitution of the aqueous acid for dry HCI the nitronate salt 
was converted to the chloro-oxime using a similar mechanism to that described in figure 
68.
The evidence presented gives a new impetus to the synthesis of the chloro-oxime 
through treatment of the nitronate salt with concentrated HCI, or with dry HCI in ether 
using molecular sieves.
The second viewpoint to producing the chloro-oxime is to modulate the trapping 
procedure. If it is assumed that the chloro-oxime was trapped but was too hindered to 
react sufficiently then a solution to this situation must be found. There are two avenues 
of work that might provide a solution to this problem.
The first would be to increase the reactivity of the trapped oxime with regard to the thio- 
sugar. It is proposed that this may be achieved by replacing the chloride atom with a 
better leaving group such as bromide. By using thionyl bromide and acetyl bromide in 
place of their chloride counterparts this scenario could he achieved easily (figure 69).
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Figure 69; Production of bromo-oxime.
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The isolation of the chloro-acetyl protected hydroximate suggests that increasing the 
electrophilic character of the acetyl group can also increase the reactivity of the oxime 
sufficiently to allow the coupling reaction to take place. This could be achieved easily 
by replacing acetyl chloride with a halogenated acetyl chloride such as dichloroacetyl 
chloride.
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The second avenue of attack regarding use of the trapped oxime would be to utilise a 
smaller nucleophilic species in the coupling reaction. This could be accomplished with 
ease by effectively quenching the oxime (whether it contains a chloride or bromide) 
with hydrogen sulfide (or sodium sulfide). The thiol-oxime could then be coupled with 
a bromo-sugar as depicted in figure 70. Syntheses of thiol-oximes have not been 
reported in the literature.
Figure 70; Synthesis o f thiol-oxime and coupling with bromo-sugar.
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The acetyl protecting the hydroximate could subsequently be removed before forming 
the sulfate salt followed by deprotection of the remaining acetyl groups.
Dihydrothiazines.
As part of this thesis a series of new dihydrothiazines have been successfully 
synthesised. This portion of work has developed a novel synthetic procedure for their 
synthesis allowing three reactions to be performed in the one reaction apparatus. The 
result of this is to provide an efficient route to the dihydrothiazines.
Conclusions Chapter 5
As discussed previously it has been possible to functionalise the thiazine ring. The 
differing reactivity of the thiazines containing different functionalities has been 
highlighted through this work. The inclusion of a chloride in the 5-position in the 
dihydrothiazine appears to activate the sulfoxide towards being oxidised to a sulfone, as 
observed when attempting to epoxidise the thiazine. It was suggested the product 
epoxide readily oxidises the dihydrothiazine. A series of dihydrothiazines have been 
epoxidised successfully with high stereoselectivity. Relative stereochemistry could be 
unambiguously assigned using a combination of a single X-ray diffraction study and 
NMR methods. Oxygenated dihydrothiazines have been converted into allylic alcohols. 
All new compounds are valuable building blocks in organic synthesis. In particular 
they possess all functionalities to obtain sulforaphane analogues.
Also, it was discovered that the dihydrothiazines are capable of degrading through two 
separate mechanisms depending on the environment they experience to yield allylic 
amines or hydroxyallylic amines.
Synthesis of sulfinic esters
Dihydrothiazines have been shown to be a reactive material susceptable to degradation 
through hydrolysis, however, it proved difficult to open the dihydrothiazine ring to form 
the sulfmic esters. Synthesis of sulfinic esters through the opening of a dihydrothiazine 
ring was only achieved in two cases using methanol and the chiral secondary alcohol 
cholesterol, to give a single diastereomer. This combined with the observation of the 
dihydrothiazine ring degrading through hydrolysis indicates it is possible to open the 
ring. It would be sagacious to employ other alcohols not used to date, in particular, 
chiral primary alcohols may prove to be useful reactants providing a slightly more 
reactive hydroxyl group.
A number of dihydrothiazines have been produced with groups in all four positions 
around the dihydrothiazine ring. It would be interesting to produce a range of sulfinic 
esters containing different steric groups and thus different sulfur chiralities and 
characterise their anti-cancer potential. As highlight above, this could be achieved 
using simple non-chiral alcohols. This scheme of work would provide a range of novel,
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homochiral sulfinic ester diastereomers, which is interesting from a chemical 
perspective, but in addition, once these compounds are converted into the respective 
isothiocyanates their biological potency can be assessed. Despite this portion of work 
being currently problematic in scope, the proposed scheme was shown to have promise.
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General details
All chemicals and solvent used were bought through the Sigma-Aldrich Chemical 
Company and solvents used were dried according to literature methods127. Thin layer 
chromatography was carried out using Merck 0.25 mm precoated 60 F254 silica gel 
aluminium plates and column chromatography was performed using Fluka silica gel 
pore size 33-70 jam. All solvent ratios quoted refer to volumes prior to mixing.
Melting points (mp) were determined using a Kofler hot-stage apparatus and are 
uncorrected. Proton and carbon NMR spectra were obtained using a Bruker AC300 and 
DRX500 spectrometer. All spectra are referenced internally to tetramethylsilane (TMS), 
chemical shifts are quote in ppm while coupling constants (J) are reported in Hz. Peak 
assignments in the proton NMR spectra are abbreviated as follows; s — singlet, d = 
doublet, dd = double doublet, t = triplet and m = multiplet. The dihydrothiazines and 
their derivatives purity was assessed by t.l.c. and have the following Rf values (2:1, 
diethylether: hexane); dihydrothiazines 0.19, dihydrothiazine epoxide derivatives 0.29,
4-hydroxy dihydrothiazine derivatives 0.13, sulfur dioxide dihydrothiazine derivatives 
0.65, sulfinic esters 0.82. Infrared absorption spectra were obtained using a Perldn- 
Elmer System 2000 spectrometer, samples were analysed as chloroform solutions or 
Nujol mulls, absorptions (vmax) are reported in cm'1. Elemental analysis was carried out 
using a Leeman CE440 elemental analyzer by Ms. N. Walker, University of Surrey. 
Mass spectra (m/z) and accurate mass were canied out using a Finnigan MAT 95XP 
spectrometer by Mr R. Chaundy, University o f  Surrey. X-ray crystallography was 
determined using a modified Siemens P4 diffractometer by D r N. Burzlaff at the 
Universitat Konstanz.
The nomenclature for naming and numbering the thiazine type compounds used by 
Weinreb and co-workers" has been utilised in this thesis. The core six membered ring 
containing the sulfinylsulfonamide functionality is referred to as the thiazine and the 
subsequent functionality and saturation of the ring is then described.
However, it is acknowledged that using the UP AC nomenclature system it is possible to 
name the compounds by describing the ring system and subsequently identifying the
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sulfmylsulfonamide functionality as an azathiane S oxide. Thus (1 RS)-5-methyl-N- 
(toluenesulfonyl)-3, 6 -dihydro-1 , 2-thiazine S-oxide would be called (l&S)-5-Methyl-N- 
(toluenesulfonyl)-l, 2-azathiane-cyclohex-4-ene S-oxide.
Synthetic procedures.
a-D -Brom o-2,3 ,4 , 6 -Tetraacetylglucose 133104.
OAc
43.2 g (400 ml, 0.42 mol) Of acetic anhydride were placed in a flask and cooled to 4 °C 
before adding 0.24 ml 60 % perchloric acid. The solution was allowed to warm to room 
temperature, 10 g (0.056 mol) D-glucose was added in portions that maintained the 
temperature between 30-40 °C. The solution was then cooled to 14 °C and 3.1 g red 
phosphorus followed by 5.8 ml (0.226 mol) bromine added, 3.6 ml water was then 
added over half an hour while still maintaining the temperature at 14 °C. The reaction 
mixture was allowed to stand for two hours before diluting with 30 ml CH2CI2 and 
filtering through a glass wool plug. The filtrate was washed with 160 ml ice cold water 
before adding to 50 ml saturated solution of sodium hydrogen carbonate. Once the 
evolution of carbon dioxide had ceased the organic layer was separated and allowed to 
stand over 1 g of silica for 10 minutes. The silica was filtered from the solution and the 
solvent removed under reduced pressure at 60 °C. 50 ml of diethyl ether were stirred 
into the syrup, a cream solid crashed out of solution, the solid was washed with 50 ml 
diethyl ether:petroleum ether 1:2 mixture. The a- bromotetraacetylglucose was 
obtained in 90 % yield as a cream crystalline solid and stored briefly in a sealed opaque 
vial in the fridge, due to its degradative nature the compound was only characterised 
using proton NMR and melting point (89-90 °C). 5H (300 MHz, CDC13, Me4Si), 6.60 
(IH, d, J4.0, OCHBr), 5.55 (IH, t, J  10.1, Cif(OAc)), 5.15 (IH, t, J  10.1, Ctf(OAc)), 
4.86, (IH, dd, J  6.2 and 4.0, Ci/(OAc)), 4.31 (2H, m, CH2(OAc)), 4.15-4.26 (IH, m, 
CH(OAc)) and 2.09 (12H, broad s, Orfc).
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p-D-Thiol-2, 3 ,4 , 6 -Tetraacetylglucose 100128.
OAc
AcO ^ °
AcO SH
OAc
5 g (12.2 mmol) a-Bromotetraacetylglucose 133 was added to a flask with 1 g (13 
mmol) thiourea, the reactants were dissolved in 50 ml acetone and refluxed for 1 hour. 
(A little white precipitate formed during the reaction). The acetone was removed under 
reduced pressure before dissolving the white thim-oniumbromide salt in the minimum 
volume of water. 50 ml 2 M sodium metabisulfate was added to the solution before 
heating to 80 °C for ten minutes. 50 ml Chloroform was added with caution! The two 
phase system was refluxed for 15 minutes. The organic layer was separated and the 
water layer was extracted with two 15 ml portions of chloroform. The organic solution 
was dried over sodium sulfate before filtering and removing the solvent under reduced 
pressure to give 100 as a syrup. vmax (CHCD/cm ' 1 3473, 2974, 2550, 1751, 1433, 1370 
and 1230. 8 H (300 MHz, CDC13, Me4Si), 5.18 (1H, t, J  9.1, Ctf(AcO)), 5.09 (1H, t, J
9.4, Ctf(AcO)), 4.96 (1H, t, J9.4, Ctf(AcO)), 4.53 (1H, t, J  10.0, CtfSH), 4.15 (2H, m, 
CH2(AcO)\ 3.73 (1H, m, Ci7CH2 OAc), 2.30 (1H, d, J  10.0, SH) and 2.08-2.00 (12H, 
4s, (OAc)). 8 C (75 MHz, CDC13, Me4Si), 170.8 (CHOCCH3), 170.3 (CHOCOCH3), 
169.8 (CHOCCH3), 169.5 (CH2OCOCH3), 78.9, 76.5, 73.7, 68.3, 62.2, 61.5, 20.9 
(CHOCOCH3), 20.9 (CHOCOCH3), 20.8 (CHOCOCH3) and 20.7 (CH2OCOCH3).
p-D-2, 3 ,4 , 6 -TetraacetyIpyranosyImethylthiohydroximate 140
OAc
AcO
AcO S M e
OAc It
0.54 g (0.01 mol) Sodium methoxide was dissolved in 5 ml methanol, the solution was 
cooled to 0 °C before adding 0.46 g (0.01 mol) nitroethane. A cream precipitate formed
-128-
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immediately, 50 ml diethyl ether was added to force further precipitation of the salt. 
The nitronate salt 138 was filtered and dried under reduced pressure. The salt was 
dispersed in 30 ml chloroform and 1.46 ml (24 mmol) thionyl chloride was added at -60  
°C. The mixture was stirred for 5 minutes, filtered into a solution of 10 ml ice-cold 
water. The filtrate was shaken, the organic layer separated and dried over CaCl2. The 
chloro-oxime was too reactive to characterise and was used instantly. The solution of 
139 was cooled to -10 °C before adding 1.82 g (5 mmol) 100 and 4.8 ml (0.065 mol) 
triethylamine, the solution was stirred for 30 min. The resulting solution was washed 
with two 200 ml portions of 0.5 M H2SO4 followed by two 200 ml portions of water. 
The combined organic layers were separated and dried over sodium sulfate. The solvent 
was removed imder reduced pressure to yield a straw-coloured syrup in (0.5 g) 24 % 
yield. As a model compound this was only confirmed through proton NMR before 
being used to synthesise the glucosinolate. 5H (300 MHz, CDCI3, Me4 Si) 5.27 (1H, t, J  
8.9, CH), 5.07 (1H, m, CH), 5.04 (1H, m, CH), 4.98 (1H, d, J  10.1, CH), 4.15 (2H, m, 
CH2), 3.80 (1H, m, CH), 2.25 (3H, s, SC(NOH)Cff3) and 2.08 (1 2 H, broad s, AcO).
p-Methylglucosinolate 141.
OH
OH IT 
K+'03SO/N
To a solution of 140 (1 g, 2.4 mmol) in 20 ml chloroform was added 1 g (6.3 mmol) 
pyridinesulfurtrioxide and stirred for 24 hours. The suspension was then poured into 80 
ml 10 % KHCO3 before freeze-drying. The solid was extracted with three 100 ml 
portions of hot ethanol. The product was crystallised from the combined extracts and 
obtained in an 84 % yield ( 1 . 1  g) as white crystals, mp 160 °C (decomposed). vmax 
(Nujoiycm' 1 3469, 2909, 1651 and 1272. 5H (500MHz, D20 , Me4 Si) 4.97 (1H, d, J9.9, 
CH), 3.83 (1H, dd, J  10.4 and 2.1, CH2), 3.64 (1H, dd, J6.0 and 6.7, CH2), 3.49 (2H, m, 
CH + CH), 3.37 (2H, m, CH) and 2.22 (3H, s, Me). 8 C (125MHz, D2 0 , Me4 Si) 153.9,
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81.3, 79.8, 77.1, 72.0, 69.2, 60.6, 17.7. m/z(El) 366 ([M+]-5H, 15 %). The NMR is 
found in Appendix C.
2 , 3, 4, 6 -Tetra-O-acetyl-p-D-pyraiiosyl-O-beiizoylmethyltIiiohydroximate 140a
OAc
0.32 g (0.76 mmol) 140, 0.11 g (0.76 mmol) Benzoyl chloride, 0.084 g (0.8 mmol) and 
0.007 mmol DMAP were dissolve in 20 ml CH2CI2 and allowed to stir overnight at 
room temperature. The solution was washed with three 100 ml portions of water before 
separating the organic phase and drying it over sodium sulfate. The solvent was 
removed under reduced pressure to give a white crystalline solid in 80 % yield (0.32 g), 
mp 173-174 °C. vImx (Nujoiycm ' 1 2922, 1755, 1648, 1597 and 1242. 8 H (500 MHz, 
CDCI3 , Me4Si) 7.99 (2H, d, J  7.2, ArH), 7.53 (IH, t, J  7.4, ArH), 7.42 (2H, t, J  7.9, 
ArH), 5.23 (IH, t, /9 .1 , CH),5.04 (2H, m, CH), 4.99 (IH, d, J  10.1, 4.11 (2H, m,
CH2), 3.74 (IH, m, CH), 2.43 (3H, s, CHs), 2.01 (3H, s, O/tc) 1.99 (3H, s, OAc), 1.98 
(3H, s, O Ac)and 1.96 (3H, s, O Ac).5C (125 MHz, CDC13> Me4Si) 170.4, 170.1, 169.3,
169.2, 162.9, 160.1, 133.6, 129.8, 128.7, 128.4, 80.4, 76.2, 73.6, 69.8, 67.9, 62.2, 20.6, 
2 0 .6 , 20.5, 20.5 and 18.7. m/z (El) 526 ([Mj-H, 17 %), 331 ((Mj-CsJHgNOjS, 97 %), 
[Found: M++H, 526.1378. C23H2SOnNS requires M'+H, 526.1384],
<5*
l-Bromo-5-nitropentane 144.
iO’
10 g (4.38 mmol) dibromopentane and 1.5 g (21.9 mmol) sodium nitrite was dissolved 
in 50 ml dimethylformamide. The solution was stirred at room temperature for 24 
horns. 100 ml of diethyl ether was added to the stirring solution followed by 300 ml 
water. The organic layer was separated and the aqueous layer was extracted with three
- 1 3 0 -
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50 ml portions of diethyl ether. The combined organic extracts were added to 10 ml of
2.19 M sodium methoxide in methanol at 0 °C producing a cream precipitate of the 
nitronate salt. The suspension was filtered and washed with three 50 ml portions of 
diethyl ether, the salt was recovered and dilute hydrochloric acid added until slightly 
acidic (a blue colour appeared for a short period of time before disappearing). The 
aqueous solution was extracted with three 30 ml portions of diethyl ether, using a 
separatory funnel the organic layer was isolated and dried over sodium sulfate before 
filtering and removing the solvent under reduced pressure. The product was obtained as 
a dark orange oil, 65 % yield (2.7 g). vmax (chloroformycm' 1 2925, 1495, 1149, 972. 8 H 
(300 MHz, CDC13, Me4 Si) 4.37 (2H, t, J6.9, CH2), 3.38 (2H, t, J 6.6, CH2), 2.00 (2H, 
m, CH2), 1.86 (2H, m, CH2) and 1,50 (2H, m, CH2). 8 C (75MHz, CDC13, Me4 Si) 75.7,
33.5.32.4, 28.4 and 27.6.
2.3 .4 , 6-Tetra-0-acetyI-p-I)-pyranosyl-0“Cliloroacetyl-4-broino- 
butyltkiohydroximate 158.
OAc
0.9 g (4.6 mmol) l-Bromo-5-nitropentane was added to 10 ml 0.46 M sodium 
methoxide solution in methanol. The solution turned cloudy and upon the addition of 
2 0 0  ml diethyl ether a milky suspension was produced, filtered and the solvent removed 
under reduced pressure. The nitronate salt is known to degrade over a period of time 
and was used directly once it was sufficiently dry for grinding. 1 g (4.6 mmol) of the 
nitronate salt was ground, dispersed in 30 ml CH2CI2 and cooled to -78 °C, 0.34 ml (4.6 
mmol) acetylchloride was added, the suspension was allowed to stir for 30 min. 0.47 
ml (4.6 mmol) thionyl chloride was added to the solution still maintained at -78 °C, an 
intense blue colour appeared and the solution was allowed to stirred for 5 minutes. 1.74 
g (4.6 mmol) 1 0 0  was deprotonated in a solution of CH2C12 using 1.28 ml (9.2 mmol) 
triethylamine over a 2 0  minute period previously before adding to the blue solution 
slowly. The solution was allowed to warm to room temperature over the following hour
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before work up. The resulting solution was washed with two 200 ml portions of 0.5 M 
H2SO4 followed by two 200 ml portions of water. The organic layer was isolated and 
dried over sodium sulfate before removing the solvent under reduced pressure to yield a 
straw-coloured syrup. The mixture of products were separated using column 
chromatography (ethyl acetate :hexane, 1 :1), the major product was the starting material 
100 recovered in a 90% yield, the hydroximate 158 was also recovered in a 4 % yield 
(0.1 g) as a straw coloured syrup. vmax (chloroform)/cm_1 3480,2958, 1756, 1603,
1432, 1228, 1044 and 731. 5H (500 MHz, CDC13, Me4 Si) 5.21 ( 1 H, t, J9.3, CH), 5.05 
(1 H, t,J9J, CH), 5.01 ( 1 H, t, J9.1, CH), 4.86 (1 H, d, / l  1.9, ClCtf2), 4.78 (1H, d, J
10.2, CH), 4.61 (1H, d ,/1 1 .9 , CIOH2), 4.20 (1H, dd,J7.5 and 4.9, CH2), 4.10 (1H, dd, 
J  10.3and 2.1, CH2), 3.71 (1H, m, CH), 3.38 (2H, m, Ctf2Br), 2.63 (2H, t, J7.2, CH2),
2.02 (3H, s, CH3CO), 1.99 (3H, s, CH3CO), 1.97 (3H, s, CH3CO), 1.94 (3H, s, CH3CO) 
and 1.70-1.90 (4H, m, 2CH2). 5C (125 MHz, CDC13, Me4Si) 170.5 (CH3 COO), 170.1 
(CH3 COO), 169.4 (CH3 COO), 169.4 (CH3 COO), 157.1 (SCN), 81.1, 76.0, 73.6, 69.8,
68.1, 61.8, 45.3 (CH2C1), 31.4, 31.1 (CH2Br), 30.3, 21.4, 2 0 . 6  (CH3 CO) and 20.5 
(CH3CO). m/z (El) 450 ([M+]-C8H80 4, 9 %), 331 ([M+]-C7HioBrClN0 2 S, 98 %), 289 
([M+]-C14H 190 9, 2  %) and 2 1 1  ([M+]- C16H2iC1Oi0) 6  %).
On inspection of the proton NMR (found in Appendix C) it is clear* the sample is 
present although a small amount of side chain impurity may be present. The peak found 
at 2.63ppm was identified as the side chain methylene group alpha to the 
hydroximate129.
SuIfinyl-N-toIuenesulfonamide 162.
o
11s
I
o=s=o
1.9 g (27.6 mmol) imidazole was dissolved in 50 ml CH2C12, the solution was cooled to 
-10 °C and 0.5 ml (13.8 mmol) thionyl chloride was added and stirred for 10 minutes. 
A further 0.5 ml (13.8 mmol) of thionyl chloride was added and stirred for 10 minutes.
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The solution was cooled to -10 °C and 2.36 g (13.8 mmol) toluenesulfonamide were 
added to the solution. The solution was stirred for 1 horn*. The apparatus described in 
figure 71 was inverted to filter the solution through the glass sinter, leaving a clear 
yellow solution in the second flask. This was used in-situ for the synthesis of the 
following dihydrothiazines.
Figure 71; Synthetic apparatus for dihydrothiazine synthesis.
(l/?*S1)“5-Methyl-2-(toIuenesulfonyl)-3, 6 -dihydro-l, 2-thiazine S-oxide 165 l30.
To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2CI2) at -1 0  °C. 1.9 g 
(27.6 mmol) isoprene was added. The mixture was stirred for 24 hours at room 
temperature. The solvent was removed under reduced pressure and the resulting solid 
was washed with three cold 50 ml portions of diethyl ether. The solid was dried under 
reduced pressure to remove any residual diethyl ether. 165 was obtained as a cream 
solid in an 85 % yield (3.33 g), mp 128-130 °C. vmax (Nujoiycm ' 1 2925, 1597, 1349, 
1167 and 1103. 5H (500 MHz, CDC13, Me4Si) 7.80 (2H, d, *7 8.2, ArH), 7.34 (2H, d, J
8.2, ArH), 5.64 (IH, s, C//CH 2), 4.05 (IH , d, J  16.0, Ctf2N), 3.58 (2H, m, CH2SO and 
Ctf2N), 3.21 (IH , d, J  15.3, CH2SO), 2.43 (3H, s, C i/3C6H4), 1.81 (3H, s, C i/3CCH2), 
5C (125 MHz, CDCI3 , Me4Si) 145.9, 134.9, 130.9, 128.8, 123.4, 118.4, 55.3 (CH2SO),
-133  -
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40.4 (CH2N), 25.1 (CH3) and 22.5 (CH3Ar). m/z (El) 285 ([M+], 15 %), 237 ([M+]-SO, 
75 %) and 155 ([M+]-C5H8NSO, 100 %). (Found: C 50.43, H 5.33, N 4.76. 
Ci2Hi5NS20 3 requires: C. 50.53, H. 5.26, N 4.91).
(li?5) 4, 5-Dimethyl-2-(toluenesulfonyl)-3, 6 -dihydro-l, 2-thiazine 1-oxide 167 131.
To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2C12) at -10 °C. 2.26 
g (27.6 mmol) 2,3-dimethylbutadiene was added and the solution was stirred for 24 
hours at —10 °C. The solvent was removed under reduced pressure to leave a cream 
coloured solid. The solid was washed with three cold 50 ml portions o f diethyl ether to 
yield a cream powder that was dried under reduced pressure to remove any residual 
ether. The dihydrothiazine was produced in a 90 % yield (3.71 g), mp 112-114 °C. vm,x 
(Nujol)/cm4  2922, 1635, 1598, 1353, 1169 and 1089. 8 H (500 MHz, CDCI3 , Me4 Si)
7.81 (2H, d, J 8 .2 , ArH), 7.35 (2H, d, J 8.2, ArH), 3.85 (1H, d, J16.0, Ci*N), 3.62 (1H, 
d, J  15.3, C7T2SO), 3.44 (1H, d, J  16.0, C7T2N), 3.21 (1H, d, 15.3, C7T2SO), 2.43 (3H, 
s, C773Ar), 1.76 (3H, s, CH3CCH2N) and 1.69 (3H, s, Ci73CCH2SO). 8 C (125MHz, 
CDCI3 , Me4 Si) 145.2, 134.2, 130.2, 128.2, 123.7, 115.1, 55.8 (CH2SO), 43.4 (CH2N),
21.9 (CH3Ar), 19.8 (CH3CH2N) and 17.2 (CH3CH2SO). m/z (El) 299 ([M+], 17 %), 251 
([M+l-SO, 21 %) and 155 ([M+]-C6Hi0NSO, 58 %). (Found C 52.20, H 5.75, N 4.73, 
Ci3Hl7N 0 3S2. Requires C 52.17, H 5.69, N 4.68.).
(IRS) 5-Chloro-2-(toluenesulfonyl)-3,6 -dihydro-l, 2-thiazine S-oxide 169132.
- 134-
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To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2 CI2) at -10  °C. 2.4 
g (27.6 mmol) chloroprene was added and stirred for 24 hours at room temperature. 
The solvent was removed under reduced pressure to leave a dark solid. The solid was 
washed with four cold 50 ml portions of diethyl ether to yield a cream coloured powder 
that was dried under reduced pressure to remove any residual ether. The 
dihydrothiazine was obtained in a 6 6  % yield (2.8 g), mp 104-107 °C. vmax (Nujol)/cm'' 
2926, 1674, 1597, 1361, 1163, 1103 and 787. 5H (500 MHz, CDCI3 , Me4Si) 7.78 (2H, d, 
J  8.2, ArH), 7.36 (2H, d, J8.2, ArH), 6.04 (IH, t, J2.5, CH), 4.22 (IH, m, Ci72N), 3.88 
(IH, m, C±T2 SO), 3.66 (IH, m, C//2N), 3.50 (IH, m, Ci72SO) and 2.44 (3H, s, C//3Ar). 
5c (125 MHz, CDCI3 , Me4 Si) 145.1, 133.3, 129.8, 127.4, 120.4, 120.2 (CH), 55.8 
(CH2SO), 40.0 (CH2N) and 21.2 (CH3Ar). m/z (El) 306/308 ([M+], 100 %). (Found: C 
43.34, H 3.90, N 4.53, CUH 12NS20 3C1. Requires C 43.21, H 3.93, N 4.58).
(1 RS, 6RS) 5,6-Dimethyl-2-(toluenesuIfonyl)-3, 6 -dikydro-l, 2-thiazine S-oxide 171.
To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2 C12) at -10 °C. 2.26 
g (27.6 mmol) 3-methylpenta-2, 4-diene was added and the solution was stirred for 24 
hours at room temperature. The solvent was removed under reduced pressure to leave a 
dark solid. The solid was washed with four cold 50 ml portions of diethyl ether to yield 
a cream coloured powder that was dried under reduced pressure to remove any residual 
ether. The dihydrothiazine was obtained in 83 % yield (3.42 g), mp 121-122 °C. vmax 
(chloroform)/cm‘l 3055, 1598, 1354, 1266 and 1170. 5H (500 MHz, CDCI3 , Me4Si)
7.73 (2H, d, *78.2, ArH), 121 (2H, d, .78.2, ArH), 5.53 (IH, s, C77CH2N), 3.92 (IH, d, J
16.2, Ctf2N), 3.45 (2H, m, CT/SO and C772N), 2.34 (3H, s, CT/jAr), 1.69 (3H, s, CH3C) 
and 1.38 (3H, d, *7 7.3, CT/3CHSO). SH (500 MHz, C6D6, Me4Si) 7.91 (2H, d, J  8.2, 
ArH), 6.74 (2H, d, *78.2, ArH), 4.98 (IH, s, C77CH2N), 3.85 (IH, d, J  16.2, C7f2N), 3.41 
(IH, d, J  16.2, C772N), 2.71 (IH, broad s, CT7SO), 1.81 (3H, s, C/foAr), 1.22 (3H, s, 
CHiC) and 0.91 (3H, d, *77.5, CTZ3 CHSO). 5C (125MHz, CDC13, Me4Si) 145.0, 134.0,
- 135-
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130.0, 128.1, 126.8, 118.2 (CHCH2N), 56.7 (CHSO), 40.2 (CH2N), 21.6 (CH3A1*), 21.2 
(CH3C) and 13.1 (CH3CH). m/z (El) 300 ([M+], 100 %) [Found: M++H, 300.07162. 
Ci3H180 3NS2 requires M++H, 300.0723],
(1/?A) 3, 3, 5-Trimethyl-2-(toluenesulfonyl)-3, 6 -dihydro-l, 2-thiazine S-oxide 173.
To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2C12) at -10 °C. 2.65 
g (27.6 mmol) 2,4-dimethylpenta-2,4-diene was added and stirred for 24 hours at room 
temperature. The solvent was removed under reduced pressure to leave a dark solid. 
The solid was washed with four cold 50 ml portions of diethyl ether to yield a cream 
coloured powder that was dried under reduced pressure to remove any residual ether. 
The dihydrothiazine was obtained in an 89 % yield (3.84 g), mp 118-119 °C. vmax 
(chloroform)/cm'‘ 2926, 1596, 1341 and 1161. 5H (500 MHz, CDC13, Me4Si) 7.69 (2H, 
d, J  8.2, Ar.H), 7.24 (2H, d, J  8.2, AiH), 5.45 (1H, s, C77CN), 3.32 (1H, d, J  15.6, 
Cff2SO), 3.20 (1H, d, J  15.6, CH2SO), 2.36 (3H, s, C773Ar), 1.77 (3H, s, CH3CCH2SO), 
1.58 (3H, s, CffjCN) and 1.48 (3H, s, CH3CN). 8 C (125 MHz, CDC13, Me4 Si), 144.8,
139.2, 132.1 (CHCN), 130.1, 127.0, 118.7 (CH3CCH2SO), 53.1 (CH2SO), 50.9 
((CH3)2 CN), 30.5 (CH3CN), 28.6 (CH3CN), 24.7 (CH3CCH2SO) and 21.5 (CH3Ar). 
m/z (El) 314 ([M+]+H, 100 %) and 268 (pvT-SO, 3 %) [Found M++H, 313.98254. 
C14H2 0O3NS2 requires M++H, 313.0879].
(3aSR, 4RS, 5aftS) N-(Toluenesulfonyl)-l, 2, 3, 3a, 4, 5, 5a, 6 , 7, 8-decahydro-4- 
thia-5-aza-as-indacene S-oxide 175.
- 136-
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To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml DCM) at -10  °C. 3.69 g 
(27.6 mmol) 1, l ’-bicyclopentene was added and stirred for 24 hours at room 
temperature. The solvent was removed under reduced pressure to leave a dark solid. 
The solid was washed with four cold 50 ml portions of diethyl ether to yield a cream 
coloured powder that was dried under reduced pressure to remove any residual ether. 
The indacene was obtained in a 62 % yield (3.0 g), mp 134-136 °C. vmax 
(chloroformycm-1 2857, 1657, 1596, 1341 and 1159. 8 H (500 MHz, CDCI3, Me4 Si) 
7.85 (2H, d, J  8.2, MB), 7.34 (2 H, d, J  8 .2 , MB), 4.11 (1H, m, CBN), 3.22 ( 1 H, m, 
CHSO), 2.44 (3H, s, CffjAr), 2.25-2.43 (5H, m, C 2.11 ( 1 H, m, C 1.75-1.82 
(4H, m, CH2), 1.61 (1H, m, CH2) and 1.27 (1H, m, CH2). 8 C (125 MHz, CDCI3 , Me4 Si)
144.3, 137.6, 132.3 (CCHSO), 129.9, 127.1, 125.4 (CCHN), 63.0 (CHSO), 58.9(CHN),
35.5, 31.0, 28.4, 27.4, 24.2, 21.5 and 21.3. m/z (El) 352 ([M+]+H, 73 %) [Found 
[Mj+H, 352.06612. C17H2 2O3NS2 requires [M+J+H, 352.1036],
(IRS, 3SR, 6RS) 2-(toluenesulfonyl)-3,6-diphenyl-3,6-dihydro-l,2-tkiazine S-oxide 
177.
To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2C12) at -10  °C. 5.69 
g (27.6 mmol) 1,4-diphenylbutadiene was added and stirred for 24 hours at room 
temperature. The solvent was removed under reduced pressure to leave a dark solid. 
The solid was washed with four cold 50 ml portions of diethyl ether to yield a cream 
coloured powder that was dried under reduced pressure to remove any residual ether. 
The dihydrothiazine was obtained in a 9 % yield (0.52 g), mp 164-167 °C. vmax 
(chloroformycm' 1 3030, 1597, 1353 and 1167. 8 H (500 MHz, CDC13, Me4 Si) 7.91 (2 H, 
d, J8.0, AiH), 7.58 (2H, d, J7A, AriTCHSO), 7.39 (3H, t ,J 7.1, ArtfCHSO), 7.34 (2H,
-137-
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d, J  7.4, ArtfCHN), 7.29 (3H, t, J7 .1 , ArtfCHN), 7.21 (2H, d, J8 .0 , ArH), 6.09-6.15 
(2H, m, CH, CH), 5.84 (1H, s, CHSO), 4.25 (1H, s, CHN) and 2.45 (3H, s, CH3Ar). SH 
(500 MHz, C6D6, Me4Si) 8.03 (2H, d, J8.0, Ar 7.80 (2H, d, J7 .4 , ArHCHSO), 7.32 
(3H, t, /7 .1 ,  ArHCHSO), 7 . 2 1  (2 H, d, J7 .4 , ArHCHN), 7.09 (3H, t, 77 .1 , ArHCHN),
6.82 (2H, d, /8 .0 , ArH), 6.14 (IH, s, CHSO), 5.92 (IH, m, CH), 5.81 (IH, m, CH), 4.66 
(IH, s, CHN) and 2.45 (3H, s, CH3Ar). 8 C (125 MHz, CDC13, Me4Si) 144.4, 138.9,
136.5, 135.2, 129.6, 129.5, 129.3, 129.2, 129.2, 129.1, 128.9, 128.9, 128.8, 128.6,
128.5, 128.4, 128.2, 127.5, 56.0 (CHSO), 43.2 (CHN) and 21.7 (CH3Ar). m/z (El) 409 
([M+]+H2-0 , 26 %) and 376 ([M++H-SO, 13 %) [Found [M+]+H2-0 , 409.11015. 
C23H23N 0 2S2 requires [M+]+H2 -0 , 409.1165].
N-(toluenesuIfonamide)-3-methylbut-3-ene 178,
Upon storage the dihydrothiazine 165 degraded. The homo allylic amine degradant 178 
was isolated using column chromatography (2 : 1  diethyl ether’.petroleum ether was used 
as the eluent). The vials containing the compound were combined and dried over 
sodium sulfate and the ether was removed under reduced pressure to yield a cream 
coloured crystalline product, mp 37-39 °C. vmax (Chloroform)/cm‘l 3288, 2925, 1651, 
1599, 1326 and 1161. 5H (500 MHz, CDC13, Me4 Si) 7.67 (2H, d, J8.1, ArH), 7.25 (2H, 
d, J  8.1, ArH), 4.74 (IH, s, CH2C), 4.58 (IH, s, CH2C), 4.31 (IH, broad s, Ntf), 2.99 
(2H, q, J  6.5, Ctf2NH), 2.36 (3H, s, CH3Ar), 2.08 (2H, t, /  6.5, CH2C) and 1.52 (3H, s, 
CH3). bc (125 MHz, CDC13, Me4Si) 143.2, 141.4, 136.8 (C(CH3)CH2), 129.7, 127.1,
113.2 (CH2), 40.3 (CH2NH), 37.1 (CH2 C), 21.6 and 21.5. m/z (El) 240 ([M+]+H, 18 %) 
and 184 ([M+]-C4H7, 100 %) [Found [M+]+H, 240.1055. Ci2H18N 0 2S requires [M+]+H, 
240.1053].
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2-N-(toluenesulfonamide)-2,4-dimethyl-pent-4-ene 179.
Upon storage the dihydrothiazine 173 degraded. The homo allylic amine degradant 179 
was isolated using column chromatography (2 : 1  diethyl ethenpetroleum ether was used 
as the eluent). The vials containing the compound were combined and dried over 
sodium sulfate and the ether was removed under reduced pressure to yield a cream 
coloured crystalline product, mp 83-85 °C. vmax (Chloroformycm*1 3279, 2924, 1642, 
1595, 1313 and 1154. SH (500 MHz, CDC13, Me4Si) 7.79 (2H, d, J 8 .2 , AxH), 7.28 (2H, 
d, J  8.2, AiH), 4.97 (1H, s, Ctf2C(CH3)CH2), 4.89 (1H, s, NH), 4.80 (1H, s, 
Ci72C(CH3)CH2), 2.43 (3H, s, CH3Ax), 2.26 (2H, s, CH2\  1.81 (3H, s, CH3) and 1.21 
(6 H, s, (Ci73)2CNH). 8 C (125 MHz, CDC13, Me4 Si) 142.7, 141.5, 140.7 (C(CH3)CH2),
129.4, 126.9, 116.3 (CH2C(CH3)), 56.4 (CNH), 50.9 (CH2CNH), 27.9 ((CH3)2), 24.9 
(CH3) and 21.4 (CH3Ar). m/z (El) 268 ([M+]+H, 2 %) and 212 ([M+]-C4H7, 100 %) 
[Found [M+]+H, 268.1366. Ci4H22N 0 2S requires [M+]+H, 268.1366].
N-(Toluenesulfonamide)-3-methyleiie-7-methyl-oct-6-eiie 181.
To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2C12) at -10  °C. 3.76 
g (27.6 mmol) myrcene was added and the solution was stirred for 24 hours at room 
temperature. The solvent was removed under reduced pressure to leave a straw- 
coloured syrup. The solid was washed with four cold 50 ml portions of diethyl ether to 
give a straw-coloured syrup. This was purified using column chromatography, 2:1 
diethyl ether:petroleum ether was used as the eluent. The fractions containing the
- 1 3 9 -
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majority product were combined and dried over sodium sulfate and the solvent was 
removed under reduced pressure to give amine 181 as a golden syrup. vmax 
(Chloroformycm"1 3283, 2926, 1647, 1599, 1327 and 1161. 8 H (500 MHz, CDCI3, 
Me4 Si) 7.76 (2 H, d, 78.1, Axil), 7.30 (2H, d, 78 .1 , Ar H ),5.01 (1H, t, 76.8, CCHCH2),
4.82 (1H, t, 76.7, NH), 4.79 (1H, s, CH2C), 4.67 (1H, s, CH2C), 3.04 (2H, dd, 76.7  and
6.3, CH2NH), 2.42 (3H, s, CH3Ar), 2.16 (2H, t, 7  6 .8 , CH2CH2NH), 2.01 (2H, q, 7  7.5 
and 7 .2 , CHCH2), 1.87 (2H, t, 78.0, CH2CH2CCH2), 1.66 (3H, s, CH3) and 1.57 (3H, s, 
CH3). 8 c (125 MHz, CDCI3, Me4Si) 145.2, 143.3, 136.9 ((CH3)2CCH), 131.8 (CCH2),
129.6, 127.1, 123.5 (CHCH2), 111.8 (CH2 C), 40.8 (CH2NH), 35.6 (CCH2CH2), 35.3 
(CH2CH2C), 26.1 (CHCH2), 25.6 (CH3), 21.4 (CH3Ar) and 17.6 (CH3). m/z (El) 308 
([M+]+H, 98 %), 184 ([IsTj-CsHu, 51 %), 137 ([M+]-C7H8N 0 2S, 38 %) and 123 ([M*]- 
C8H10NO2S, 9 %) [Found [M^-t-H, 308.1662. Ci7H26N 0 2S requires pvTj+H, 
308.1679],
N-(ToluenesuIfonamide)-cyclohept-3-ene 184.
hnn
Ts
To a solution of 162 (approximately 2.9 g, 13.8 mmol in 50 ml CH2CI2) at - 1 0  °C. 2.59 
g (27.6 mmol) cycloheptadiene was added and the solution was stirred for 24 hours at 
room temperature. The solvent was removed to leave a straw-coloured syrup. The solid 
was washed with four cold 50 ml portions of diethyl ether to yield light yellow syrup. 
This was purified using column chromatography (2:1 diethyl ether:petroleum ether). 
The fractions containing the majority product were combined and dried over sodium 
sulfate and the solvent was removed under reduced pressure to give amide 184 in 10% 
yield, as a white crystalline solid, mp 60-61 °C, a further fraction contained 185. vmax 
(Chlorofoimycm"1 3230, 2921, 1654, 1597, 1323 and 1151. SH (500 MHz, CDC13, 
Me4Si) 7.76 (2H, d, 78.2, ArH), 7.27 (2H, d, 78.2, ArH), 5.86 (1H, m, CH), 5.46 (1H, 
m, CH), 5.17 (1H, d, 7  8.5, NH), 3.35 (1H, m, CHNHTs), 2.40 (3H, s, CH3Ar), 2.13-
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2.20 (2H, m), 2.03 (2H, broad m), 1.71-1.78 (2H, m) and 1.35-1.47 (2H, m). 5C (125 
MHz, CDCI3 , Me4Si ) 143.09, 138.31, 135.04, 129.61, 126.93, 126.41, 51.00, 38.54, 
34.61, 28.22, 22.77 and 21.48 (CH3Ar). m/z (El) 266 ([M+]+H, 100 %), 184 ([M*]- 
C6H9, 37 %), 172 ([Mj-CjH* 23 %) and 95 ([M+]-C7H8N 0 2 S, 36 %) [Fovmd [Mj+H, 
266.1211. CI4H20NO2S requires [M j+H, 266.1209],
(IRS, 2&SVN-CToluenesulfouamideVcyclohept-3-en-2~oI 185.
HO"'*’
The amino alcohol was isolated form the same column chromatography described for 
184. The fractions were combined and dried over sodium sulfate and the solvent 
removed under reduced pressure. An off white solid was produced in 7% yield, mp 
100-102 °C. Vmax (Chloroformycm' 1 3293, 3248, 2858, 1640, 1597, 1322 and 1153. 8 H 
(500 MHz, CDC13, Me4Si) 7.64 (2H, d, /8 .2 , ArH), 7.20 (2H, d, J8.2, ArH), 5.63-5.68 
(2H, m, CH and CHOH), 5.57 (IH, m, CH), 5.06 (IH, dd, J  10.6 and 7.1, CHOH), 4.40 
(IH, d, y  7.5, NH), 4.09 (IH, broad m), 2.35 (3H, s, CH3Ar), 1.96-2.13 (2H, m), 1.60- 
1.77 (2H, m) and 1.35 (2H, m). 8 C (125 MHz, CDC13, Me4 Si) 143.2, 138.7, 132.8,
129.4, 127.1, 126.4, 76.3, 52.9, 31.8, 28.9, 21.2 and 21.1 (CH3Ar). m/z (El) 281 ([M j, 
2 %), 278 ([M+]-3H, 98 %) and 265 ([M+]-0, 3 %). (A 'H NMR can be found in 
Appendix C).
5-Methyl-2-(toluenesulfonyl)-3, 6 -dihydro-l, 2-thiazine S-dioxide 195.
. X X Ts
0.5 g (1.75 mmol) 165 and 0.43 g (1.58 mmol) 70 % m-chloroperbenzoic acid was 
dissolved in 50 ml CH2CI2 and stirred at room temperature for 2 days. The solution was
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washed with two 50 ml portions of 2 M sodium hydroxide and two 50 ml portions of 
water. The organic layer was separated and the solvent was removed under reduced 
pressure. This was purified using column chromatography using diethyl ether, the 
fractions relating to the majority product were combined and dried over sodium sulfate 
before removing the solvent under reduced pressure. The product was obtained as a 
white crystalline solid in 90 % yield (0.47 g), mp 105-107 °C. vmax (Chloroformj/cm' 1 
2922, 1598, 1378 and 1167. 5H (500 MHz, CDC13, Me4Si) 7.82 (2H, d, J  8.3, AiH), 
7.33 (2H, d, J  8.3, ArH), 5.64 (1H, s, C#CH2), 4.65 (2H, s, Ctf2N), 3.63 (2H, s, 
Ctf2SO), 2.44 (3H, s, Ctf3Ar) and 1.77 (3H, s, Ctf3). 5C (125MHz, CDC13, Me4 Si) 
145.2, 136.5, 129.6, 128.3, 127.9, 118.5 (CHCH2), 52.7 (CH2 SO), 48.6 (CH2N), 23:2 
(CH3) and 21.7 (CH3Ar). m/z (El) 302 ([M+]+H, 99 %) and 238 ([M+]-S02, 3 %) 
[Found [M+]+H, 302.0512. Ci2Hi6N 0 4S2 requires [M+]+H, 302.0515].
5-Chloro-2-(toluenesulfonyl)-3, 6 -dihydro-l, 2-thiazine S-dioxide 196.
0.5 g (1.64 mmol) 168 and 0.43 g (1.75 mmol) 70 % m-chloroperbenzoic acid were 
dissolved in 50 ml CH2C12 and stirred at room temperature for 2 days. (A large excess 
can be used, however only the sulfone is produced). This solution was washed with two 
50 ml portions of 2 M sodium hydroxide and two 50 ml portions o f water. The solution 
was dried over sodium sulfate before removing the solvent under reduced pressure. The 
product was obtained as a white crystalline solid in 92% yield (0.48g), mp 90-92°C. 
vmax (Chloroform)/cm4  2925, 1658, 1597, 1380 and 1154. 5H (500 MHz, CDC13, 
Me4Si) 7.75 (2H, d, 78.2, Ar H).7.28 (2H, d, 78.2, A 6.04 (1H, s, C 4.60 (2 H, s,
Cff2N), 3.87 (2H, s, C772SO) and 2.38 (3H, s, Cff3Ar). 5C (125 MHz, CDC13, Me4Si)
145.7, 135.8, 129.7, 128.4, 122.9, 121.8 (CH), 54.5 (CH2SO), 47.4 (CH2N) and 21.7 
(CH3Ar). m/z (El) 322/324 ([M'O+H, 56 %) [Found [M*]+H, 321.9921. 
C„H13N 0 4 C1S2 requires [M ^ H , 321.9969],
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(IRS, 4RS, 5SR) 5-M ethyl-2-(toluenesulfonyl)-3,4, 5, 6-tetraliydro-4, 5-oxa-l, 2- 
thiazine S-oxide 194.
0.5 g (1.75 mmol) 165 and 2.58 g (10.5 mmol) 70 % ra-chloroperbenzoic acid were 
dissolved in 50 ml CH2Cl2and stirred for 2 days. This solution was washed with two 50 
ml portions of 2 M sodium hydroxide and two 50 ml portions of water. Subsequently 
the solution was dried over sodium sulfate before removing the solvent under reduced 
pressure. The product was recrystallised from diethyl ether to give a white crystalline 
solid in 94 % yield (0.49 g), mp 136-138 °C. vmax (Chloroformycm' 1 3057, 1597, 1266 
and 1171. 5H (500 MHz, CDC13, Me4Si) 7.80 (2 H, d, J  8 .2 , ArH), 7.32 (2H, d, J  8 .1 , 
ArH), 4.90 (1H, d, J  15.9, Hd), 4.23 (1H, d, J  15.9, Hc), 3.58 (1H, d, /  14.8, Hb), 3.25 
(1H, d, J  14.8, Ha), 3.06 (1H, s, He), 2.43 (3H, s, CH3Ar) and 1.48 (3H, s, CH3). 6 H 
(500 MHz, C6D6, Me4 Si) 7.89 (2H, d, /8 .2 , ArH), 6 . 6 8  (2H, d, J8.2, ArH), 4.63 (1H, d, 
J  15.7, Hd), 3.74 (1H, d, J  15.7, Hc), 3.30 (1H, d, J  14.7, Hb), 2.36 (1H, d, J  14.7, Ha), 
2.05 (1H, s, He), 1.77 (3H, s, Ctf3Ar) and 0.66 (3H, s, CH3). 5C (125 MHz, CDC13, 
Me4 Si) 145.9, 137.3, 130.2, 129.1, 56.8 (CH3 CCH2SO), 54.0 (CHCH2N), 53.2 
(CH2SO), 48.0 (CH2N), 24.5 (CH3) and 22.3 (CH3Ar). m/z (El) 302 ([M+]+H, 3 %) and 
254 ([M+]-SO+H, 12 %).(Found C 45.12, H 4.76, N 4.25, C12Hi7NS2 0 5 
(Ci2H15NS20 4 H20). Requires C45.10, H 4.62, N 4.34). ANOESY, COSY and HMQC 
spectra were also obtained to confirm the above analysis. A TH NMR can be found in 
Appendix C.
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(IRS, 4RS, 5SR) 4, 5-DimethyI-2-(tohienesulfonyI)-3,4, 5, 6-tetrahydro-4, 5-oxa-l, 
2-thiazine S-oxide 197.
0.5 g (1.75 mmol) 167 and 2.58 g (0.0105 mmol) 70 % m-chloroperbenzoic acid were 
dissolved in 50 ml CH2CI2 and stirred for 2 days. This solution was washed with two 
50 ml portions of 2 M sodium hydroxide and two 50 ml portions of water. 
Subsequently the solution was dried over sodium sulfate before removing the solvent 
under reduced pressure. The product was obtained as a white crystalline solid in 8 8  % 
yield (0.49 g), mp 122-124 °C. vm  (Chloroformycm' 1 3055, 1598, 1266 and 1168. 8 H 
(500 MHz, CDCI3, Me4 Si) 7.84 (2H, d, 78.2, A 7.35 (2H, d, 78.2, Ar 4.73 (1H, 
d, 715.6, Hd), 4.08 (1H, d, 715.6, H c) , 3.64 (1H, d, 714.8, 3.24 (1H, d, 714.8, Ha),
2.47 (3H, s, CtfjAr), 1.50 (3H, s, (C7T3 )b) and 1.43 (3H, s, (C 8 H (500 MHz, C6H6, 
Me4 Si) 7.93 (2H, d, 78.2, Ar H),6.70 (2H, d, 78.2, Ar 4.57 (1H, d, 715.5, Hd), 3.72
(1H, d, 7  15.5, Hc), 3.37 (1H, d, 7  14.7, H  2.39 (1H, d, 7  14.7, H„), 1.79 (3H, s, 
CftAr), 0.68 (3H, s, (C #3)b) and 0.66 (3H, s, 8 C (125 MHz, CDC13, Me4Si)
145.4, 137.1, 129.8, 128.8, 59.5 (OCCH2SO), 57.7 (OCCH2N), 53.4 (CH2SO), 51.7 
(CH2N), 22.0 ((CH3)2) and 16.1 (CH3Ar). m/z (El) 314 ([M+]-H, 17 %) and 268 
([M+]+H-SO, 6  %). (Found C 4.40, H 5.11, N  4.31, Ci3Hi9NS20 5 (Ci3Hi7NS2 0 4 'H20). 
Requires C 46.80, H 5.09, N 4.20). A  NOESY, COSY and HMQC spectra were also 
obtained to confirm the above analysis.
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(IRS, 4RS, 5SR, 6RS) 5,6-Dimethyl-2-(toliieiiesulfonyl)-3, 4, 5, 6-tetrahydro-4,5- 
oxa-1,2-thiazine S-oxide 198.
0.5 g (1.67 mmol) 171 and 2.47 g (10 mmol) 70 % m-chloroperbenzoic acid were 
dissolved in 50 ml DCM and stirred for 2 days. This solution was washed with two 50 
ml portions of 2 M sodium hydroxide and two 50 ml portions of water. Subsequently 
the solution was dried over sodium sulfate before removing the solvent under reduced 
pressure. The product was obtained as a pale yellow syrup in 84 % yield (0.46 g). vmax 
(ChlorofonrO/cm'1 2990, 1597, 1271 and 1157. 8H (500 MHz, CDC13, Me4Si) 7.81 (2H, 
d, 7  8.0, ArH), 7.31 (2H, d, 78.0, ArH), 4.79 (1H, d, 7  15.1, H c), 4.09 (1H, d, 7  15.1, 
Hs), 3.26 (1H, q, 77.1, H a), 3.16 (1H, s, H d), 2.42 (3H, s, CHjAr), 1.44 (3H, s, (CH3)b) 
and 1.33 (3H, d, 77.1, (CH3)a). SH (500 MHz, C6D6, Me4Si) 7.88 (2H, d, 78.2, ArH),
6.74 (2H, d, 78.2, ArH), 4.62 (1H, d, 715.0, 3.73 (1H, d, 715.0, H*), 2.60 (1H, q, 7
7.1, H a), 2.33 (1H, s, H d), 1.80 (3H, s, CffjAr), 1.20 (3H, d, 77.1, (CHj)a) and 0.78 (3H, 
s, (CH3)b). 5C (125 MHz, CDC13, Me4Si) 145.1, 136.4, 129.8, 128.4, 59.5 (OCCHSO),
57.3 (CHaSO), 56.4 (CHd), 46.0 (CH2N), 23.0 ((CH3)b), 21.6 (CH3Ar) and 20.5 
((CH3)a). m /z  (El) 332 ([M+]+HO, 3 %), 314 ([M+]-H, 1 %) and 268 ([M+]+H-SO, 24 
%) [Found [M+]+HO, 332.0624. Ci3H 18N 05S2 requires [M^+OH, 332.06721], A 
NOESY, COSY and HMQC spectra were also obtained to confirm the above analysis.
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(IKS, 5SR, 6RS, 8RS, 12RS)-31'5. 3S,U. 25'8. T'n-7-(ToliienesiiIfonyl)-l, 2 ,3 ,4 ,5 , 6,7, 
8, 9 ,1 0 ,1 1 ,12-dodecahydro-l, 12-oxa-6-thia-7-aza-as-indacene S-oxide 199.
Ts
0.5 g (1.42 mmol) 175 and 2.10 g (8.5 mmol) 70 % m-chloroperbenzoic acid were 
dissolved in 50 ml CH2CI2 and stirred for 2 days. This solution was washed with two 
50 ml portions of 2 M sodium hydroxide and two 50 ml portions of water. 
Subsequently the solution was dried over sodium sulfate before removing the solvent 
under reduced pressure. The product was obtained as a cream solid in 88 % yield (0.46 
g), mp 144-146 °C. vmax (ChloroformVcm'1 2970, 1598, 1296 and 1177. 5H (500 MHz, 
CDC13, Me4Si) 7.69 (2H, d, ^  8.1, ArH), 7-23 (2H, d, / 8.1 , ArH), 5.00 (IH, dd, J7 .6  
and 3.9, H„), 2.96 (IH, t, J 6 .8, H b), 2.33 (3H, s, CH3Ar), 2.24 (IH, m, CH2CHa), 2.00- 
2.11 (3H, m) and 1.63-1.84 (8H, m, (CH2)4). 8H (500 MHz, C6D6, Me4Si) 7.69 (2H, d,
8.2, ArH)), 7.23 (2H, d, .78.2, ArH), 5.33 (IH, dd, 7.8 and 3.6, H„), 3.22 (IH, t, 76.5, 
Hs), 2.14-2.23 (2H, m, CH2CHa and CH2CHb), 1.81 (IH, m, CH2CHa), 1.78 (3H, s, 
CH3Ar) and 1.00-1.50 (9H, m, (CH2)4 and CH2CHb). 8C (125 MHz, CDC13, Me4Si)
145.0, 136.6, 129.4, 127.8, 73.4 (OCCHa), 64.1 (OCCHb), 63.6 (CHaSO), 61.0 (CHbN), 
31.7 (CH2), 31.5 (CH2), 27.0 (CH2), 26.3 (CH2), 23.5 (CH2), 21.6 (CH3Ar) and 19.4 
(CH2). m /z  (El) 367 ([M+], 9 %) [Found [M+], 367.0852. Ci7H2,N 04S2 requires [M j, 
367.0907]. A NOESY, COSY and HMQC spectra were also obtained to confirm the 
above analysis.
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(l/RS, 4RS) 5-Methyl-4-hydroxy-2-(toluenesulfonyl)-3, 4-dihydro-l,2-thiazine S- 
oxide 200.
To a solution of 0.2 g (0.66 mmol) 194 in 30 ml dry THF 2.7 mg (0.66 mmol) sodium 
hydride (washed in petroleum ether) was added and the mixture was stirred for half an 
hour at room temperature. The solvent was removed under reduced pressure, the solid 
was dissolved in 30 ml CH2CI2 and washed with two 20 ml portions of 1M HC1 
followed by two 20 ml portions of water. The organic layer was separated and the 
solution dried over sodium sulfate and the solvent removed under reduced pressure. 
The product was obtained as a white crystalline solid in 92 % yield (0.18 g), mp 101 °C. 
vmax (Chloroformycm'1 3524, 2987, 1636, 1597, 1267 and 1179. 8H (500 MHz, CDC13, 
Me4Si) 7.90 (2H, d, 7  8.3, Ar f l ) ,7.36 (2H, d, 7  8.3, Ar 6.29  (1H, s, C#SO), 4.31-
4.44 (2H, m, C#2N), 4.19 (1H, broad m, HOC#), 2.84 (1H, d, 7  8.4, O B ), 2.46 (3H, s, 
CH 3) and 2.01 (3H, s, C B 3A i ). SH (500 MHz, C6H6, Me„Si) 8 .11  (2H, d, 7  8.3, Ar#), 
6.92 (2H, d, 7  8.3, Ax#), 5.85 (1H, s, C#SO), 4.31-4.49 (2H, m, C #2N), 3.91 (1H, 
broad m, HOC#), 3.45 (1H, v. broad s, OH), 1.95 (3H, s, C H 3) and 1.52 (3H, s, 
CH 3Ar). 8C (125 MHz, CDC13, Me4Si) 149.3 (CCHSO), 145.5, 136.0, 129.7, 128.5, 
124.6 (CHSO), 64.73 (HOCH), 51.1 (CH2N), 21.7 (CH3) and 20.5 (CH3Ar). m /z  (El) 
301 ([M+], 11 %), 300 ([M+]-H, 98 %) and 236 ([M+HSO;!, 10  %) [Found [M*], 
301.00675. Cl2HisN04S2 requires [M*], 301.0437], A NOESY, COSY and HMQC 
spectra were also obtained to confirm the above analysis.
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(IR S , 4R S) 4,5-Dimethyl-4-hydroxy-2-(toluenesulfonyl)-3, 4-dihydro-l, 2-thiazine 
S-oxide 201.
0.2 g (0.63 mmol) 197 was added to 30 ml dry THE, 1.5 mg (0.66 mmol) sodium 
hydride (washed with petroleum ether) was added to the solution and the mixture was 
stirred for half an hour at room temperature. The solvent was removed under reduced 
pressure and the solid was dissolved in 30 ml CH2CI2. The solution was washed with 
two 20 ml portions of 1 M HC1 followed by two 20 ml portions of water. The organic 
layer was separated and the solution dried over sodium sulfate before removing the 
solvent under reduced pressure. The product was obtained as a white crystalline solid in 
90 % yield (0.18 g), mp 107-108 °C. vmax (Chloroformycm'1 3443, 2995, 1633, 1597, 
1266 and 1163. SH (500 MHz, CDCI3, Me4Si) 7.90 (2H, d, 7  8.2, ArH), 7.35 (2H, d, 7
8.2, ArH), 6.17 (1H, s, CHSO), 4.26 (1H, d, 715.1, CH2N), 4.08 (1H, d, 715.1, CH2N),
2.45 (3H, s, (CH3)a), 1.95 (3H, s, CHjAr) and 1.39 (3H, s, (CH3)b). 5H (500 MHz, C6D6, 
Me4Si) 8.08 (2H, d, 7  8.2, ArH), 6.81 (2H, d, 7  8.2, ArH), 5.59 (1H, s, CHSO), 4.24 
(1H, d, 7  15.0, CH2N), 4.02 (1H, d, 7  15.0, CHjN), 1.88 (3H, s, (CH3)a), 1.26 (3H, s, 
CH3Ar) and 0.93 (3H, s, (CH3)b). 5c (500MHz, CDCI3, Me4Si) 152.0 (CCHSO). 145.5,
136.0, 129.8, 128.0, 123.3 (CHSO), 68.0 (OCCH2N), 56.0 (CH2N), 23.3 ((CH3)b), 21.7 
((CH3)b) and 17.8 (CH3Ar). m /z  (El) 315 ([M+], 14 %), 314 (]M+]-H, 99 %) and 250 
([M+]-HS02, 22 %) [Found [M+], 315.0538. C,3Hi7N 04S2 requires [M+], 315.0594], A 
NOESY, COSY and HMQC spectra were also obtained to confirm the above analysis.
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(4RS1, 5aJRS, 8ai^S)-8a-Hydroxy-5-(toluenesulfonyl)-l, 2, 3, 4, 5, 5a, 6, 7, 8, 8a- 
decaliydro-4-thia-5-aza-as-mdacene S-oxide 202.
0,2 g (0.54 mmol) 199 was added to 30 ml dry THF, 1.3 mg (0.54 mmol) sodium 
hydride was added to the solution and the mixture was stirred for half an hour at room 
temperature. The solvent was removed under reduced pressure and the solid was 
dissolved in 30 ml CH2CI2 and washed with two 20 ml portions of 1 M HCI followed by 
two 20 ml portions of water. The organic layer was separated and the solution dried 
over sodium sulfate before removing the solvent under reduced pressure. The product 
was obtained as a syrup in 83 % yield (0.16 g). vmax (Chloroformycm'1 3443, 2971, 
1709, 1596, 1364 and 1179. 5H (500 MHz, CDCI3, Me4Si) 7.80 (2H, d, J  8.2, ArH), 
1 2 1  (2H, d, *78.2, ArH ), 4.92 (IH, t, .79.6, CH b), 2.37-2.82 (4H, m, C772’s), 2.36 (3H, s, 
C77>), 2 .2 1 (2H, m, C772CHN) and 1.57-1.93 (6H, m, C772’s). SH (500 MHz, C6D5, 
Me4Si) 8.18 (2H, d, J8.2, ArH ), 6.91 (2H, d, /8 .2 , ArH ), 5.37 (IH, t, J 9.6, CH b), 2.37- 
2.58 (4H, m, Ci72’s), 2.12-2.36 (2H, m, Ci72CHN), 1.93 (3H, s, C H 2) and 1.40-1.85 
(6H, m, CT72’s). 6c (125 MHz, CDC13, Me4Si) 152.4 (CSO), 145.0, 136.5, 134.8 
(CCSO), 129.6, 128.2, 75.0 (OCCHN), 70.4 (CHN), 37.6 (CH2), 31.4 (CH2), 30.7 
(O i2), 29.9 (CH2), 21.8 (CH2), 20.9 (CH2) and 20,3 (CH3Ar). m /z  (El) 367 ([M+], 22 
%) [Found [M+], 367.0861. Ci7H2iN04S2 requires [M+], 367.0907].
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2-Methyl-4-(toluenesulfonamide)-but-2-eiie-l-sulfimc acid methanoate 204.
0.2 g (0.7 mmol) 165 and 9 pi (0.065 mmol) triethylamine was dissolved in 10 ml 
methanol and allowed to reflux overnight. The solvent was removed and the residue 
dissolved in 20 ml CH2CI2 and the solution washed with 5 ml 1 M HC1 and two 10 ml 
portions of water. The organic phase was separated and dried over sodium sulfate. The 
solvent was removed to give a brown syrup in 81 % yield (0.18 g). vmax 
(Chloroformycm'1 3276, 2927, 1714, 1628, 1600, 1330 and 1162. SH (500 MHz, 
CDClj, Me4Si) 7.75 (2H, d, 77.0, ArH), 7.30 (2H, d, 77.0, ArH), 5.61 (1H, s, CHCH2), 
5.33 (1H, broad s, NH), 3.76 (3H, s, CH30), 3.47 (2H, m, CH2NH), 3.39 (2H, d, 711.0, 
SOCH2C), 2.42 (3H, s, ArCH3) and 1.79 (3H, s, CH3C). 5C (125 MHz, CDCI3, Me4Si) 
143.3, 137.1, 129.6, 129.0, 128.0, 127.2, 60.0, 55.0, 40.5, 24.9 and 21.5. (El) 317 
([M+], 100 %) [Found [M+]+H, 318.0816. C,3H20NO4S2 requires [IvLl+H, 318.0828],
2-Chloro-4-(toluenesulfonamide)-but-2-ene-l-sulfinic acid cliolestanoate 205.
NHTs
To a solution of 0.2 g (0.65 mmol) 169 in 30 ml CH2CI2 0.65 ml SnCl4 (1 M in CH2CI2) 
was added and stirred at room temperature for 10 mins. 0.25 g (0.65 mmol) cholesterol 
and 0.091 ml (0.65 mmol) triethylamine was dissolved in 30 ml CH2CI2 and stirred 
before adding to the dihydrothiazine/SnCl4 solution at 0 °C. The solution was stirred at
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room temperature for 2 hours. The solution was washed with two 30 ml portions of 1 
M sodium hydrogen carbonate followed by two 30 ml portions water. The organic layer 
was separated and the solution dried over sodium sulfate. The solvent was removed 
under reduced pressure to leave a cream crystalline solid in 67 % yield (0.3 g), mp 172- 
174 °C. (Chloroformycm-1 3391, 3020, 1651, 1598, 1216, 1173 and 755. 8H (500 
MHz, CDCI3, Me4Si) 7.71 (2H, d, J  8.1, ArH), 7.29 (2H, d, J  8.1, ArH), 5.9 (IH, m, 
CHCH2), 5.3 (IH, s, CH), 4.15 (IH, d, J  16.8, CH2NH), 3.81 (IH, d, 16.5, CH2SO),
3.45 (IH, d, J  16.8, CHZNH), 3.42 (2H, m, CH2SO+CHO), 2.37 (3H, s, CH3Ar), 2.20 
(2H, m, CH2CHOSO), 0.85-1.92 (27H, m, CH/CH2’s), 0.84 (3H, s, CH3), 0.80 (3H, s, 
CH3), 0.79 (3H, s, CH3), 0.78 (3H, s, CH3) and 0.61 (3H, s, CH3). 8C (125 MHz, 
CDC13, Me4Si) 145.9, 141.2, 134.2, 130.6, 128.3, 122.1, 121.3, 121.0, 72.2, 57.2, 56.7, 
56.5, 50.5, 42.7, 42.7, 40.9, 40.1, 39.9, 37.6, 36.9, 36.6, 36.2, 32.3, 32.0, 28.6, 28.4, 
24.7, 24.2, 23.2, 22.9, 2 2 .1 , 21.5, 19.8, 19.1 and 1 2 .2 . m /z (CI) 690 ([M+]-H, 5 %), 674 
([M+]-OH, 23 %), 611/613 ([M+]-C6H8, 100 %) and 460 ([M+]-C9H9ClN02S, 100 %).
3-Methyl-N-(toIuenesuIfonyl) pyrrole 209120.
A solution of 0.1 g (0.35 mmol) 165 in 10 ml THF was cooled to -78 °C and 0.14 ml 
(2.5 M in hexane) BuLi was added, stirred for 15 minutes. Subsequently, 0.02 g (0.33 
mmol) isopropyl alcohol was added and the reaction stirred for 1 hour before washing 
with two 10 ml portions of 2 M HCI followed by two 10 ml portions of water. The 
organic layer was separated and the solution was dried over sodium sulfate and the 
solvent removed under reduced pressure. The product was obtained as a white 
crystalline product in 83 % yield (0.07 g), mp 61-63 °C. vmax (Chloroformycm'1 3055, 
1596, 1278 and 1171. 5H (300 MHz, CDC13, Me4Si) 7.63 (2H, d ,78.2, A rH ), 7.19 (2H, 
d, 78.2, ArH ), 6.97 (IH, d, 71.6, CHN), 6.00 (IH, s, CCCHN), 6.03 (IH, d, 71.6, 
CCH ), 2.31 (3H, s, CH3) and 1.94 (3H, s, CH2Ar). The data is the same as that found in 
the literature120.
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2, 3-DimethyI-N-(toIuenesulfonyl) pyrrole 210.
To a solution of 0.26 g (0.26 mmol) 171 in 10 ml methanol 4.7 g (0.26 mmol) sodium 
methoxide was added and stirred overnight. The solution was washed with two 10 ml 
portions of 2 M HC1 followed by two 10 ml portions of water. The organic layer was 
separated and the solution was dried over sodium sulfate and the solvent removed under 
reduced pressure. The product was obtained as a white crystalline product in 80 % yield 
(0.2 g), mp 58-60 °C. SH (300 MHz, CDCI3, Me4Si) 7.63 (2H, d, 77.6, Ar#), 7.28 (2H, 
d, 77.6, Ar#), 7.20 (1H, s, C#N), 6.06 (1H, s, C#CHN), 2.40 (3H, s, C# 3), 2.18 (3H, s, 
C H i)and 1.93 (3H, s, C #3Ar).
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Appendix A; Synthesis of naturally occurring ITCs
As mentioned earlier during the project a series of Sokrates and Final Year project 
students (Anja ICasten, Sandra Dorreribecher, Dave Folkered and Steve Masters) have 
under my and Dr Kuhnert’s supervision synthesised a series of naturally occurring 
ITCs. Their work is summarised in this appendix.
Introduction
The inverse relationship between vegetable consumption and the incidence of various 
cancers in human is well established. It is not only the high concentration of vitamins, 
minerals and fibre that are responsible for these effects but a group of compounds 
summarised as phytochemicals.
One major group of phytochemicals are glucosinolates (GLS). GLS p e r  se  are 
biological inactive but following cell disruption, the GLSs undergo enzymatic or 
nonenzymatic hydrolysis. Depending on the reaction conditions and the structure of the 
individual GLS they form structurally different breakdown products (Fig. a) with 
different biological activities. Some of the breakdown products e.g. goitrin, several 
isothiocyanates and nitriles may have adverse and in higher doses toxic effects; others, 
especially isothiocyanates (e.g. sulforaphane), are very likely responsible for the 
protective, anticarcinogenic effects of a high B rassica  vegetable consumption [6, 7].
Figure a; Glucosinolate breakdown products.
O H
Glucoraphanine 1 Sulforaphane 2
Due to a statement of the National Cancer Institute, sulforaphane (SFN), the 4- 
Methylsulfmylbutylisothiocyanate, is one of the 40 most promising anticarcinogens. 
Four chemical syntheses of sulforaphane have been reported to date. The synthesis of 
the remaining ITCs has been briefly mentioned, however no experimental details have 
been reported and only selected spectroscopic data have been reported. Our synthetic 
strategy for the synthesis of the ITCs follows in part the synthesis by Karrer. We have
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reported the synthesis of 14-C labelled SFN and eracin recently using this optimised 
strategy and now report on its extension to give erysolin, iberverin, iberin, cheirolin, 
berteroin and alyssin.
Starting with phthalimido bromides 3a-c displacement of the bromide with freshly 
prepared sodium methanethiolate gave after prolonged reflux the thioethers 4a-c in 
good yields. Selective oxidation with sodium periodate in methanol yielded the 
sulfoxides 5a-c in good yields. Oxidation with 30 % H2O2 yielded the sulfones 6a-c in 
good yields. All compounds display the expected spectroscopical features.
Figure b; Reagents and conditions: (i) NaSMe/EtOH, reflux; (ii) N aI04/MeOH; (iii) 30 % 
H20 2/Et0H/reflux
3a-6a: n = 1 
3b-6b: n = 2 
3c-6c: n = 3
O
4 a-c
O
(Hi)
N" ' 'H r +
n
O 6 a-c
O
Cleavage of the phthalimides using hydrazine monohydrate was uneventful to give the 
amines 7a-c to 9a-c, which were isolated as their hydrochlorides. For the final 
transformations to give the desired ITCs thiophosgene and 3 equivalents of NaOH in a 
diethylether/water two phase solvent system gave the title compounds in reasonable to 
good overall yield. The pure ITCs lOa-c to 12a-c were purified by Kugelrohr 
distillation. Their spectroscopic data are in agreement with the data reported in the 
literature.
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Figure c; reagents and Conditions: (i) 1. N 2H4 monohydrate/EtOH/reflux, 2. 2N-HC1; (ii) S=CCl2/3 eq 
Na0H/Et20-H 20  1:1.
4 a-c
(i)
F 3nA T ss ' cr
(ii)
7 a-c 10 a-c
5 a-c
0)
tH3N » ' S
n
8 a-c
O
cr
.*c n " O
11 a,b, 2
(i)
6 a-c
O
% N » S
" 6
9 a-c
(ii)
cr
4a-12a: n = 1 
4b-12b: n = 2 
4c-12c: n = 3
. u ' ~ y r in
12 a-c
Table a; Yields of compounds.
Compound Yield Compound Yield Compound Yield Compound Yield
4a 8 6 % 6b 65% 8b 98% 10 c 41 %
4b 91 % 6c 70% 8c 91% 1 1 a 67%
4c 90% 9a 8 8 % lib 70%
5a 92% 7a 67% 9b 81 % 1 1 c 32%
5b 8 8 % 7b 82% 9c 74% 1 2 a 43%
5c 78% 7c 85% 10 a 51 % 1 2 b 70%
6a 82% 8a 90% 10 b 48% 1 2 c 56%
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The trivial names of the ITCs synthesised are summarised in the scheme below.
Figure d; Trivial names of isothiocyanates.
Iberverin 10a 
O
Iberin 11a
O
SCN\ / \ / S \
o
Cheirolin 12a
SCN' 
Erucin 10b
Oii
SCN' v  v  x  
Sulforaphane 1 (11b)
O
ii
SCN' O
Erysolin 12b
Berteroin 10c
On
Alyssin 11c
12c (no trivial name given)
Appendix B; X-ray crystallographic data.
3,4-Dimethyl-N-toluenesulfonamidedihydrothiazine 171.
Appendix
Crystal data: Unit cell dimensions; a = 8.186(2) A, alpha = 90 deg, b = 19.182(3) A, 
beta = 101.284(16) deg, c = 9.2955(14) A and gamma = 90 deg. Monoclinic, crystal 
size 0.6 x 0.5 x 0.4mm, P2 (l)/c, a = 8.186(2)A, = 90°, b = 19.182(3)A, =
101.284(16)°, c -  9.2955(14)A, = 90°, Z = 4, D = 1.389mg/m3, F(000) -  632, =
0.375mm'1, 3332 reflections collected, 3122 unique, Rint 0.0321, R l 0.0391, wR2
0.1058 for I> 2  1 ,173 parameters, largest diff. Peak and hole: 0.365 and-0.461 e.A'3.
Measurements a were taken at 188(2)° K using radiation of X = 0.71073A. Accurate 
cell dimensions and crystal orientation matrix were determined using the full matrix 
least square refinement method with 0 in the range of 2.12 to 27.01°.
Table 11; Atomic co-ordinates (x 104) and equivalent isotropic displacement parameters 
(A2 x 103). U(eq) is defined as one third of the trace of the orthogonalised Uij tensor.
X_____________Y_____________ Z___________ U(eq)
S(l) 805(1) 6761(1) 8344(1) 26(1)
S(2) -2534(1) 6209(1) 7650(1) 26910
0 (1 ) 1470(2) 6631(1) 9925(1) 32(1)
0(3) -4054(2) 6458(1) 6747(1) 34(1)
0 (2 ) -1547(2) 5695(1) 7083(2) 35(1)
N(l) -1306(2) 6910(1) 8054(2) 25(1)
C (ll) -2991(2) 592(1)0 9333(2) 26(1)
0(3) 585(2) 8185(1) 8864(2) 30(1)
C(1 2 ) -1726(2) 5616(1) 10380(2) 33(1)
C(15) -4915(2) 5803(1) 10965(2) 30(1)
C(13) -2087(2) 5407(1) 11715(2) 35(1)
0 (2) -893(2) 8084(1) 9227(2) 30(1)
0(16) -4586(2) 6012(1) 9620(2) 29(1)
0(4) 1340(2) 7658(1) 7963(2) 28(1)
0(14) -3674(2) 5504(1) 12036(2) 30(1)
0 (6) 3257(2) 7672(1) 8181(3) 40(1)
0 (1) -1987(2) 7460(1) 8894(2) 37(1)
C(17) -4045(3) 5286(1) 13499(2) 42(1)
0(5) 1546(3) 8852(1) 9283(3) 52(1)
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Table 12; Bond lengths.
Bond Bond length (A)
S(l)-0(1) 1.4847(14)
S(l)-N(l) 1.7201(14)
S(l)-C(4) 1.8276(19)
S(2)-0(4) 1.4376(14)
S(2)-0(3) 1.4398(14)
S(2)-N(l) 1.6762(15)
S(2)-C(ll) 1.7679(18)
N(l)-C(l) 1.485(2)
C(ll)-C(16) 1.394(2)
C(ll)-C(12) 1.402(3)
C(3)-C(2) 1.332(3)
C(3)-C(5) 1.512(3)
C(3)-C(4) 1.520(3)
C(12)-C(13) 1.390(3)
C(12)-H(12) 0.9500
C(15)-C(16) 1.389(3)
C(15)-C(14) 1.398(3)
C(15)-H(15) 0.9500
C(13)-C(14) 1.402(3)
C(13)-H(13) 0.9500
C(2)-C(l) 1.490(3)
C(2)-H(2) 0.9500
C(16)-H(16) 0.9500
C(4)-C(6) 1.543(2)
C(4)-H(4) 0.9500
Table 13; Bond angles.
0(1)-S(1)-N(1) 1 1 0 .2 2 (8)
0(1)-S(1)-C(4) 107.10(8)
N(l)-S(l)-C(4) 94.84(8)
0(2)-S(2)-0(3) 119.86(8)
0(2)-S(2)-N(l) 106.07(8)
0(3)-S(2)-N(l) 106.03(8)
0(2)-S(2)-C(ll) 109.93(8)
0(3)-S(2)-C(l 1) 108.13(8)
N(l)-S(2)-C(ll) 105.91(8)
C(l)-N(l)-S(2) 114.71(12)
C(l)-N(l)-S(l) 120.31(12)
S(2)-N(l)-S(l) 116.21(9)
C(16)-C(l 1)-C(12) 120.82(16)
C(16)-C(ll)-S(2) 119.87(13)
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C(12)-C(ll)-S(2) 119.28(14)
C(2)-C(3)-C(5) 120.72(19)
C(2)-C(3)-C(4) 121.98(16)
C(5)-C(3)-C(4) 117.25(18)
C(13)-C(12)-C(ll) 118.87(17)
C(13)-C(12)-H(12) 120.6
C(ll)-C(12)-H(12) 120.6
C(16)-C(15)-C(14) 121.21(17)
C(16)-C(15)-H(15) 119.4
C(14)-C(15)-H(15) 119.4
C(12)-C(13)-C(14) 121.31(17)
C(12)-C(13)-H(13) 119.3
C(14)-C(13)-H(13) 119.3
C(3)-C(2)-C(l) 127.12(17)
C(3)-C(2)-H(2) 116.4
C(l)-C(2)-H(2) 116.4
C(15)-C(16)-C(ll) 119.28(17)
C(15)-C(16)-H(16) 120.4
C(ll)-C(16)-H(16) 120.4
C(3)-C(4)-C(6) 115.41(16)
C(3)-C(4)-S(l) 112.42(12)
C(6)-C(4)-S(l) 105.46(13)
C(3)-C(4)-H(4) 107.7
C(6)-C(4)-H(4) 107.7
S(l)-C(4)-H(4) 107.7
C(15)-C(14)-C(13) 118.48(17)
C(15)-C(14)-C(17) 120.60(18)
C(13)-C(14)-C(17) 120.91(17)
C(4)-C(6)-H(6A) 109.5
C(4)-C(6)-H(6B) 109.5
H(6A)-C(6)-H(6B) 109.5
C(4)-C(6)-H(6C) 109.5
H(6A)-C(6)-H(6C) 109.5
H(6B)-C(6)-H(6C) 109.5
N(l)-C(l)-C(2) 114.07(15)
N(1)-C(1)-H(1A) 108.7
C(2)-C(1)-H(1A) 108.7
N(1)-C(1)-H(1B) 108.7
C(2)-C(1)-H(1B) 108.7
H(1A)-C(1)-H(1B) 107.6
C(14)-C(l 7)-H(l 7 A) 109.5
C(14)-C(17)-H(17B) 109.5
H(17A)-C(17)-H(17B) 109.5
C(14)-C(17)-H(17C) 109.5
H(17A)-C(17)-H(17C) 109.5
H(17B)-C(17)-H(17C) 109.5
C(3)-C(5)-H(5A) 109.5
C(3)-C(5)-H(5B) 109.5
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H(5A)-C(5)-H(5B) 109.5
C(3)-C(5)-H(5C) 109.5
H(5A)-C(5)-H(5C) 109.5
H(5B)-C(5)-H(5 C) 109.5
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Appendix C; Proton NMR spectra (500 MHz) 
Methyl glucosinolate 141.
Appendix
2 ,3 ,4 ,6 , -Tetra-O-acetyl-p-D-pynmosyl-O-chloroacetyl-4-bromo- 
butylthiohydroximate 158.
-171-
Appendix
(IRS, 2RS) N-(Toluenesulfonamide)-cyclohept-3-eii-2-ol 185.
-172-
PP
M
Appendix
(1 RS, 4RS, 5SR) 5-Methyl-2-(toluenesulfonyl)-3,4, 5 ,6-tetrahydro-4,5-oxa-l, 2- 
thiazine S-oxide 194.
-173-
PP
M
Appendix
(1RS, 4RS, 5SR) 4 ,5-Dimethyl-2-(toluenesulfonyl)-3,4 ,5 ,6-tetrahydro-4, 5-oxa- 
1 ,2-thiazine S-oxide 197.
-174-
PP
M
Appendix
2-Chloro-4-toluenesulfonamide)-but-2-ene-l-sulfinic acid cholestanoate 205.
-175-
P
P
M
